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Abbreviations 
 
Ǻ  angstrom 
AI  active ingredient 
AIDS  acquired immunodeficiency syndrome 
AUC  area under the plasma concentration-time curve 
BSA  bovine serum albumin  
BSE  bovine spongiform encephalopathy  
CH  Switzerland 
cm  centimeter 
Cmax  maximal concentration 
d  day 
D  Germany 
Da  dalton 
DMSO  dimethyl sulfoxide 
DNA  desoxy-ribonucleic acid 
HPLC  high pressure liquid chromatography 
ICH  International Conference on Harmonization 
i.m.  intramuscular 
i.v.  intravenous 
EDTA  ethylene diamine tetraacetic acid 
EMEA  European Agency for the Evaluation of Medicinal Products 
F  France 
FDA  Food and Drug Administration 
FSH  follicle stimulating hormone 
FT  Fourier transform 
f1  difference factor 
f2  similarity factor 
g  gram 
G  gauge 
GPC  gel permeation chromatography 
GnRH  gonadotropin releasing hormone  
h  hour 
hGH   human growth hormone  
IR  infrared 
k  reaction rate 
 Abbreviations 
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kg  kilogram 
kJ/mol   kilojoule per mole 
log P  partition coefficient 
max  maximum 
mg  milligram 
min  minute 
ml  milliliter 
µl  microliter 
mm  millimeter 
µm  micrometer 
mol  mole 
mPa*s  millipascal second 
MS  mass spectroscopy 
mW  milliwatt 
MW  molecular weight 
N  newton 
NIH  National Institutes of Health 
NMP  N-methyl-2-pyrrolidone 
NIR  near infrared 
ng  nanogram 
nm  nanometer 
O/W  oil-in-water 
Pa*s  pascal second 
PEG  polyethylene glycol 
PLA  poly-lactic acid 
PLG  poly-glycolic acid 
PLGA  poly-(lactic-co-glycolic) acid 
psi  pounds per square inch 
PVA  polyvinyl alcohol 
PVP  polyvinyl pyrrolidone 
rpm  revolutions per minute 
s  second 
s.c.  subcutaneous 
S.D.  standard deviation 
sh  shoulder 
t  time 
THF  tetrahydrofuran 
 Abbreviations 
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TM  trademark 
Tmax  time to reach maximum plasma concentration 
TNF  tumor necrosing factor 
USP  The United States Pharmacopoeia 
UV  ultraviolet light 
V  volt 
v/v  by volume 
w/v  weight by volume 
w/w  by weight 
°C  degree Celsius 
%  percent 
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Objectives 
 
The aim of this work was to explore sustained release injectables formed in-situ by 
precipitation of polymer and to develop a parenteral formulation for dogs with an extended 
drug release over several months. In order to investigate this technology for lipophilic drugs, 
the active ingredient selected for this exploration was the highly potent, lipophilic anti-
infective milbemycine derivative with the internal name-code NOA449851. The new 
formulation is expected to be attractive to patients and veterinarians and competitive on the 
market. It therefore must show advantages over existing products. These include predictable 
and controlled drug release over a longer time period, with preferably no or only a limited 
burst effect, simple and cost effective manufacturing method, good stability of the formulation 
during storage and excellent tolerability for the patient.  
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Summary 
 
Repetitive oral administration of tablets to companion animals is particularly challenging and 
there is a continuing need for alternative options such as long acting injections or implants. 
Therefore, properties of sustained release injectables formed in-situ for use in dogs were 
investigated. These formulations comprise a biocompatible solvent in which the 
biodegradable PLA/PLGA polymers and the lipophilic anti-infective NOA449851, derivative of 
milbemycin against the parasite Dirofilaria immitis are dissolved. These formulations 
coagulate into solid implants on contact with aqueous fluids after i.m. or s.c. injection, 
thereby releasing the incorporated drug slowly over a period of weeks to months. This 
technology has several attractive features such as simplicity of concept, ease of 
manufacturing as well as use of FDA approved polymers. 
 
Dissolution tests were performed to investigate in-vitro drug release characteristics from 
injectable formulations varying in polymer type, polymer concentration, active ingredient 
concentration and solvent composition. At high drug loads, release properties were 
independent of polymer type. However, in case of very low drug loads, drug release was 
controlled by polymer properties. Major releasing mechanism was found to be drug diffusion 
and therefore was influenced by drug concentration. Significant reduction of initial burst was 
observed when polymer concentration was increased. Also the solvent composition 
influenced in-vitro drug release. Especially a significant reduction of the initial burst was 
observed when a fraction of the main solvent triacetin was substituted with hydrophilic 
co-solvents such as ethanol absolute or anhydrous glycerol, while a lipophilic co-solvent 
such as Miglyol 812 did increase the initial drug release. Solvent composition, depending on 
its affinity to the dissolution medium, influences the rate of fluid-convection, the hardening 
process of the polymers, the internal structure of the implant and therefore its drug release 
rate.  
 
Raman and IR spectroscopy revealed that the active ingredient was incorporated in the 
amorphous conformation in all investigated batches. No evidence of any interaction between 
the active ingredient and the polymeric matrix could be detected. 
 
Tolerability and pharmacokinetic properties of six sustained release injectables formed 
in-situ, varying in polymer concentration and solvent composition were explored after 
subcutaneous administration to Beagle dogs. The high viscosity of the formulations and 
consequently the poor syringeability turned out to be a critical issue. Viscosity of the 
 Summary 
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formulations was decreased by reducing the polymer concentration and by varying the 
composition of the solvent mixture. All investigated formulations were very good tolerated by 
the animals. In agreement with in-vitro investigations, reduction of polymer concentration 
gave rise to increased initial drug release. Presence of hydrophilic co-solvents reduced 
maximum drug concentration in dog plasma profiles. The active ingredient NOA449851 was 
detectable in blood of experimental animals over 450 days after subcutaneous injection of 
sustained release formulations. However, very high inter-animal variations were found for 
some formulations and important differences in AUC values were calculated, despite the 
same amount of drug injected to each dog. These differences could be explained by possible 
encapsulation of the subcutaneous implant with connective tissue. 
 
The degree of correlation between the in-vitro dissolution parameters and the in-vivo 
pharmacokinetic data was investigated. Cmax was positively correlated to cumulative in-vitro 
drug release at Tmax, however not in a significant manner. In general, for this type of dosage 
form and drug, no satisfactory IVIVC are observed. The model used for in-vitro drug release 
testing neglect probably some crucial aspects of physiological conditions governing in-vivo 
release and cannot replace biological systems. 
 
Stability studies were performed for three sustained release injectables formed in-situ during 
six months storage at the four selected temperatures 5°C, 25°C, 30°C and 40°C. The 
formulations were based on PLA polymers, active ingredient NOA449851, solvent triacetin 
and in case of one formulation, co-solvent ethanol absolute. An HPLC-method was utilized 
for determination of the active ingredient content. No differences between the three 
formulations were observed. The content of active ingredient slightly decreased with time 
and temperature. Molecular weights of PLA polymers were determined with GPC. Decrease 
in molecular weight was significantly increased with storage temperature and time. These 
results are in agreement with the findings of Wang et al. [Wang et al., 2003]. No significant 
influence of co-solvent ethanol absolute on the PLA stability could be measured. However, 
presence of active ingredient seemed to decrease hydrolysis process of PLA polymer, 
probably by competitively attracting water molecules responsible for polymer degradation. 
NIR data analysis of solvent triacetin showed spectral changes for wavelengths at 1900 nm. 
These spectral changes were consistent in every analyzed spectra set as solvent triacetin 
was in excess in all investigated samples. Influence of solvent effect could not be removed 
by study design, as no specific wavelength could be attributed to PLA polymers. 
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Surprisingly, in-vitro drug releases from a formulation tested directly after manufacturing and 
after six months storage at 40°C were found to be similar, despite the important reduction of 
the molecular weight of the PLA polymers. This confirms a drug release mechanism mainly 
controlled by drug diffusion through the matrix and not erosion controlled. 
 
Microspheres and sustained release injectables formed in-situ are both technologies 
intended for parenteral application, planned to achieve a long lasting drug release. In both 
technologies, the sustained effect is caused by biodegradable PLA/PLGA polymer matrix in 
which the active ingredient is embedded. In order to investigate the influence of the 
preparation method of the polymer matrix on the release of the drug substance, 
microparticles batches were prepared for comparison with regards to in-vitro release 
properties. For all tested microsphere batches, drug release was independent on type of 
biodegradable polymer. A bigger fraction of active ingredient was released from the 
microparticles at high drug loads. In every investigated case, drug release from sustained 
release injectables formed in-situ was faster and to a much larger extent than from related 
microparticles. As possible explanation of the slower release from microparticles may be the 
denser packing of the polymer matrix compared to the in-situ formed implants. The 
microspheres polymer matrix is solidified before injection by applying a much more efficient 
solvent extraction procedure then the implants which only solidifies slowly at the site of 
injection. For that reason, diffusion controlled drug release is slower from the more densely 
packed microsphere matrix.  
 
Sustained release injectables formed in-situ showed, under in-vitro as well as in-vivo 
conditions, a prolonged active ingredient release, confirming that this drug delivery 
technology is a suitable approach to achieve a controlled long term release of the lipophilic 
anti infective NOA449851. This technology fulfills, for this particular compound, some basic 
requirements such as a good tolerability, controlled release of the active ingredient over a 
long period of time as well as an acceptable stability of formulation during storage for several 
months at low temperature conditions. Release properties of the active ingredient could be 
modified by changing composition of the formulation and possible detrimental burst effects 
could be suppressed by careful selection of polymer concentration and solvent mixture. 
Especially, the latter finding, the suppression of a burst effect can be considered as a 
significant improvement of the in-situ implant technology. It is to be expected that in the 
future, development of new implantable systems will, increasingly, help reducing cost for 
drug therapy, potentate medical treatments and, simultaneously enhance patient compliance. 
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Chapter 1 
 
General Introduction 
 
 
Today’s veterinary needs and expectations reflect more than ever requirements typical for 
current human medication. Therefore, veterinary pharmaceutical companies are investigating 
ways to maximize effectiveness and convenience for the administration of compounds to 
animals. To meet future market expectations, requirements for formulation development 
continue to increase: the new product should be innovative and of superior efficacy. Major 
driving forces for the development of innovative veterinary controlled release products 
include the reduction of frequency of administration, duration of medical treatment and stress 
for the animals. As a consequence, an increased ease of use by the veterinarians and the 
pet’s owner as well as a decreased treatment costs should be typical for these products. 
These factors have stimulated the development of extended or modified releasing drug 
delivery systems for use in both companion and farm animals [Bowersock, 1999; Matschke 
et al., 2002, Medlicott et al., 2004; Sun et al., 2004; Ahmed et al., 2002; Rathbone et al., 
2002]. 
 
While oral drug delivery continues to be the primary route of administration, the parenteral 
route offers an interesting alternative when oral administration is difficult or useless. The 
development of new injectable drug delivery systems has received extensive attention over 
the past few decades. This interest has been fostered by the potential advantages these 
technologies may provide including ease of application, decrease of overall drug dose 
associated with possible reduction of local or systemic side effects, as well as prolonged 
delivery periods at desired releasing rates. The minimization of dosing frequency enhances 
patient compliance and comfort. Injectable drug delivery systems capable of releasing an 
active ingredient in a controlled manner for a desired period has therefore a high priority. A 
zero order release kinetic is often the preferred delivery profile which assures a constant 
blood level of the drug for a given period. Additionally, biodegradable systems allowing the 
administration without the need for a subsequent medical procedure to remove the device 
contribute to higher patient compliance. However, these innovative therapies are developed 
at the expense of increased complexity, leading often to issues such as high development 
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and production costs [Chien et al., 1981; Yewey et al., 1997; Arnold, 1988; Rathbone et al., 
2002]. Therefore, such developments are only pursued when the benefits outweigh the 
increase of development investments and risks. Controlled release parenteral dosage forms 
may be difficult to develop because of the prerequisite to understand and investigate 
innovative formulation manufacturing and packaging, product stability, injectability, injection 
site absorption, tissue drug residues, tissues irritation, extended pharmacokinetic profiles as 
well as efficacy over long period of time [Medlicott et al., 2004; Packhaeuser et al., 2004; 
Ahmed et al., 2002; Arnold, 1988; Chien, 1981; Dash et al., 1998; Sun et al., 2004]. 
 
Delivery systems such as emulsions, liposomes, microspheres and implants are successful 
in certain parenteral applications as modified release formulations [Rothen-Weinhold et al., 
2000; Winzenburg et al., 2004; Packhaeuser et al., 2004]. Since drug release from emulsions 
or liposomes lasts for a limited period of only a few weeks, injectables in-situ solidifying drug 
depots are under development as alternative systems with more extended drug delivery 
periods. These innovative formulations are made of biodegradable polymers which can be 
dissolved in suitable solvents and injected into the body as a liquid. Upon administration and 
dilution with tissue water, the polymers solidify to form a depot. They can be classified in four 
groups based on the mechanism of solidification in-vivo: the thermoplastic pastes, the in-situ 
cross-linked systems, the in-situ solidifying organogels and the in-situ solidifying system by 
precipitation [Hatefi et al., 2002; Sinha et al., 1998]. 
 
1. Sustained release injectables formed in-situ by precipitation 
 
Parenteral depot system can minimize side effects by achieving infusion-like plasma level 
time profiles, especially for drugs with narrow therapeutic indices. An overall dose reduction, 
resulting from the constant blood level as well as the enhancement of patient compliance by 
reducing the frequency of application are further potential benefits.  
 
The sustained release injectable formed in-situ by precipitation is a drug delivery technology 
which combines a biodegradable polymer with a biocompatible solvent, resulting in a solution 
that can be injected using standard syringes and needles. For controlled release 
applications, an active ingredient can be either dissolved or suspended in the injectable 
formulation. When the system comes in contact with physiological fluids, the water-insoluble 
polymers precipitate as the solvent diffuses into the surrounding tissues. As a result, a 
biodegradable polymeric implant matrix is formed and encapsulates the dissolved or 
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suspended drug. During precipitation of the polymer, the incorporated drug is entrapped 
within the solidified matrix and is then slowly released [Yewey et al., 1997]. 
 
Since this technology has been patented [Dunn et al., 1990], numerous in-vitro release 
experiments and in-vivo trials were performed to understand the drug release mechanisms of 
the sustained release injectable formed in-situ and to improve the prediction of the drug 
release kinetics. A summary of the most relevant publications investigating this technology is 
listed in Tables 1.1 and 1.2. The different polymer types, solvents and active ingredients 
used as well as their concentration in the formulations are mentioned. In Table 1.1, the active 
ingredients used are all water soluble substances whereby the selected drug of the 
experiment listed in Table 1.2 were only slightly water soluble, very slightly water soluble or 
water insoluble compounds, according to the usual classification of pharmacopoeias. 
 
 
Table 1.1: List of publications on the sustained release injectables formed in-situ drug delivery 
technology for water soluble active ingredients. 
 
Reference Polymer composition Solvent(s) Active ingredient 
Radomsky et 
al., 1993 
PLA; 50/50 PLGA; 
polylactidecaprolactone 
(40-55 %) 
NMP ganirelix acetate (10-15 %) 
Shah et al., 
1993 50/50 PLGA (1-20 %) 
triacetin; 
triethyl citrate myoglobin (0.40-0.45 %) 
Lambert et al., 
1995 
PLA; PGA; 85/15 
PLGA; 50/50 PLGA 
(10-40 %) 
NMP; DMSO BSA (1 %) 
Eliaz et al., 
1997 75/25 PLGA (10-20 %) glycofurol 
BSA; sp55-TNF-receptor 
(3-10 %) 
Yewey et al., 
1997 PLA; PLG (5-45 %) NMP; DMSO 
pellucida antigen protein (0.2 %); FSH 
(1 %); GnRH antagonist (1 %); BSA 
(0.01-20 %); lysozyme (5 %); trypsin (5 
%); horse radish peroxidase (5 %); 
bovine insuline (1 %); myoglobin (10 %) 
McHugh et al., 
1999 PLGA (50 %) 
NMP; triacetin; 
ethyl benzoate lysozyme (10 %) 
Brodbeck et 
al., 1999 (1) 50/50 PLGA (50 %) 
ethyl benzoate; 
NMP; triacetin lysozyme (10 %) 
Jain et al., 
1999 (2) PLA (20 %) NMP isoniazide (10 %) 
Graham et al., 
1999 PLGA (32.3-50 %) NMP; triacetin lysozyme (10 %) 
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Table 1.1 (Continued): 
 
Reference Polymer composition Solvent(s) Active ingredient 
Brodbeck et 
al., 1999 (2) 50/50 PLGA 
NMP; triacetin; 
ethyl benzoate; 
benzyl benzoate 
hGH (5-10 %); lysozyme (5-10 %) 
Ravivarapu et 
al., 2000 (1) 75/25 PLGA (40-50 %) NMP leuprolide acetate (3-6 %) 
Ravivarapu et 
al., 2000 (2) 
50/50 PLGA; 75/25 
PLGA (28-45 %) NMP leuprolide acetate (3 %) 
Ravivarapu et 
al., 2000 (3) 75/25 PLGA (45 %) NMP leuprolide acetate (3-6 %) 
Eliaz et al., 
2000 (1) 75/25 PLGA (10-20 %) glycofurol BSA; sp55-TNF-receptor (3-10 %) 
Eliaz et al., 
2000 (2) 
50/50 PLGA; 75/25 
PLGA (10-20 %) glycofurol BSA; sp55-TNF-receptor (1.5-30 %) 
DesNoyer et 
al., 2001 
PLA; polycaprolactone 
(13.5-45 %) ethyl benzoate lysozyme (10 %) 
Kranz et al., 
2001 PLA; PLGA (10-40 %) 
NMP, DMSO, 
2-pyrrolidone 
bupivacaine hydrochloride; 
buserelin acetate (2 mg/ml) 
Eliaz et al., 
2002 75/25 PLGA (10 %) glycofurol 
plasmid DNA 
(500 µg/ml) 
DesNoyer et 
al., 2003 
PLA; poly(ethylene 
oxide); poly(propylene 
oxide) (10.8-18 %) 
NMP lysozyme (10 %) 
Pechenov et 
al., 2004 50/50 PLGA (50 %) acetonitrile 
crystalline amylase 
(10-300 mg/ml) 
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Table 1.2: List of publications on the sustained release injectables formed in-situ drug delivery 
technology using slightly water soluble (*), very slightly water soluble(**)  or water 
insoluble(***)  compounds. 
 
Reference Polymer composition Solvent(s) Active ingredient 
Shah et al., 
1993 50/50 PLGA (1-20 %) 
triacetin; 
triethyl citrate 
hydrochlorothiazide(***) (0.4 %); 
theophyllin(*) (1 %); cytochrome C(*) 
(0.4 %) 
Shively et al., 
1995 
PLA; 85/15 PLGA; 
75/25 PLGA; 65/35 
PLGA; 50/50 PLGA 
(35-57 %) 
NMP; DMSO; 
ethyl acetate naltrexone base
(
***
)
 (5 %) 
Chandrashekar 
et al., 1996 
50/50 PLGA; 70/30 
PLGA; 80/20 PLGA; 
90/10 PLGA (5-20 %) 
triacetin diclofenac sodium(*) (5 %) 
Dunn et al., 
1996 
85/15 PLGA; 
polylactide-co-
caprolactone (70-50 %) 
DMSO cisplatine(**) (8 %) 
Singh et al., 
1997 (1) 
50/50 PLGA; 70/30 
PLGA; 80/20 PLGA; 
90/10 PLGA (5-25 %) 
triacetin plumbagin(*) (5 %) 
Singh et al., 
1997 (2) 50/50 PLGA (5-25 %) triacetin methotrexate
(
***
)
 (5 %) 
Dernell et al., 
1998 
PLGA; polylactide-co-
caprolactone DMSO; NMP cisplatine
(
**
)
 (8 %) 
Jain et al., 
2000 (1) PLGA (12.5 %) triacetin cytochrome C
(
*
)
 (0.08 %) 
Matschke, 
2002 
PLA; 85/15 PLGA; 
75/25 PLGA (2.5-15 %) NMP; triacetin NOA440094
(
*
)
 (7-37%) 
 
 
The drug release mechanism from this polymeric system is complex. Just after injection the 
solvent diffuses into the medium as the polymer matrix begins to solidify. The release of 
active ingredient is presumably due to diffusion of the drug out of the polymer matrix as well 
as erosion of the solid implant surface of the matrix, depending on the properties of polymer 
and drug substance [Lambert et al., 1995; Yewey et al., 1997; Eliaz et al., 2000 (1); 
Brodbeck et al., 1999 (2)]. 
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The release rate from sustained release injectables formed in-situ is affected by the 
properties of the drug substance and a large number of parameters of the formulation. These 
parameters include type, concentration and molecular weight of the polymer used to form the 
matrix of the implant, type and amount of the solvent as well as the presence of additives like 
surfactants or co-solvents. Amount and physicochemical characteristics such as hydrophilic 
or lipophilic properties, water miscibility or molecular weight of the active ingredient also have 
an impact on the characteristics of the drug delivery device [Yewey et al., 1997; Graham et 
al., 1999; Eliaz et al., 2000 (1), (2); Matschke, 2002]. 
 
1.1. The polymers 
 
Candidates of biodegradable polymers for the sustained release injectable formed in-situ 
technology include homopolymers of poly(DL-lactide) (PLA) and co-polymers of  
poly(DL-lactide-co-glycolide) (PLGA) [Yewey et al., 1997; Jain, 2000; Shively et al., 1995; 
Singh et al., 1997 (1); Lambert et al., 1995]. PLA and PLGA were two of the first polymers 
used and established in parenteral controlled-release technology. They have been utilized in 
biomedical applications such as sutures and orthopedic devices prior to their use in drug 
delivery [Middleton et al., 2000]. Safety, excellent tolerability and biocompatibility of these 
biodegradable polymers as well as their ease of availability made them ideal candidates for 
parenteral controlled release excipients. PLA/PLGA polymers are already FDA approved for 
parenteral application for specific products and widely used as polymeric matrix for implants 
or microspheres [Heller, 1993; Sinha et al., 1998; Chien et al., 1981; Dash et al., 1998; Shah 
et al., 1992; Vert et al., 1998]. Some marketed sustained release products based on 
PLA/PLGA polymers and formulated as solid implant, injectable implant or microspheres are 
listed in Table 1.3. All active ingredients of the sustained release products mentioned in 
Table 1.3 are water soluble compounds. 
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Table 1.3: List of various commercial sustained release products based on PLA/PLGA 
polymers. 
 
Product Distributor Form Active ingredient 
Atridox Atrix Laboratories injectable implant doxycycline hyclate 
Decapeptyl® Depot Ferring microspheres triptorelin acetate 
Decapeptyl® Gyn Ferring microspheres triptorelin acetate 
EligardTM Atrix Laboratories injectable implant leuprolide acetate 
Enantone® Gyn  Takeda Pharma microspheres leuprorelin acetate 
Lucrin Depot®  Abbott microspheres leuprorelin acetate 
Nutropin Depot® Genentech microspheres human growth hormone 
Parlodel® LAR Sandoz microspheres bromocriptin mesilate 
Profact ® Depot Aventis Pharma implant buserelin acetate 
Risperdal Consta® Janssen-Cilag microspheres risperidon 
Sandostatin® LAR Depot Novartis Pharma microspheres octreotide acetate 
Trelstar® Depot Debiopharm microspheres triptorelin pamoate 
Trenantone® Takeda Pharma microspheres leuprorelin acetate 
Uropeptyl® Depot Uropharm microspheres triptorelin acetate 
Zoladex® AstraZeneca  implant goserelin acetate 
Zoladex® GYN  AstraZeneca  implant goserelin acetate 
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For the synthesis of both polylactide and polyglycolide, an intermediate cyclic diester is 
prepared prior to polymerization from the lactic acid and glycolic acid, respectively. These 
cyclic dimers are called lactide and glycolide. Poly(lactide) exists in two stereo-isomers, 
charcaterised by a D or L for dexorotary or levorotary or by DL for the racemic mixture. Ring-
opening polymerization of the lactide and/or glycolide is the most frequently used method for 
synthesis of PLA/PLGA with a molecular weight greater than 10’000 Da. By varying the 
synthesis conditions, it is possible to obtain PLA and PLGA polymers of various 
lactide/glycolide ratios and molecular weights [Middleton et al., 2000; Wang et al., 2000; 
Hollinger et al., 1986]. The various steps of the synthesis of poly(lactide) and poly(lactide-co-
glycolide) polymers are illustrated in Figure 1.1. 
 
 
 
Figure 1.1: Synthesis of poly(lactide) and poly(lactide-co-glycolide) from the lactic acid and the 
glycolic acid. 
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The principal mode of degradation for PLA and PLGA polymers in-vitro as well as in-vivo is 
hydrolysis [Middleton et al., 2000; Yewey et al., 1997; Gunatillake et al., 2003; Jain, 2000; 
Hollinger et al., 1986]. The degradation proceeds first by diffusion of water into the polymeric 
matrix, followed by random hydrolysis and fragmentation of the material. The products of 
hydrolysis are then either metabolized or excreted. Poly(lactide) undergoes hydrolytic de-
esterification into lactic acid which is transformed to pyruvate by lactate dehydrogenase. 
Pyruvate is decarboxylated into acetyl co-enzyme A which is incorporated into the 
tricarboxylic acid cycle to form carbon dioxide and water as schematized in the Figure 1.2. 
Poly(glycolide) is degraded by hydrolysis to glycolic acid. Glycolic acid may be excreted 
directly via urine or may react to form glycine. In the body, glycine can be used to synthesize 
serine and subsequently transformed into pyruvic acid where it enters the tricarboxylic acid 
cycle as depicted in the Figure 1.2 [Middleton et al., 2000; Athanasiou et al., 1998; Hollinger 
et al., 1986]. 
 
 
 
Figure 1.2: Biodegradation pathways of poly(lactide) and poly(glycolide). 
 
 
The rate of hydrolysis of PLA/PLGA polymers is affected by the size and hydrophilicity of the 
polymer bulk, by the crystallinity and molecular weight of the polymers and by the pH and 
temperature of the environment. In general, degradation time is shorter for lower molecular 
weight polymers, more hydrophilic or amorphous polymers and therefore for co-polymers 
with higher numbers of glycolic units. Increase of lactic acid content in the matrix decreases 
the degradation rate by reducing water uptake and making the ester bond less accessible to 
water, due to hindrance by the bulky methyl groups. Although there is no linear relationship 
between co-polymer composition and degradation rate, the degradation time can 
theoretically be varied from one month up to several years [Göpferich, 1996; Middleton et al., 
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2000; Wang et al., 1997; Athanasiou et al., 1998]. More specifically, the time for complete 
resorption of the polymers was reported to be between 12 and 16 months for the amorphous 
poly-DL-lactic acid, between 5 and 6 months for 85/15 PLGA polymer and between 4 and 5 
months for 75/25 PLGA polymer [Middleton et al., 2000; Gunatillake et al., 2003].  
 
As already mentioned, the degradation products of the PLA/PLGA polymers are acidic 
compounds. Due to their inability to diffuse away from the bulky device, they lead to a local 
acidic environment in the interior of the polymeric implant [Wang et al., 1997; Middleton et 
al., 2000]. This lowering of the environmental pH can be detrimental for stability of active 
ingredients with a pH driven degradation process.  
 
Because these polymers are hydrolytically unstable, the presence of moisture can lead to 
their degradation during processing or storage. Passive hydrolysis is by far the most 
important degradation mechanism for synthetic polymers, since for most of them no specific 
enzymes exist [Göpferich, 1996]. In theory, the reduction of sensitivity for hydrolysis of the 
polymer bonds can be achieved by simply eliminating moisture. As the materials are 
hygroscopic by nature, keeping the polymers free of water is difficult. Polymer drying may be 
accomplished by vacuum drying or drying in a resorption circulating air dryer. The drying 
process should occur at room temperature to avoid thermal degradation, despite the 
consequently higher percentage of residual moisture and lower efficacy of the procedure 
[Middleton et al., 2000].  
 
Numerous investigations on the biocompatibility of the polymers in-vivo have been 
performed, with mostly very favorable results. The PLA/PLGA do not invoke any 
inflammatory or toxic response, and the degradation products are metabolized in the body 
leaving no trace. Despite the good biocompatibility of the implanted PLA/PLGA polymeric 
system, the formation of a fibrous capsule surrounding the system is often described. This 
tissue response is not inert and is expected to modulate the in-vivo release of the implanted 
systems [Medlicott et al., 2004; Royals et al., 1999; Dernell et al., 1998; Dunn et al., 1996; 
Athanasiou et al., 1998].  
 
Synthetic polymers such as PLA/PLGA offer in general significant advantages over materials 
from natural origin. They can be tailored to give a wider range of characteristics and have 
more predictable lot-to-lot uniformity than natural polymers. A more reliable source of raw 
materials is obtained with synthetic polymers, with little concerns regarding immunogenicity 
[Middleton et al., 2000]. Despite these considerations, natural excipients such as albumin, 
collagen, gelatin and alginate have been suggested as suitable polymers for the formulation 
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matrix of the injectable depot formulations [Dunn et al., 1990]. These substances are more 
critical with regard to possible contamination with viruses (AIDS, hepatitis) and prions (BSE). 
Further alternatives to the PLA and PLGA polymers for the matrix of the sustained release 
injectables formed in-situ consist in excipients such as chitosan, poly(anhydrides), 
poly(orthoester), poly(amides) and the poly(ester) polycaprolactone [Heller, 1993; Dunn et 
al., 1990; Gunatillake et al., 2003; Uhrich et al., 1999, Davis, 2000]. Although all these 
options may be usable and have potential applicability for future drug delivery systems, the 
most serious candidates for parenteral application remain the PLA/PLGA polymer which 
have been selected to form the implant matrix in the present study [Burgess et al., 2004; 
Middleton et al., 2000]. 
 
1.2. The solvent 
 
The injectable in-situ forming drug delivery system requires pharmaceutically acceptable 
solvents that are able to form concentrated polymer solutions in order to achieve high drug 
entrapment and suitable drug release profiles [Shively et al., 1995]. The vehicle not only acts 
as a solvent but also serves as a plasticizer for the polymers. The gel matrix is not just a 
precipitated polymer but a polymer matrix with a rubbery state depending on the 
concentration of the vehicles entrapped into the polymer on injection [Singh et al., 1997 (1)]. 
The choice of an appropriate solvent is also an essential factor, as this excipient plays a 
determinant role during the implant forming process and therefore highly influences the drug 
release rate [Graham et al., 1999]. 
 
The solvent for the biodegradable polymer implant should be well tolerated and 
biocompatible. It should cause neither pain following administration, nor tissues irritation or 
necrosis at the site of injection. The solvent should be water miscible to a major extent and 
diffuse into the body fluids and, reciprocally, allow water permeation into the polymer solution 
and cause it to coagulate or solidify [Dunn et al., 1990; Kranz et al., 2001]. 
 
Among the numerous pre-clinical trials reported in the literature (see Tables 1.1 and 1.2), 
mostly tested on mice, rats or dogs, the solvents used were often NMP (N-methyl-2-
pyrrolidone) [Radomsky et al., 1993; Shively et al., 1995; Yewey et al., 1997; Brodbeck et al., 
1999 (2); Jain et al., 1999; Ravivarapu et al., 2000 (1), (2), (3); Kranz et al., 2001] and DMSO 
(dimethylsulfoxide) [Shively et al., 1995; Dunn et al., 1996; Yewey et al., 1997; Dernell et al., 
1998; Kranz et al., 2001]. Both solvents NMP and DMSO allow the formation of highly 
concentrated polymer solutions up to 70 % in weight [Dunn et al., 1996]. Biocompatibility and 
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tolerability of placebo biodegradable in-situ forming injectable systems with NMP and DMSO 
as solvents were studied in rhesus monkeys [Royals et al., 1999]. A mild fibroplasias was 
observed, resulting in bands of connective tissue with inflammatory cells circumscribing the 
polymer implants. This effect can be related to the toxicity of the solvents. There are 
extensive toxicity data for oral, intraperitoneal and intravenous administration of these 
solvents [Fiedler Lexikon, 2002; Martindale, 1993; Bertholom et al., 2000; Wells et al., 1988]. 
In spite of these positive findings in monkeys, in general parenteral injection of pure solvents 
(i.e. not diluted with isotonic aqueous media) is not very well accepted and a continuous 
debate on the use of these vehicles in animals and men is ongoing. Further, the use of the 
organic solvent acetonitrile allows the formation of a concentrated PLGA solution up to 50 % 
[Pechenov et al., 2004], but considering its toxicity, parenteral application is excluded [Fiedler 
Lexikon, 2002; Martindale, 1993]. 
 
As listed in Tables 1.1 and 1.2, further solvents which have been used in this approach for 
in-vitro experiments or for in-vivo trials include triacetin [Shah et al., 1993; Chandrashekar et 
al., 1996; Singh et al., 1997 (1), (2); Brodbeck et al., 1999 (1), (2); Graham et al., 1999; Jain 
et al., 2000 (1)], triethyl citrate [Shah et al., 1993], ethyl acetate [Shively et al., 1995], 
glycofurol [Eliaz et al., 1997; Eliaz et al., 2000 (1), (2); Eliaz et al., 2002], ethyl benzoate 
[Brodbeck et al., 1999 (1), (2); DesNoyer et al., 2001], benzyl benzoate [Brodbeck et al., 
1999 (2)] and 2-pyrrolidone [Kranz et al., 2001]. In comparison to the formulations based on 
NMP, DMSO and acetonitrile, the injectables with these alternative solvents contain a 
reduced concentration of polymers as the solubility of the PLA/PLGA in these solvents is 
relatively low. However, some of these solvents may be less toxic and better tolerated 
[Fiedler Lexikon, 2002; The Merck Index, 1996; Bertholom et al., 2000; Bleiberg et al., 1993].  
 
1.3. The active ingredient  
 
A wide range of active ingredients can be used for the sustained release injectable formed 
in-situ technology as the drug can be either suspended or dissolved in the formulation. The 
physical state of the active ingredient in the formulation depends on the physicochemical 
properties of the active ingredient and on the solvent used. For example, water soluble 
compounds such as leuprolide acetate or BSA were dispersed in formulations based on the 
solvent NMP [Ravivarapu et al., 2000 (1), (2), (3); Lambert et al., 1995], while the active 
ingredients bupivacain hydrochloride and buserelin acetate, both also hydrophilic, were 
dissolved in the same solvent NMP [Kranz et al., 2001]. The slightly water soluble anticancer 
drug cisplatine as well as the water soluble protein BSA were both suspended in DMSO 
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formulations [Dunn et al., 1996; Lambert et al., 1995]. Using the solvent triacetin, active 
ingredients such as the antihypertensive hydrochlorothiazide [Shah et al., 1993], the 
antitumor agent plumbagin [Singh et al., 1997 (1)], or the protein cytochrome C [Jain et al., 
2000 (1)] were dissolved in the formulations. Contrarily, diclofenac sodium and methotrexate 
were dispersed in the formulations with triacetin as sole solvent. The addition of an 
appropriate co-solvent can solubilise an active ingredient which was previously in 
suspension, influencing the release mechanism and therefore the drug release rate. This 
was the case for the practically water insoluble drugs diclofenac sodium [Chandrashekar et 
al., 1996] and methotrexate [Singh et al., 1997 (2)], both actives being in suspension in the 
solvent triacetin, and in solution with the use of the hydrophilic co-solvent propyleneglycol.  
 
The lower dose limit of active ingredient incorporated into the formulation depends on the 
activity of the drug and the length of time needed for treatment. The upper limit is defined by 
the technical feasibility of the viscosity for injection through a syringe needle and by the 
solubility of the active compound in the solvent, when a solution is preferred to a suspension. 
In the different trials reported in the literature (see Tables 1.1 and 1.2), the drug 
concentration was in general between 5 % and 10 %. However, the concentrations varied in 
a range from 0.01 % [Yewey et al., 1997] to 37 % [Matschke, 2002]. 
 
In any case, the active ingredient must be highly potent so that the necessary dose for the 
extended treatment period can be incorporated in the smallest possible injectable volume of 
the formulation. The substance should preferably have a broad therapeutic index and cause 
no side effects or tissues irritation at the injection site. Obviously, the disease indication of 
the drug must be in agreement with a long term treatment. The physicochemical properties of 
the active ingredient which influence the drug release profiles from the injectable depot are 
mainly the molecular weight, the structure and the hydrophilicity/lipophilicity of the substance 
[Shah et al., 1993; Hatefi et al., 2002, Burgess et al., 2002]. In the various studies reported in 
the literature, the substances selected to be incorporated into sustained released injectables 
formed in-situ included natural substances like the enzymes lysozyme [McHugh et al., 1999; 
Brodbeck et al., 1999 (1), (2); Graham et al., 1999; DesNoyer et al., 2001] and crystalline 
amylase [Pechenov et al., 2004] or model proteins such as myoglobin [Shah et al., 1993], 
cytochrome C [Shah et al., 1993; Jain et al., 2000 (1)], BSA [Yewey et al., 1997; Eliaz et al., 
2000 (1), (2)], pellucida antigen protein [Yewey et al., 1997] or fluorescein isothiocyanate-
labeled bovine serum albumin [Lambert et al., 1995]. The sustained release of a plasmid 
DNA was also studied [Eliaz et al., 2002]. The use of the following hormones has been 
widely investigated: natural hGH [Brodbeck et al., 1999 (2)], FSH [Yewey et al., 1997] and 
GnRH [Yewey et al., 1997] or the synthetic LHRH-analog, leuprolide acetate [Ravivarapu et 
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al., 2000 (1), (2), (3)]. Some hormone-antagonists have also been tested, like ganirelix 
acetate, a GnRH-antagonist [Radomsky et al., 1993] and the substance buserelin acetate 
[Kranz et al., 2001]. Cancer treatment has been explored, using the substances cisplatin 
[Dunn et al., 1996; Dernell et al., 1998], plumbagin [Singh et al., 1997 (1)] and methotrexate 
[Singh et al., 1997 (2)]. Other substance models with a large range of physicochemical 
properties and for various indications have also been investigated such as 
hydrochlorothiazide [Shah et al., 1993], theophyllin [Shah et al., 1993], naltrexone base 
[Shively et al., 1995], diclofenac sodium [Chandrashekar et al., 1996], sp55-TNF-receptor 
[Eliaz et al., 1997; Eliaz et al., 2000 (1), (2)], isoniazide [Jain et al., 1999 (2)] and bupivacain 
hydrochloride [Kranz et al., 2001]. 
 
Most of the studied active ingredients are water soluble and are therefore subject to fast 
metabolism and elimination processes (Table 1.1) Only few investigated substances, are 
slightly soluble in water  practically insoluble in water or insoluble in water (Table 1.2) with a 
respective slower elimination metabolism. The use of lipophilic compounds may amplify the 
sustained released effect of PLA/PLGA delivery systems. 
 
A derivative of the lipophilic anti-infective milbemycine, the NOA449851, was selected as 
active ingredient for the development and exploration of the sustained release injectables 
formed in-situ. It is a potent water insoluble drug which has a prophylactic protective activity 
against the parasite Dirofilaria immitis in dogs, when a blood level of 10 ng/ml is achieved 
(unpublished internal data of Novartis Animal Health Inc.). These characteristics of the drug 
substance can be ideally combined with the in-situ formed sustained release injectable 
technology. 
 
2. General issues 
 
In the numerous trials reported in the literature, the major problems concerning the sustained 
release injectables formed in-situ are recurrent. Until now, the release mechanism has not 
been entirely clarified due to its high complexity and of the numerous parameters which 
simultaneously influence it. These include polymer type and polymer concentration, solvent 
type and amount as well as concentration and physicochemical properties of the active 
ingredient, especially regarding solubility in water. The influence of these parameters seems 
not to be constant and sometimes even contradictory. In addition, the drug releasing 
mechanism from the matrix is a consequence of concomitant processes such as solidification 
kinetics of the polymers, precipitation kinetics of the active ingredient, diffusion of the active 
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ingredient through the polymer-matrix along a concentration gradient, dynamic of solvents 
and water flows, erosion of biodegradable polymers by hydrolysis, bulk water uptake, 
swelling of polymers as well as release through pores formed in the matrix.  
 
The drug release rate from a polymeric matrix may also depend on interactions between 
active ingredient and polymer. High interactions resulting from e.g. hydrogen bonds between 
drug and polymer would lead to reduced release rate of the drug substance from the matrix. 
Investigations for detection of polymer/drug interactions can be performed using vibrational 
methods such as Raman and IR spectroscopy [Geze et al., 1999; Breitenbach et al., 1999]. 
Additionally, Raman spectroscopy allows the characterization of polymorphic forms or 
physical state of the drug within a matrix. These parameters affect the solubility properties 
and dissolution kinetics, and therefore influence the drug release rate of substances from a 
polymeric matrix [Bolton et al., 1984; Taylor et al., 1997; Broman et al., 2001].  
 
An initial burst release is an undesired effect which should be controlled to avoid the loss of 
an important amount of active ingredient during the first days of the treatment and to prevent 
possible toxic effects caused by high peak levels of the drug. The latter factor is more 
relevant to achieve a therapy which is safe for the patient. The released drug dose should 
not give rise to a critical high blood levels to prevent systemic or local side effects. Since the 
injectable implant system is administered as a liquid, it is reasonable to assume that there is 
a lag time between injection and formation of the solid implant. Especially during this time 
period, at which no encapsulating matrix exists, the initial burst of drug may very well exceed 
the therapeutic plasma concentration [Dernell et al., 1998]. 
 
The high viscosity of the sustained release injectable formed in-situ system is an important 
issue of this technology, since it directly determines the syringeability. The viscosity of the 
final formulation should be low enough to allow application with standard syringes and 
needle diameters. The thinner needle diameters are, the more tolerable are the injections, 
leading to better acceptance by patients. The viscosity of the formulation can be adjusted in 
a limited range by varying in the amount of polymer and of active ingredient as well as by use 
of solvent type in the formulation. The toxicity problems generated by solvents such as NMP 
or DMSO stimulates the use of alternative solvents which are better tolerated such as 
triacetin, possibly in combination with co-solvents, despite a higher viscosity of the 
formulation.  
 
The sustained release injectables formed in-situ are formulations intended for parenteral 
application and must therefore be sterile. As terminal sterilization commonly leads to a higher 
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sterility assurance level compared to aseptic manufacturing, different processes have been 
evaluated in the literature. Sterilization by autoclaving is not recommended due to the 
sensitivity of the polymers to heat and moisture. The effects of γ-irradiation on the 
physicochemical properties of biodegradable drug delivery systems have been 
controversially described in the literature [Mohr et al., 1999; Volland et al.,1994; Dunn et al., 
1996; Burgess et al., 2002; Martínez-Sancho et al., 2004; Athanasiou et al., 1998; Davis, 
2000]. It is now generally accepted that γ-irradiation causes a radiation dose-dependent 
decrease in polymer molecular mass by radiolytic chain scission. Therefore, the sterilization 
conditions as well as the radiation need to be carefully adjusted for the final dosage form.  
 
3. Aim of the work 
 
The aim of this work was to explore in-situ solidifying systems by precipitation of the 
polymers with the goal to develop a parenteral formulation for dogs for a drug with extended 
drug release over several months. In order to investigate this technology for lipophilic drugs, 
the active ingredient selected for this exploration was the highly potent, lipophilic anti-
infective milbemycine derivative with the internal name-code NOA449851. The new 
formulation is expected to be attractive to patients and veterinarians, and competitive on the 
market. It therefore must show advantages over existing products. These include a 
predictable and controlled drug release over a longer time period, with preferably no or only a 
limited burst effect, a simple and cost effective manufacturing method and an excellent 
tolerability for the patient.  
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Chapter 2 
 
Characterization of the Active Ingredient NOA449851 
 
 
1. Objective and introduction 
 
The objective of the present study was to develop a sustained release injectable formed 
in-situ based on PLA/PLGA biodegradable polymers. The active ingredient selected as 
marker for this purpose was a derivative of the anti-infective Milbemycin. The drug release 
from the novel formulation depends highly on the physico-chemical characteristics of the 
substance model. Therefore, the active ingredient was characterized with regard to solubility 
in different solvents and to conformation properties using vibrational spectroscopy and X-ray 
diffraction analytical method. 
 
First, the solubility of the active ingredient in various organic solvents was determined. All 
investigated excipients can be used either as solvent or as co-solvent in sustained release 
injectables formed in-situ, since they are physiologically well tolerated and already approved 
for parenteral application by the regulatory authorities. 
 
Various solid samples of the active ingredient were prepared by recrystallisation from 
different solvents and analyzed using IR and Raman spectroscopy. Further IR spectral 
analysis was performed on two liquid samples of the active ingredient. Special attention was 
paid to detect different morphological conformations of the active ingredient as well as its 
ability to interact with the solvents. In addition, the X-ray patterns of two solid samples were 
obtained for analysis of the cristallinity parameters of the different conformations. 
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2. Materials and methods 
2.1. Materials 
 
The drug substance NOA449851 was manufactured at and obtained from CarboGen 
Laboratories, Aarau, CH. The selected active ingredient NOA449851 has two homologues, 
S-1238 and S-1262, in a ratio of 80 % for S-1238 to 20 % for S-1262. The empirical formula 
are C47H63NO11 and C46H61NO11, respectively. These compounds have a molecular weight of 
818.03 and 804.00, respectively. The chemical structure of the active ingredient is illustrated 
in Figure 2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Chemical structure of the active ingredient NOA449851. S-1238 represents 80 % 
while S-1262 represents only 20 % of the active ingredient. 
 
 
The solvents dichloromethane, triacetin, NMP, glycerol formal, anhydrous glycerol, 
propylenglycol and PEG 300 were purchased from Fluka AG, Buchs, CH. Ethanol absolute, 
methanol, water for chromatography and DMSO were obtained from Merck Inc., Darmstadt, 
D. Miglyol 812 was provided by Hänseler AG, Herisau, CH. All solvents were of reagent 
analytical grade. 
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2.2. Methods 
2.2.1. HPLC-method 
 
An HPLC-method was used for quantitative analysis of the active ingredient NOA449851 in 
solutions. For this purpose, a LC HP 1100 (Hewlett Packard, Basel, CH) apparatus was 
employed. The column (250 mm length and 4.6 mm internal diameter) was packed with 
Nucleosil 5 µm, C18 (Macherey-Nagel, Düren, D) and maintained at a temperature of 37°C. 
The elution medium consisted of a mixture of water for chromatography and methanol. The 
composition of the mobile phase permanently changed in relation to the time of 30 min. The 
flow rate was 1.3 ml/min during the whole analyze-run. A volume of 10 µl of the sample 
solution was injected per run with an auto-sampler. The samples were detected and 
analyzed with UV-light at a wavelength of 240 nm. 
 
The tailing factor determined on the peaks of both homologues S-1238 and S-1262 was 
between 0.5 and 1.5. The resolution between the two peaks of the NOA449851 components 
was over 2.5. As reference, a solution of 0.040 % (w/v) NOA449851 in methanol was used. 
 
2.2.2. Solubility of NOA449851 in various organic solvents 
 
The solubility of the active ingredient NOA449851 was determined for the solvents NMP, 
ethanol absolute, glycerol formal, triacetin, PEG 300, Miglyol 812, propylenglycol, anhydrous 
glycerol and water for chromatography. 
 
An excess of active ingredient was equilibrated in the corresponding solvent by stirring over 
night at room temperature (Magnetic stirrer, Ikamag, RET S8TM, Ikawerke, Stauffen, D). After 
centrifugation (Centrifuge 5415, Eppendorf, Netheler + Hinz GmbH, 2000 Hamburg, D) and 
appropriate dilution, the concentration of NOA449851 in the supernatant solution was 
determined with the HPLC-method described in Section 2.2.1. 
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2.2.3. Preparation of solid samples for spectroscopic and X-ray analysis 
 
Different solid samples of the active ingredient NOA449851 were prepared for subsequent 
analysis with vibrational spectroscopy and X-ray diffraction method.  
 
Sample A represented the active ingredient as received from CarboGen: the substance was 
obtained by solving the active ingredient in ethyl acetate and by gently adding heptane until 
recristallisation. Samples B to G were obtained after solubilizing the active ingredient in 
various solvents and after evaporation at reduced pressure (Salvis Trockenschrank, Typ 
KVTS11, Reussbühl, CH). The solvents used were dichloromethane (sample B), NMP 
(sample C), triacetin (sample D), ethanol absolute (sample E), Miglyol 812 (sample F) and 
glycerol formal (sample G). An overview of the different solid samples and the applied 
analytical methods is listed in Table 2.1. 
 
 
Table 2.1: Overview of the NOA449851 solid samples used for IR spectroscopy, Raman 
spectroscopy and X-ray analysis. 
 
Sample Solvent for recristallisation IR Raman X-ray 
A ethyl acetate/heptan (CarboGen) yes yes yes 
B dichloromethan yes yes yes 
C NMP yes yes no 
D triacetin yes yes no 
E ethanol absolute yes yes no 
F Miglyol 812 yes yes no 
G glycerol formal yes yes no 
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2.2.4. IR spectroscopy 
 
IR spectroscopy is widely used for determination of organic structures as well as for 
investigations of hydrogen bonding. Therefore, IR spectroscopy was applied to the solid 
samples A to G prepared in Section 2.2.3. Additionally, two saturated solutions of the active 
ingredient NOA449851 in DMSO and dichloromethane were analyzed. Bands were assigned 
according to their localization and intensity. 
 
IR spectra of solid samples were run on a Perkin Elmer i-Series FTIR microscope coupled 
with a spectrum 2000 spectrometer over a wavenumber range from 4000 cm-1 to 700 cm-1 
with a resolution of 4 cm-1.  
 
IR spectra of solution samples were run on a Bruker IFS 66 FTIR spectrometer over a 
wavenumber range from 4000 cm-1 to 700 cm-1 with a resolution of 2 cm-1. 
 
2.2.5. Raman spectroscopy 
 
Raman spectroscopy is a useful tool for the analytical assessment of molecular structure of 
drugs. Complementary to the infrared spectroscopy, it is particularly appropriate for the 
detection of different polymorphic forms. Therefore, Raman spectroscopy was performed on 
the solid active ingredient samples A to G prepared in Section 2.2.3. 
 
The FT Raman spectra were recorded with a Bruker RFS 100 FT Raman spectrometer 
equipped with a liquid nitrogen cooled germanium detector. The resolution was 4 cm-1 and 
250 scans were accumulated by using a laser output of 600 mW. The spectrum was 
corrected for instrumental response. 
 
2.2.6. X-ray powder diffraction 
 
The active ingredient samples A and B were analyzed with X-ray diffraction method. The 
cristallinity of the active ingredient in both samples was investigated qualitatively by wide-
angle X-ray diffraction with a Philips PW1710 X-ray diffractometer. X-ray diffraction spectra 
were recorded on a diffractometer equipped with a Cuκα source and a diffracted beam 
monochromator. The diffractograms were taken from 2θ = 0° - 50° with a step size of 0.02° 
and a time interval of 2.4 seconds. 
 Chapter 2: Characterization of the active ingredient NOA449851 
 
 
38 
3. Results 
3.1. Solubility of NOA449851 in various organic solvents 
 
The maximal solubility [% (w/v)] of the active ingredient NOA449851 in various organic 
solvents was determined with the HPLC-method described in Section 2.2.1. A relative low 
solubility was found for the active ingredient NOA449851 in water (< 0.001 %), anhydrous 
glycerol (0.05 %), propylenglycol (3.02 %), Miglyol 812 (5.60 %) and PEG 300 (19.04 %). 
However, higher solubility for NOA449851 was measured in triacetin (35.22 %), glycerol 
formal (37.14 %), in ethanol absolute (50.93 %) and in NMP (53.18 %). All results are 
depicted in Figure 2.2. 
 
0.0
0.05
3.02
5.60
19.04
35.22
37.14
50.93
53.18
0 10 20 30 40 50 60
water
anhydrous gylcerol
propylenglycol
Miglyol 812
PEG 300
triacetin
gylcerol formal
ethanol absolute
NMP
Active ingredient solved [% (w/v)]
 
Figure 2.2: Maximal solubility [% (w/v)] of the active ingredient NOA449851 in various organic 
solvents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 2: Characterization of the active ingredient NOA449851 
 
 
39 
3.2. IR spectroscopy 
 
IR spectra were taken from the different solid samples of the active ingredient NOA449851 
prepared in Section 2.2.3 as well as from two solutions in dichloromethane and DMSO, 
respectively. The IR spectra of the solid samples A and B and of both liquid samples are 
represented in Figure 2.3. The assignments of the specific IR bands are listed in Table 2.2. 
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Figure 2.3: IR spectra of the active ingredi nt NOA449851 plotted in the region from 700 cm-1 to 
4000 cm-1 as solid samples A (A) and B (B) as well as in solution in 
dichloromethane (C) and DMSO (D). 
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Table 2.2: Assignments of IR bands of the active ingredient NOA449851 from the spectra 
illustrated in Figure 2.3. 
 
Sample A 
 
 
 
[cm-1] 
Sample B 
 
 
 
[cm-1] 
NOA449851 
dissolved in 
dichloro-
methane 
[cm-1] 
NOA449851 
dissolved in 
DMSO 
 
[cm-1] 
Assignment of the bands 
3582  3567  -OH stretch 
3478 3467  ~3260 -OH stretch 
3398 3395 3388  -NH stretch 
3100 ~ 3000 3100 ~ 3000  3109, 3050 aromatic CH stretch 
2948, 2933 2961 2964 2970 C-H stretch 
 2875 2876 2874 C-H stretch 
1722 1725 1716 1729 C=O stretch ester 
~1700 (sh) ~1700 (sh) 1692 1681 C=O stretch amide 
1610, 1591 1610, 1592 1590 1605 benzene ring stretch 
1524 1526 1527 1527 amide II of sec amide + benzene ring stretch 
1455 1454 1454 1454 C-H bend 
1407 1408 1408 1408 benzene ring stretch 
1374 1373 1371 1371 CH bend of CH3 groups 
1170 1169 1173 1170 C-O-C asymmetric stretch C-O of ester 
1110 1116 1116 1103 C-O stretch of CH2-O-CH3 
1034 1044 1043   
991 991 989  mainly C-O stretch 
896 895 900 896  
955 962 966 954 CH o.p. bend of trans-disubst C=C 
865 864 863 861 aromatic CH o.p. bend 
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Figure 2.4 represents the IR spectra of samples A and B in the region between 3000 cm-1 
and 3700 cm-1. The spectra exhibit important differences in this region which is specific for 
changes involving hydrogen bonding. The spectra of the sample A exhibit sharp signals at 
3581 cm-1 and 3398 cm-1, corresponding to a OH-stretch and a NH-stretch, respectively. The 
spectra of sample B showed only a slight shoulder at 3580 cm-1 and also a weaker peak at 
3398 cm-1. The IR patterns of the samples C to G were similar to the spectra of the sample B 
and were therefore not shown. 
 
 
Figure 2.4: IR spectra of the active ingredient sample A, recristallized in 
ethyl acetate/heptane ( ) and B, recristallized in dichloromethane ( ), plotted in 
the region 3000 cm-1 to 3700 cm-1. 
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3.3. Raman spectroscopy 
 
Raman spectra were taken from the solid samples A to G prepared as described in Section 
2.2.3. The Raman spectra of sample A, obtained by recrystallisation in ethyl acetate/heptane 
and of sample B, obtained by recrystallisation in dichloromethane are illustrated in Figure 
2.5. Two conformations can be distinguished, mainly concerning the shift of the band from 
1528 cm-1 (sample A) to 1520 cm-1 (sample B). Changes in this region correspond to different 
conformations of the amid II and of the benzene ring of the side chain of the molecule. The 
ratio of the bands at 1500 cm-1 - 1400 cm-1 also significantly changed. The Raman spectra of 
solid samples C to G were identical to the spectra of sample B and are therefore not shown. 
          
Figure 2.5: Raman spectra of sample A (a) and sample B (b) of the active ingredient 
NOA449851 plotted in the region between 300 cm-1 and 2000 cm-1. 
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3.4. X-ray analysis 
 
The morphology of the active ingredient in samples A and B was checked by X-ray 
diffraction. The diffractogram of sample A obtained by recrystallisation in 
ethyl acetate/heptane is illustrated in Figure 2.6 and shows sharp diffraction maxima. This 
indicates crystal conformation of active ingredient in sample A. 
 
Figure 2.6: X-ray diffractogram of sample A, obtained after recrystallization in 
ethyl acetate/heptane. The sharp diffraction maxima indicates that the substance is 
in crystalline form.  
 
The diffractogram of the solid sample B which was obtained after rectisallization in 
dichloromethane is illustrated in Figure 2.7. The broad diffusion band observed in the spectra 
is typical for amorphous compound. 
 
 
Figure 2.7: X-ray diffractogram of the solid sample B, obtained after rectristallization in 
dichlorometane. The broad diffusion band indicates that the substance is 
amorphous.  
 
 
 
 
°2 Theta 
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4. Discussion 
4.1. Solubility of the drug substance in various solvents 
 
The development of sustained release injectables formed in-situ based on PLA/PLGA 
polymers requires previous physico-chemical characterisation of the active ingredient. 
Therefore, the solubility properties of the drug substance NOA449851 in organic solvents 
were tested. All solvents investigated were appropriate candidates for parenteral application. 
Glycerol formal, NMP and triacetin are strong solvents for the PLA/PLGA polymers and could 
therefore be used as main solvent for the sustained release injectables formed in-situ 
[Matschke, 2002]. These three excipients are also very good solvents for the active 
ingredient NOA449851 as the maximum concentration for the active substance was 35.22 % 
in triacetin, 37.14 % in glycerol formal and 53.18 % in NMP. 
 
A solubility of less than 5 % of NOA449851 was observed in hydrophilic solvents such as 
anhydrous glycerol (0.05 %), propylenglycol (3.0 %) and water for chromatography 
(< 0.001 %). Better solubility for the active ingredient was found in the solvents PEG 300 
(19.04 %) and ethanol absolute (50.93 %). Miglyol 812, a mixture of medium-chain 
triglycerides, only solves 5.6 % of the active ingredient. These excipients are not able to 
solve enough PLA/PLGA polymers to form a matrix after precipitation [Matschke, 2002]. 
However, they could be added to the formulations as hydrophilic, respectively lipophilic 
co-solvents and act as release modifying factors or viscosity enhancing excipients. 
 
4.2. Morphology conformation 
 
A number of techniques has been employed to characterize the active ingredient, including 
infrared spectroscopy, Raman spectroscopy and X-ray crystallography. 
 
Raman and IR spectroscopy depend on chemical composition but are also sensitive to 
configuration, polymorphism and to the presence of crystalline domains. Data from Raman 
spectroscopy is complementary to that from IR spectroscopy in the sense that both give 
information on the vibrational structure of a molecule, however, they are based on different 
features. IR spectroscopy is useful for the analysis of strongly polar bonds while Raman is 
more useful for analysis of non-polar or symmetrical bonds. Raman spectroscopy has been 
shown to be more sensitive to the detection of different polymorphs than IR spectroscopy, 
whereas, when polymorphic changes involve hydrogen bonding, IR spectra exhibit larger 
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differences than Raman spectra [Deeley et al., 1991; Tudor et al., 1991; Sloane, 1971]. IR 
and Raman spectra are complex with a large number of bands in the fingerprint region 
(1500 cm-1 - 500 cm-1). Such detailed spectra are not unexpected since the active ingredient 
contains a large number of different functional groups, as illustrated in Figure 2.1. 
 
The IR spectrum illustrated in Figure 2.4 shows that the active ingredient is able to form 
hydrogen bonds, depending on its conformation. This is an important information for further 
investigations of the active ingredient interaction in the different polymer matrix.  
 
The Raman spectra as illustrated in Figure 2.5 clearly show two conformations of the active 
ingredient. Sample A which is the active ingredient as received from CarboGen is 
distinguished from samples B to G (recrystallisation in diverse solvents) by a shift from 
1528 cm-1 to 1520 cm-1. This region represents the amid II and the benzene ring of the side 
chain of the molecule as previously determined with IR spectra which is more specific for 
functional group determination. There are, additionally to this shift, other changes concerning 
band ratio intensity. Raman confirms the IR assumptions that there are two conformations of 
active ingredient in the solid state.  
 
In further investigations using X-ray diffraction analysis, the crystalline parameters of both 
conformations were checked by analyzing the solid samples A and B. The patterns of the 
diffractogram (Figure 2.6) exhibited well-defined bands for sample A which was in the 
crystalline form. However, sample B was in the amorphous form as indicated by the broad 
diffusion bands (Figure 2.7). It was therefore conclude that all samples with the same Raman 
spectra as sample B were also in the amorphous conformation. This was the case for all 
solid samples recrystallized in the various solvent listed in Table 2.1. 
 
This set of analyses indicated that sample A was crystalline and sample B was amorphous. 
As the Raman spectra of sample C, D, E, F and G were identical to the spectra of sample B, 
it can be concluded that the conformation of the active ingredient of the five samples was 
also amorphous.  
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5. Conclusion 
 
Prior to the development of new sustained release injectables formed in-situ, the selected 
active ingredient NOA449851 was characterized with regard to solubility parameters in 
various organic solvents. A high solubility for the active ingredient was found in NMP, 
glycerol formal and triacetin, which are also strong solvents for the PLA/PLGA polymers. The 
solubility of NOA449851 was also investigated in other excipients which could be used in the 
formulation as co-solvents. Low solubility was observed in the lipophilic solvent Miglyol 812, 
as well as for hydrophilic solvents such as propylenglycol, anhydrous glycerol and water for 
chromatography. However, NOA449851 was highly soluble in ethanol absolute and in 
PEG 300.  
 
In addition, morphological conformation of the active ingredient NOA449851 was 
investigated using Raman and Infrared spectroscopy, as well as X-ray diffraction. Two 
conformations of the active ingredient in the solid state could be distinguished. The 
crystalline compound as received from CarboGen and the amorphous compound, after 
recrystallized in any of the solvents investigated. The conformation of the active ingredient in 
the solid state may influence its solubility and therefore its release rate from the injectable 
implant. 
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Chapter 3 
 
In-vitro investigations of sustained release injectables 
formed in-situ  
 
 
1. Introduction and objectives  
 
Dissolution testing has emerged as a highly valuable in-vitro test to characterize drug product 
performance. It is an important tool to guide drug product development and to select 
appropriate formulations for in-vivo tests. In order to investigate in-vitro release of the active 
ingredient NOA449851 from different sustained release injectables formed in-situ, several 
formulations varying in type of solvent, type of polymer, amount of solvent and of drug 
substance were manufactured and injected in a dissolution test apparatus. The release 
kinetics of the drug from these polymer based formulations were followed over a period of 40 
days. 
 
In addition, interactions between PLA polymers, active ingredient, solvents and water were 
evaluated through the construction of ternary phase diagrams. Compositions at precipitation 
were recorded in function of the components concentration and of the solvent mixture used. 
 
Finally, vibrational spectroscopy was used to investigate in-vitro solidified implants. Raman 
spectroscopy appeared to be a suitable method for analysing the samples directly from solid 
devices without any special preparation. The analysis focused mainly on possible polymorph 
conformations of the active ingredient in the solid implants, depending on the solvent mixture 
used in the formulation. Detection of interactions between active ingredient and polymer 
matrix was also of interest. 
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2. Materials and methods 
2.1. Materials 
 
The drug substance NOA449851 was obtained from CarboGen Laboratories, Aarau, CH. 
The polymers PLA, 85/15 PLGA and 75/25 PLGA (inherent viscosity of 0.68 dl/g, 0.63 dl/g 
and 0.67 dl/g in trichloromethane at 30°C, respectively) were provided by Birmingham 
Polymers Inc., Birmingham, AL, USA. Triacetin, NMP, glycerol formal and anhydrous glycerol 
were purchased from Fluka AG, Buchs, CH. Ethanol absolute, methanol and water for 
chromatography were obtained from Merck Inc., Darmstadt, Germany. Miglyol 812 was 
provided by Hänseler AG, Herisau, CH. Solutol HS 15® was purchased from BASF, 
Ludwigshafen, D. All solvents were of reagent analytical grade. 
 
2.2. Methods 
 
2.2.1. In-vitro releasing profiles 
2.2.1.1. Preparation of sustained release injectables formed in-situ  
 
Polymer (PLA, 85/15 PLGA or 75/25 PLGA) and solvent (triacetin, NMP or glycerol formal) 
were weighed into a 50 ml beaker and stirred at 300 rpm for approximately 12 hours at a 
temperature of about 60°C (magnetic stirrer, Ikamag, RET S8TM, Ikawerke, Stauffen, D). After 
complete dissolution of the polymer, the solution was cooled to room temperature and the 
active ingredient was added and mixed with the polymer solution. The mixture was gently 
stirred at 100 rpm until the active ingredient was completely dissolved and finally the 
formulation was drawn up in a 2 ml syringe. 
 
In case of addition of co-solvent to the formulation (e.g. Miglyol 812, ethanol absolute, 
glycerol formal or anhydrous glycerol), the active ingredient was first triturated with this 
excipient before the mixture was added to the polymer solution.  
 
Changes in composition of the formulations concerned type of solvent, type of polymer, drug 
loading, polymer loading as well as substitution of a fraction of the main solvent with 
co-solvents. The exact compositions (% w/w) of the sustained release injectables formed 
in-situ investigated in-vitro are listed in Tables 3.1 to 3.10. 
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Table 3.1: Composition (% w/w) of formulations using different solvents (triacetin, NMP and 
glycerol formal). 
 
Component PLA-AI(1:1) NMP; PLA-AI(1:1) GF; PLA-AI(1:1) 
 [% (w/w)] [% (w/w)] [% (w/w)] 
NOA449851 
PLA 
triacetin 
NMP 
glycerol formal 
17.00 
17.00 
66.00 
- 
- 
17.00 
17.00 
- 
66.00 
- 
17.00 
17.00 
- 
- 
66.00 
 
Table 3.2: Composition (% w/w) of formulations using different types of polymer (PLA, 85/15 
PLGA and 75/25 PLGA). The weight polymer to drug ratio was 1:1 in all three 
formulations. 
 
Component PLA-AI(1:1) 85/15 PLGA-AI(1:1) 75/25 PLGA-AI(1:1) 
 [% (w/w)] [% (w/w)] [% (w/w)] 
NOA449851 
PLA 
85/15 PLGA 
75/25 PLGA 
triacetin 
17.00 
17.00 
- 
- 
66.00 
17.00 
- 
17.00 
- 
66.00 
17.00 
- 
- 
17.00 
66.00 
 
Table 3.3: Composition (% w/w) of formulations using different types of polymer (PLA, 85/15 
PLGA and 75/25 PLGA). The weight polymer to drug ratio was 5:1 in all three 
formulations. 
 
Component PLA-AI(5:1) 85/15 PLGA-AI(5:1) 75/25 PLGA-AI(5:1) 
 [% (w/w)] [% (w/w)] [% (w/w)] 
NOA449851 
PLA 
85/15 PLGA 
75/25 PLGA 
triacetin 
3.40 
17.00 
- 
- 
79.60 
3.40 
- 
17.00 
- 
79.60 
3.40 
- 
- 
17.00 
79.60 
 
Table 3.4: Composition (% w/w) of formulations using different types of polymer (PLA, 85/15 
PLGA and 75/25 PLGA). The weight polymer to drug ratio was 100:1 in all three 
formulations. 
 
Component PLA-AI(100:1) 85/15 PLGA-AI(100:1) 75/25 PLGA-AI(100:1) 
 [% (w/w)] [% (w/w)] [% (w/w)] 
NOA449851 
PLA 
85/15 PLGA 
75/25 PLGA 
triacetin 
0.17 
17.00 
- 
- 
82.83 
0.17 
- 
17.00 
- 
82.83 
0.17 
- 
- 
17.00 
82.83 
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Table 3.5: Composition (% w/w) of formulations with different amounts of PLA polymer. The 
weight polymer to drug ratios were 1:1, 3:4 and 1:2. 
 
Component PLA-AI(1:1) PLA-AI(3:4) PLA-AI(1:2) 
 [% (w/w)] [% (w/w)] [% (w/w)] 
NOA449851 
PLA 
triacetin 
17.00 
17.00 
66.00 
17.00 
12.75 
70.25 
17.00 
8.50 
74.50 
 
Table 3.6: Composition (% w/w) of the formulation with 10.00 % Miglyol 812 as lipophilic 
co-solvent. 
 
Component Co-solvent (10 %) Miglyol, PLA-AI(1:1) 
 [% (w/w)] 
NOA449851 
PLA 
Miglyol 812 
triacetin 
17.00 
17.00 
10.00 
56.00 
 
Table 3.7: Composition (% w/w) of formulations with 5.00 %, respectively 10.00 % anhydrous 
glycerol as hydrophilic co-solvent. 
 
Component Co-solvent (5 %) 
glycerol, PLA-AI(1:1) 
Co-solvent (10 %) 
glycerol, PLA-AI(1:1) 
 [% (w/w)] [% (w/w)] 
NOA449851 
PLA 
glycerol anhydrous 
triacetin 
17.00 
17.00 
5.00 
61.00 
17.00 
17.00 
10.00 
56.00 
 
Table 3.8: Composition (% w/w) of the formulation with 10.00 % glycerol formal as hydrophilic 
co-solvent. 
 
Component Co-solvent (10 %) GF, PLA-AI(1:1) 
 [% (w/w)] 
NOA449851 
PLA 
glycerol formal 
triacetin 
17.00 
17.00 
10.00 
56.00 
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Table 3.9: Composition (% w/w) of the formulation with 10.00 % NMP as hydrophilic 
co-solvent. 
 
Component Co-solvent (10 %) NMP, PLA-AI(1:1) 
 [% (w/w)] 
NOA449851 
NMP 
glycerol formal 
triacetin 
17.00 
17.00 
10.00 
56.00 
 
Table 3.10: Composition (% w/w) of formulations with 10.00 % ethanol absolute as hydrophilic 
co-solvent. The weight polymer to drug ratios were 1:1, 3:4 and 1:2. 
 
Component Co-solvent (10 %) 
ethanol, PLA-AI(1:1) 
Co-solvent (10 %) 
ethanol, PLA-AI(3:4) 
Co-solvent (10 %) 
ethanol, PLA-AI(1:2) 
 [% (w/w)] [% (w/w)] [% (w/w)] 
NOA449851 
PLA 
ethanol absolute 
triacetin 
17.00 
17.00 
10.00 
56.00 
17.00 
12.75 
10.00 
60.25 
17.00 
8.50 
10.00 
64.50 
 
2.2.1.2. Solubilizing effect of Solutol HS 15®on solubility of NOA449851 in water 
 
The solubilizing effect of Solutol HS 15® on solubility of NOA449851 in water was 
investigated to determine an adequate composition for the dissolution medium solution. 
Therefore five aqueous solutions containing 0 %, 1 %, 3 %, 5 % and 10 % (w/w)  
Solutol HS 15® were prepared. An excess amount of NOA449851 was equilibrated in these 
solutions by stirring at 300 rpm over night at room temperature. After centrifugation and 
appropriate dilution, concentration of NOA449851 in the supernatant solutions was 
determined using the HPLC-method described in Chapter 2, Section 2.2.1. 
 
2.2.1.3. Dissolution method: modified USP basket method  
 
A Sotax AT 7 SmartTM (Sotax AG, Basel, CH) was used as the dissolution apparatus. The six 
vessels of the apparatus were each filled with one liter of dissolution medium which 
consisted of an aqueous solution containing 5 % (w/w) Solutol HS 15®. Since this excipient is 
semi solid at room temperature, it was first liquified in a microwave oven for five minutes and 
then added to demineralised water. The solution was finally homogenised using a magnetic 
stirrer at 300 rpm for about ten minutes. The vessels of the dissolution apparatus were 
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immersed in a water bath and subsequently heated to a temperature of 37°C. Copper sulfate 
2 % was used as anti-microbial preservative in the water bath.  
 
Water permeable felt bags were individually prepared and placed in each basket of the 
dissolution apparatus. Formulations were taken up into 2 ml syringes (Braun Inc., 
Melsungen, Germany) and injected through 16 G needles (Becton and Dickenson, Basel, 
CH) into the felt bags. The syringes were weighed before and after injection and the 
corresponding amount of active ingredient was calculated from the concentration of 
NOA449851 in the formulation. Approximately 2.5 g of each formulation, equivalent to an 
injection volume of 2 ml, were injected into the baskets. Each formulation was investigated 
for in-vitro dissolution test in triplicate. To keep sink conditions, dissolution medium was 
replaced as soon as the drug concentration reached 0.01 %. 
 
The baskets rotated at 100 rpm over a period of 40 days. However in case of formulations 
“Co-solvent (10 %) ethanol, PLA-AI(3:4)” and “Co-solvent (10 %) ethanol, PLA-AI(1:2)”, 
dissolution tests were continued up to 120 days.  
 
Samples were taken initially after 2, 4, 8, 24 and 32 hours and subsequently at almost every 
working day until the end of the experiment. A volume of 1 ml of the dissolution medium was 
taken from each vessel, using a 2 ml syringe and filled into a 2 ml vial. Afterwards, about 
0.5 ml of each sample were transferred into an amber coloured HPLC-vial. The NOA449851 
concentration in the dissolution medium was determined immediately after sample collection, 
using the HPLC-method as described in Chapter 2, Section 2.2.1. 
 
2.2.1.4. Graphical and statistical evaluation of the release profiles 
 
The concentration of active ingredient detected in the dissolution medium was plotted against 
time. On the X-axis, time was represented in days, whereas on the Y-axis, cumulative 
percentage (% w/w) of active ingredient released from the formulation was illustrated. 
 
The linear phase of the release profile was selected to extrapolate a straight line with, when 
possible, a correlation coefficient value of at least 0.98. The corresponding equation of type 
“y = ax + b” was calculated, where “a” is the rate of release of active ingredient per day 
during the linear phase (%/day), and “b”, the ordinate to the origin, give indication about 
magnitude of the initial burst effect. An additional factor “b/a” was also calculated to qualify 
and compare the various kinetic profiles. 
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2.2.2. Ternary phase diagrams 
2.2.2.1. PLA precipitation 
 
Stock PLA polymer solutions (30.00 % w/w) were prepared with triacetin or NMP as solvent. 
Serial dilutions using the appropriate solvent were made to prepare different concentrations 
of the polymer. Additionally, PLA polymer solutions were prepared substituting a fraction of 
the solvent triacetin with one of the co-solvents Miglyol 812, glycerol formal or ethanol 
absolute. The concentration of the co-solvent represented 10.00 % (w/w) of the initial 
polymer solution. The vials containing the polymeric solution were placed in a water bath 
kept at 25°C. Demineralised water was added to 10 µl aliquots until polymer precipitation 
was observed. Composition at precipitation was recorded using the known initial weight of 
polymer, solvent and the weight of water that was added. Composition at precipitation were 
then plotted as ternary graphs. 
2.2.2.2. NOA449851 precipitation 
 
Similar process as described in Section 2.2.2.1 was applied to active ingredient solutions to 
determine the quantity of water needed to observe drug precipitation. The solvents triacetin 
and NMP were used for preparing active ingredient solutions of different concentrations.  
 
2.2.3. Raman spectroscopy 
 
Raman spectroscopy was used for analytical assessment of molecular structure of the active 
ingredient within the polymeric matrix. This analytic method is particularly appropriate for the 
detection of different polymorphic forms. 
2.2.3.1. Preparation of in-vitro formed solid implants for Raman spectroscopy 
 
Various formulations were selected for Raman spectroscopy investigations. First, the 
formulation “PLA-AI(1:1)” which contained PLA as polymer and triacetin as unique solvent 
was chosen. Three further formulations containing as co-solvents glycerol formal 
(“Co-solvent (10 %) GF, PLA-AI(1:1)”), absolute ethanol (“Co-solvent (10 %) ethanol, PLA-
AI(1:1)”) and Miglyol 812 (“Co-solvent (10 %) Miglyol, PLA-AI(1:1)”) were selected for 
 Chapter 3: In-vitro investigations  
 
 
54 
spectral investigations. Exact compositions of formulations are described in Tables 3.1, 3.6, 
3.8 and 3.10.  
 
For preparation of the solid implants, 0.5 g of each formulation were injected into a 100 ml 
beaker containing 75 ml demineralised water. Formulations were kept for 48 hours at room 
temperature to allow fluid convection and formation of the solid implants. 
2.2.3.2. Raman measurements 
 
Raman spectroscopy was performed on in-vitro formed solid implants according to the 
method described in Chapter 2, Section 2.2.5. 
 
The FT Raman spectra were recorded with a Bruker RFS 100 FT Raman spectrometer 
equipped with a liquid nitrogen cooled germanium detector. The resolution was 4 cm-1 and 
250 scans were accumulated by using a laser output of 600 mW. The spectra were corrected 
for instrumental response. 
 
3. Results 
 
In-vitro release of the active ingredient NOA449851 from various sustained release 
injectables formed in-situ was studied using dissolution testing during 40 days. Composition 
of investigated formulations varied with respect to the type of solvent and biodegradable 
polymer as well as the use of different co-solvents. Different drug and polymer 
concentrations were also tested. In addition, ternary phase diagrams with different solvent 
mixtures were carried out to determine the amount of water needed to reach polymer or 
active ingredient precipitation. Finally, Raman spectra were taken from solid implants formed 
in-vitro to observe possible conformation changes or interactions due to the different solvent 
mixtures of the formulation compostition. 
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3.1. Solubilizing effect of Solutol HS 15® for NOA449851 in aqueous solution 
 
Figure 3.1 illustrates solubility of NOA449851 in aqueous solutions containing  
Solutol HS 15®. Concentration of Solutol HS 15® in water varied from 0 % to 10 %. Solubility 
of the active ingredient NOA449851 in the different solutions increased with the amount of 
surfactant added to the water. In pure water, the amount of NOA449851 dissolved was below 
the detection limit of the HPLC method, whereby a concentration of 0.002 % NOA449851 
was measured with 1 % of Solutol HS 15®. In solutions with 3 % and 5 % Solutol HS 15®, a 
concentration of 0.041 % and 0.083 %, respectively, of the active ingredient were reached. A 
concentration of 0.219 % NOA449851 was found in a 10 % Solutol HS 15® solution. 
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Figure 3.1: Maximal concentrations [% (w/v)] of NOA449851 in aqueous Solutol HS 15® 
solutions. Concentration of Solutol HS 15® varied from 0 % to 10 % (w/w). 
 
3.2. In-vitro release profiles 
 
Results of in-vitro release profile parameters from sustained injectables formed in-situ are 
summarised in Table 3.11. Initial burst duration (in days) as well as fraction of total drug 
released during this period (in % w/w) are listed. Rate of drug release during the second 
phase (in fraction of total per day (%/d)) was derived from the observed linear release 
profiles. The fraction of the total drug released after the 40 days of dissolution testing was 
listed (in % w/w). The equation of type “y = ax + b” extrapolated from the linear phase as well 
as the factor “b/a” were calculated for each tested formulation. The “b/a” factor of an ideal 
sustained release profile of zero order kinetic without any initial burst would converge to the 
value of 1. It is also indicated if the formulation was selected for further in-vivo tests in 
animals (Chapter 4).  
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Table 3.11: Overview of parameters describing the in-vitro drug release profiles of in-situ formed 
release injectables. 
 
Formulation Initial burst  
Drug 
release 
during 
initial 
burst  
Release 
rate 
during 
linear 
phase 
Drug 
release 
after 40 
days 
 
Mathematical 
equation of type 
“y = ax + b” 
Factor 
“b/a” 
Test 
in-
vivo 
 
 
[d] [%] [%/d] [%] 
   
PLA-AI(1:1) 6 17.57 0.73 42.64 y = 0.73x + 14.29 19.5 Yes 
NMP; PLA-AI(1:1) 7 35.21 0.51 52.51 y = 0.51x + 34.05 67.0 No 
GF; PLA-AI(1:1) 7 24.13 0.71 49.79 y = 0.71x + 21.37 30.1 No 
85/15 PLGA-AI(1:1) 6 16.55 0.72 41.90 y = 0.72x + 12.43 17.2 No 
75/25 PLGA-AI(1:1) 6 13.00 0.75 39.08 y = 0.75x + 8.04 10.7 No 
PLA-AI(5:1) 6 14.15 0.05 16.05 y = 0.05x + 14.22 296.2 No 
85/15 PLGA-AI(5:1) 6 12.91 0.06 14.75 y = 0.06x + 14.69 268.6 No 
75/25 PLGA-AI(5:1) 6 14.11 0.05 16.39 y = 0.05x + 13.16 284.9 No 
PLA-AI(100:1) 6 18.03 0.06 21.69 y = 0.06x + 19.76 329.3 No 
85/15 PLGA-AI(100:1) 6 18.76 0.11 25.06 y = 0.11x + 19.81 180.1 No 
75/25 PLGA-AI(100:1) 6 19.59 19.59 76.54 y = 0.18x + 19.31 107.3 No 
PLA-AI(1:2) 6 72.89 0.29 83.58 y = 0.29x + 72.84 248.5 No 
PLA-AI(3:4) 6 60.13 0.35 72.85 y = 0.35x + 60.11 173.7 Yes 
Co-solvent (10 %) 
Miglyol, PLA-AI(1:1) 13 38.50 0.15 42.60 y = 0.15x + 36.72 241.6 No 
Co-solvent (5 %) 
glycerol, PLA-AI(1:1) 7 12.76 0.87 40.54 y = 0.87x + 5.65 6.5 No 
Co-solvent (10 %) 
glycerol, PLA-AI(1:1) 7 9.82 0.84 36.65 y = 0.84x + 2.67 3.1 Yes 
Co-solvent (10 %) GF, 
PLA-AI(1:1) 7 15.86 0.45 31.31 y = 0.45x + 13.46 30.2 Yes 
Co-solvent (10 %) 
NMP, PLA-AI(1:1) 7 12.40 0.70 37.51 y = 0.70x + 6.85 9.8 No 
Co-solvent (10 %) 
ethanol, PLA-AI(1:1) 1 4.46 1.25 52.22 y = 1.25x + 2.46 1.9 Yes 
Co-solvent (10 %) 
ethanol, PLA-AI(3:4) 7 30.76 0.29 52.15* y = 0.29x + 37.51 129.7 Yes 
Co-solvent (10 %) 
ethanol, PLA-AI(1:2) 7 49.94 0.11 59.78* y = 0.11x + 53.77 505.3 No 
 
* Experiments continued for 120 days. 
 Chapter 3: In-vitro investigations  
 
 
57 
3.2.1. Influence of type of solvent  
 
The excipients used to dissolve the polymer have a strong influence on the way the 
formulation coagulates after injection into an aqueous medium and therefore on the release 
characteristics of the sustained release injectables. Physico-chemical characteristics of the 
main solvent such as viscosity, lipophilicity and partition coefficient (octanol/water) are 
determinant during implant hardening process. The in-vitro drug release from formulations 
based on different solvents was compared. The selected solvents were triacetin 
(“PLA-AI(1:1)”), NMP (“NMP; PLA-AI(1:1)”) and glycerol formal (“GF; PLA-AI(1:1)”). The 
dynamic viscosity of triacetin is 17.4 mPa*s at 25°C and its log P-value is +0.25. NMP has a 
dynamic viscosity of 1.65 mPa*s and a log P-value of -0.38 [The Merck Index, 1996; Fiedler 
Lexikon, 2002]. 
 
All three excipients are excellent solvents for the PLA polymer [Matschke, 2002; Hatefi et al., 
2002; Brodbeck et al., 1999 (2)] as well as for the drug substance NOA449851 (Chapter 2). 
Concentrations of PLA polymer and of active ingredient in formulations were 17.00 % (w/w). 
For composition details, see Table 3.1. 
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The release profiles from formulations based on triacetin and on NMP are illustrated in 
Figure 3.2. Formulation “PLA-AI(1:1)” released 43 % of active ingredient after 40 days of 
dissolution test, while formulation “NMP; PLA-AI(1:1)” released 53 % in the same test 
conditions. Formulation with NMP showed a large initial burst, corresponding to 35 % of 
active ingredient released during the first 7 days and a relatively slow release rate during the 
second phase of the kinetic profile, which represented almost 0.51 %/d. In contrast, 
formulation with triacetin showed a slight initial burst corresponding to 18 % of active 
ingredient released within the first 7 days and a faster release rate during the linear phase 
representing 0.73 %/d. 
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Figure 3.2: Influence of solvent type on release of NOA449851 [% (w/w)] from sustained 
release injectables formed in-situ, related to time. Solvents used in the formulations 
were triacetin ( ) and NMP ( ).  
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The release profile from formulation based on the solvent glycerol formal is compared in 
Figure 3.3 to the release profile of the triacetin based formulation. Formulation “GF; PLA-
AI(1:1)” showed a slight increased initial release, with a fraction of 24 % of the total active 
ingredient released during the first 7 days of the dissolution test, while the formulation “PLA-
AI(1:1)” released only 18 % of the active ingredient into the medium during the same period. 
Release rate during the linear phase was very similar for both formulations, i.e. about 
0.73 %/d. The “b/a” factor was therefore higher for formulation “GF; PLA-AI(1:1)” than for 
formulation “PLA-AI(1:1)”, with values of 30.1 and 19.5, respectively . 
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Figure 3.3: Influence of solvent type on release of NOA449851 [% (w/w)] from sustained 
release injectables formed in-situ, related to time. Solvents used in the formulations 
were triacetin ( ) and glycerol formal ( ).  
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3.2.2. Influence of type of polymer 
 
In order to study the influence of polymers with different biodegradation properties on the 
in-vitro release of NOA449851 from sustained release injectables formed in-situ, formulations 
containing PLA (“PLA-AI(1:1)”), 85/15 PLGA (“85/15 PLGA-AI(1:1)”) or 75/25 PLGA polymers 
(“75/25 PLGA-AI(1:1)”) were investigated. Three batches were prepared changing only the 
type of polymer. All formulations contained 17.00 % NOA449851 and 66.00 % triacetin, with 
a weight polymer to drug ratio of 1:1. For composition details, see Table 3.2. 
 
Release curves of the active ingredient from the three formulations based on three types of 
polymer did not show any significant difference. Formulation “PLA-AI(1:1)” released 43 %, 
formulation “85/15 PLGA-AI(1:1)” 42 % and formulation “75/25 PLGA-AI(1:1)” 39 % 
NOA449851, respectively, during the 40 days of the dissolution test. Only small initial burst 
effects were observed in the three release profiles: after 6 days, 18 % of NOA449851 from 
PLA formulation, 17 % from 85/15 PLGA formulation and 13 % from 75/25 PLGA formulation, 
respectively, were released into the dissolution medium. Drug release observed during the 
second phase of the profile was similar for all three formulations, with a release rate of 
approximately 0.7 % of active ingredient per day. The three release profiles are illustrated in 
Figure 3.4. 
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Figure 3.4: Influence of polymer type on release of NOA449851 [% (w/w)]  from sustained 
release injectables formed in-situ, related to time. Formulations were based on 
PLA ( ), 85/15 PLGA ( ) and 75/25 PLGA ( ) polymers with a weight polymer to 
drug ratio of 1:1. 
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A second experiment was carried out in order to study the influence of polymers with 
different biodegradation properties, where the amount of active ingredient was reduced in all 
three formulations from 17.00 % to 3.40 %; polymer concentration was maintained at 
17.00 %, which resulted in a weight polymer to drug ratio of 5:1. In all three formulations, 
triacetin was used as solvent. For composition details, see Table 3.3. 
 
The release profiles of all three formulations were again very similar as showed in Figure 3.5. 
The drug released after 40 days dissolution test was 16 % for formulation “PLA-AI(5:1)”, 
15 % for formulation “85/15 PLGA(1:1)” and 16 % for formulation “75/25 PLGA(5:1)“. All 
formulations showed a substantial initial burst: within 6 days, already 14 % (“PLA-AI(5:1)”), 
13 % (“85/15 PLGA(5:1)”) and 14 % (“75/25 PLGA(5:1)“) of the active ingredient was 
released. Release rate of NOA449851 from the implant during the linear phase was very low 
for all formulations and represented about 0.05 % of active ingredient released per day. 
Consequently, the factors “b/a” in all three cases were very high (296, 268 and 284, 
respectively). 
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Figure 3.5: Influence of polymer type on release of NOA449851 [% (w/w)]  from sustained 
release injectables formed in-situ, related to time. Formulations were based on 
PLA ( ), 85/15 PLGA ( ) and 75/25 PLGA ( ) polymers with a weight polymer to 
drug ratio of 5:1. 
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A further dissolution test was carried out in order to study the influence of polymers with 
different biodegradation properties on the in-vitro drug release. This time, the polymer 
concentration was maintained at 17.00 % and the amount of active ingredient was reduced 
to 0.17 %, which resulted in a weight polymer to drug ratio of 100:1. In all three formulations, 
triacetin was used as solvent. For composition details, see Table 3.4. 
 
Release profiles of the three formulations were very similar for the first 20 days of the 
experiment. Formulations showed an initial burst effect within 6 days representing a release 
of active ingredient 18 % for “PLA-AI(100:1)”, 19 % for “85/15 PLGA(100:1)” and 20 % for 
“75/25 PLGA(100:1)“. Release rate during the second phase was very low for all three 
formulations and represented less than 0.2 % of active ingredient released per day. This lag 
phase ended for formulation “75/25 PLGA(100:1)“ at day 20 and was followed by a rapid 
drug release which could be described with the exponential formula “y = 5.7893 * e0.0613”. For 
the two other formulations “PLA-AI(100:1)” and “85/15 PLGA(100:1)”, the second phase 
lasted until the end of the dissolution experiment. After 40 days, the cumulative drug release 
was 22 % for formulation “PLA-AI(100:1)”, 25 % for formulation “85/15 PLGA(100:1)” and 
77 % for formulation “75/25 PLGA(100:1)“.  
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Figure 3.6: Influence of polymer type on release of NOA449851 [% (w/w)] from sustained 
release injectables formed in-situ, related to time. Formulations were based on 
PLA ( ), 85/15 PLGA ( ) and 75/25 PLGA ( ) polymers with a weight polymer to 
drug ratio of 100:1. 
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3.2.3. Influence of polymer load 
 
In order to study the influence of polymer load on the in-vitro release of NOA449851 from 
sustained release injectables formed in-situ, three different formulations were produced, 
containing, respectively 8.50 %, 12.75 % and 17.00 % PLA. The amount of active ingredient 
NOA449851 was kept constant at 17.00 % resulting in a weight polymer to drug ratio of 1:2, 
3:4, and 3:4, respectively. The amount of triacetin was adjusted (74.50 %, 70.25 %, 66.00 %) 
to compensate for the increased polymer concentration. For composition details, see Table 
3.5. 
 
The amount of active ingredient released during the 40 days of the dissolution testing was 
43 % for formulation “PLA-AI(1:1)”, 73 % for formulation “PLA-AI(3:4)” and 84 % for 
formulation “PLA-AI(1:2)”. Formulations “PLA-AI(3:4)” and “PLA-AI(1:2)” showed very strong 
initial burst effects, since 60 %, respectively 73 %, of the active ingredient was released 
within 6 days. During the same period of time, only 18 % of the NOA449851 was released 
from formulation “PLA-AI(1:1)”. The release rate during the linear phase was about 0.7 %/d 
for “PLA-AI(1:1)”, but only 0.3 %/d and 0.4 %/d for formulations “PLA-AI(3:4)” and “PLA-
AI(1:2)”. This resulted in high “b/a” factors of 248.5 and 173.7 for these two formulations. The 
drug release from the three different formulations is plotted in Figure 3.7.  
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Figure 3.7: Influence of polymer load on release of NOA449851 [% (w/w)] from sustained 
release injectables formed in-situ, related to time. PLA content varied from 
17.00 % ( ), to 12.75 % ( ) and to 8.50 % ( ). 
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3.2.4. Influence of co-solvents 
3.2.4.1. Influence of Miglyol 812 as co-solvent 
 
The influence of substituting a fraction of triacetin with Miglyol 812 as lipophilic co-solvent on 
drug release from sustained release injectables formed in-situ was investigated. For this 
purpose, release from two formulations was compared. Both formulations were based on 
PLA polymer and triacetin. Formulation “PLA-AI(1:1)” consisted of PLA (17.00 %), 
NOA449851 (17.00 %) and triacetin (66.00 %). In formulation “Co-solvent (10 %) Miglyol, 
PLA-AI(1:1)”, 10.00 % triacetin was replaced by Miglyol 812. The amount of NOA449851 and 
PLA polymer in both formulations resulted in a weight polymer to drug ratio of 1:1. For 
composition details, see Tables 3.1 and 3.6.  
 
Both formulations released about 43 % of the active ingredient during the 40 days of the 
dissolution test experiment. However, formulation “Co-solvent (10 %) Miglyol, PLA-AI(1:1)” 
showed an increased initial release, with a fraction of 39 % of active ingredient released 
during the first 13 days of the dissolution test. During the same time, the formulation “PLA-
AI(1:1)” released only about half of the amount, i.e. 24 % of the active ingredient into the 
medium. Thus, the release rate of the second phase was lower for the formulation 
“Co-solvent (10 %) Miglyol, PLA-AI(1:1)” (0.15 %/d) than for the formulation “PLA-AI (1:1)” 
(0.73 %/d). Both release profiles are represented in Figure 3.8. 
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Figure 3.8: Influence of co-solvent Miglyol 812 on release of NOA449851 [% (w/w)] from 
sustained release injectables formed in-situ, related to time. Formulation “PLA-
AI(1:1)” ( ) had triacetin as sole solvent, formulation “Co-solvent (10 %) Miglyol, 
PLA-AI(1:1)” ( ) contained triacetin as well as 10.00 % Miglyol 812. 
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3.2.4.2. Influence of anhydrous glycerol as co-solvent 
 
The influence of anhydrous glycerol used as hydrophilic co-solvent in the formulation on the 
drug release of NOA449851 from sustained release injectables formed in-situ was studied. 
Neither the PLA polymer, nor the active ingredient NOA449851 were soluble in the pure 
excipient. Formulation “PLA-AI(1:1)” consisted of 17.00 % PLA as biodegradable polymer, 
17.00 % of NOA449851 as active ingredient and 66.00 % of triacetin as solvent. In 
formulations “Co-solvent (5 %) glycerol, PLA-AI(1:1)” and “Co-solvent (10 %) glycerol, PLA-
AI(1:1)”, 5 % respectively 10 % triacetin was replaced with anhydrous glycerol. As anhydrous 
glycerol was not completely miscible with triacetin, a very viscous emulsion was formed. For 
composition details, see Tables 3.1 and 3.7. 
 
The three release profiles are represented in Figure 3.9 where it can be seen that the burst 
effect was reduced with increased amount of co-solvent anhydrous glycerol. In formulation 
“PLA-AI(1:1)”, which did not contain co-solvent, 18 % of the active ingredient was released 
during the first 7 days, while 13 % and 10 % of drug were released from formulations 
“Co-solvent (5 %) glycerol, PLA-AI(1:1)” and “Co-solvent (10 %) glycerol, PLA-AI(1:1)” 
respectively. The release rate during the linear phase was very similar for all three 
formulations, i.e. about 0.7 to 0.8 %/d. The “b/a” factor decreased when the amount of 
anhydrous glycerol was increased, with values of 19.5, 6.5 and 3.1, respectively. 
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Figure 3.9: Influence of co-solvent anhydrous glycerol on release of NOA449851 [%(w/w)] from 
sustained release injectables formed in-situ, related to time. Formulation ( ) had 
only triacetin as solvent. To the other formulations, 5.00 % ( ) or 10.00 % ( ) of 
anhydrous glycerol was added.  
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3.2.4.3. Influence of glycerol formal as co-solvent 
 
In order to examine the influence of a second hydrophilic co-solvent on the NOA449851 
in-vitro release from sustained release injectables formed in-situ, two further release profiles 
were compared. The hydrophilic co-solvent investigated was glycerol formal in a 
concentration of 10.00 %. Both formulations were based on PLA polymer and triacetin. For 
composition details, see Tables 3.1 and 3.8.  
 
It was found that 43 % of the drug was released after 40 days from formulation “PLA-AI(1:1)” 
and only 31 % from formulation “Co-solvent (10 %) glycerol formal, PLA-AI(1:1)”. Both 
release profiles showed a slight initial burst: after 7 days, formulation “PLA-AI(1:1)” released 
18 % of the active ingredient and formulation “Co-solvent (10 %) glycerol formal PLA-AI(1:1)” 
17 %. The main difference in the release behaviour was observed during the second linear 
phase. The release rate of the formulation “PLA-AI(1:1)” was 0.73 %/d, while drug release 
from formulation “Co-solvent (10 %) glycerol formal, PLA-AI(1:1)” was slower with a rate of 
0.45 %/day. Both dissolution profiles are illustrated in Figure 3.10. 
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Figure 3.10: Influence of co-solvent glycerol formal on release of NOA449851 [% (w/w)] from 
sustained release injectables formed in-situ, related to time. Formulation “PLA-
AI(1:1)” ( ) contained triacetin as unique solvent. In formulation “Co-solvent (10 %) 
glycerol formal, PLA-AI(1:1)” ( ), 10.00 % triacetin was substituted with glycerol 
formal.  
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3.2.4.4. Influence of NMP as co-solvent 
 
The influence of NMP used as hydrophilic co-solvent at concentration of 10.00 % in the 
formulation on the drug release of NOA449851 from sustained release injectables formed 
in-situ was studied. For this purpose the release from this formulation was compared with the 
one of formulation “PLA-AI(1:1)”, which contains only triacetin as solvent. Both formulations 
were based on PLA polymer and triacetin. Formulation “PLA-AI(1:1)” consisted of PLA 
(17.00 %), NOA449851 (17.00 %) and triacetin (66.00 %). In formulation “Co-solvent (10 %) 
NMP, PLA-AI(1:1)”, 10.00 % triacetin was replaced by NMP. The amount of NOA449851 and 
PLA polymer in both formulations resulted in a polymer to drug ratio of 1:1. For composition 
details, see Tables 3.1 and 3.9.  
 
Both release profiles are represented in Figure 3.11 where it can be seen that the burst effect 
was reduced with the use of NMP as co-solvent. In formulation “PLA-AI(1:1)”, which did not 
contain co-solvent, 18 % of the active ingredient was released during the first 7 days, while 
12.4 % of drug were released from formulations “Co-solvent (10 %) NMP, PLA-AI(1:1)”. The 
release rate during the linear phase was similar for both formulations, i.e. about 0.7 %/d. 
Consequently, the “b/a” factor was lower for formulation “Co-solvent (10 %) NMP, PLA-
AI(1:1)” than for formulation “PLA-AI(1:1)”, with values of 9.8 and 19.5, respectively . 
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Figure 3.11: Influence of co-solvent NMP on release of NOA449851 [% (w/w)] from sustained 
release injectables formed in-situ, related to time. Formulation “PLA-AI(1:1)” ( ) 
contained triacetin as unique solvent. In formulation “Co-solvent (10 %) NMP, PLA-
AI(1:1)” ( ), 10.00 % triacetin was substituted with NMP.  
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3.2.4.5. Influence of ethanol as co-solvent 
 
The effect of 10 % absolute ethanol as co-solvent on the in-vitro release from sustained 
release injectables formed in-situ was studied by comparing the release profiles of the 
formulations “PLA-AI(1:1)” and “Co-solvent (10 %) ethanol PLA-AI(1:1)”. The amounts of 
PLA polymer and active ingredient were constant (17.00 %) in both formulations. There were 
only changes in the solvent which consisted of 66.00 % of triacetin in formulation “PLA-
AI(1:1)” and of 56.00 % of triacetin and 10.00 % of ethanol in formulation “Co-solvent (10 %) 
ethanol, PLA-AI(1:1)”. For composition details, see Tables 3.1 and 3.9. 
 
The release of active ingredient from both formulations was quite similar. The drug amount 
released during the 40 days of the experiment was 43 % for formulation “PLA-AI(1:1)” and 
52.2 % for formulation “Co-solvent (10 %) ethanol PLA-AI(1:1)”. However, the slight initial 
burst effect observed for formulation “PLA-AI(1:1)” practically disappeared for formulation 
“Co-solvent (10 %) ethanol PLA-AI(1:1)”. The drug release was linear from the second day 
after application and reached a release rate of 1.25 %/d. The drug release profile converged 
to the desired zero order kinetic with a “b/a” factor of 1.9. Formulation profiles of  
“PLA-AI(1:1)” and of “Co-solvent (10 %) ethanol PLA-AI(1:1)” are represented in Figure 3.12. 
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Figure 3.12: Influence of co-solvent ethanol on release of NOA449851 [% (w/w)] from sustained 
release injectables formed in-situ, related to time. Formulation ( ) contained 
triacetin as unique solvent, while in formulation ( ) 10.00 % of triacetin was 
replaced by ethanol. 
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Two additional formulations with 10.00 % ethanol as co-solvent and containing 12.75 % PLA 
polymer (“Co-solvent (10 %) ethanol PLA-AI(3:4)”) and 8.5 % PLA polymer (“Co-solvent (10 
%) ethanol PLA-AI(1:2)”) were produced. The concentration of active ingredient was 
maintained at 17.00 %, leading to polymer to drug ratios of 3:4 and 1:2, respectively. Their 
release profiles were compared with the formulation “Co-solvent (10 %) ethanol PLA-AI(1:1)” 
which contained also 10.00 % ethanol as co-solvent and 17.00 % PLA polymer. The in-vitro 
release profiles of both new formulations were determined over a period of 120 days. 
 
The three release profiles are represented in Figure 3.13. They showed high initial burst 
effects with a drug release after 7 days of 31 % for formulation “Co-solvent (10 %) ethanol 
PLA-AI(3:4)” and 50 % for formulation “Co-solvent (10 %) ethanol PLA-AI(1:2)”. The release 
rates of the second linear phase were of 0.3 %/d and 0.1 %/d, which resulted in high “b/a” 
factors of 129.7 and 505.3, respectively. The total drug released into the medium after 120 
days was 70.6 % for “Co-solvent (10 %) ethanol PLA-AI(3:4)” and 64.9 % for “Co-solvent (10 
%) ethanol PLA-AI(1:2)”. 
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Figure 3.13: Influence of polymer load on release of NOA449851 [% (w/w)] from sustained 
release injectables formed in-situ, related to time. All three formulations contained 
10.00 % ethanol as co-solvent. The amount of PLA polymer was 17.00 % ( ), 
12.75 % ( ) and 8.50 % ( ). 
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3.3. Ternary phase diagrams 
3.3.1. PLA precipitation 
 
Ternary phase diagrams were drawn to determine the necessary amount of demineralised 
water needed to induce PLA polymer precipitation. The exact composition of the mixtures 
based on the solvents triacetin or NMP at precipitation of the PLA polymers are represented 
in Figure 3.14. The compositions at the left of the precipitation curves are single phase 
systems while compositions at the right of the curves are two-phases systems with 
precipitated polymers and dissolved polymers. For NMP based polymer solutions, the higher 
the PLA polymer concentration of the initial solution was, the less water was needed to reach 
precipitation. The quantity of water needed for precipitation varied from 0.5 % to 11.9 %. For 
triacetin based polymer solutions, the amount of water needed for precipitation also reduced 
with increased polymer concentration of the initial solution. However, the amount of water 
needed to induce polymer precipitation remained in a range between 3.2 % and 4.3 %. 
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Figure 3.14: Ternary phase diagram of polymer precipitation as a function of PLA polymer, 
solvent and water concentration [% (w/w)]. The solvents used were triacetin ( ) and 
NMP ( ). 
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Further ternary plots were constructed to investigate PLA polymer precipitation when water 
was added to polymer solutions based on various solvent mixtures. PLA polymers dissolved 
in triacetin mixed with 10 % of diverse co-solvents showed other precipitation properties as 
when dissolved in triacetin only. The co-solvents used were ethanol absolute, Miglyol 812 
and glycerol formal. The compositions of all mixtures at precipitation of the PLA polymers are 
represented in Figure 3.15. When the lipophilic co-solvent Migylol 812 represented  
10 % (w/w) of the solution, less water was needed for precipitation as without co-solvent. The 
water added to the Miglyol 812 containing polymer solution to observe PLA precipitation 
represented 0.7 % to 3.4 % of the mixture, while 3.2 % to 4.3 % of water were necessary for 
polymer precipitation when dissolved in the sole solvent triacetin. On the other hand, 
precipitation required more water when a hydrophilic co-solvent was added to the polymer 
solution. This was the case with the co-solvent ethanol absolute and with the co-solvent 
glycerol formal. For ethanol absolute containing solutions, the amount of water needed to 
reach PLA precipitation represented 6.1 % to 10.5 % of the mixture, while it represented 
5.0 % to 7.2 % for glycerol formal containing polymer solutions. For all solvent mixtures, the 
quantity of water required for PLA precipitation slightly decreased as the PLA concentration 
was increased in the initial mixture.  
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Figure 3.15: Ternary phase diagram of polymer precipitation as function of PLA polymer, solvent 
mixture and water concentration [% (w/w)]. The solvent mixtures were triacetin 
alone ( ), triacetin/Miglyol 812 ( ), triacetin/ethanol ( ) and triacetin/glycerol formal 
( ). 
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3.3.2. Active ingredient precipitation  
 
The ternary phase diagrams for both systems active ingredient/triacetin/water and 
active ingredient/NMP/water are shown in Figure 3.16. The amount of water needed to 
observe active ingredient precipitation increased with increased concentration in the initial 
mixture. The higher the drug concentration of the initial solution was, the less water was 
needed to reach precipitation. The quantity of water needed for active ingredient precipitation 
in NMP based solutions varied from 11.5 % to 33.2 %. For triacetin based drug solutions, the 
amount of water needed to induce polymer precipitation was in a range between 3.4 % and 
21.5 %. 
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Figure 3.16: Ternary phase diagram of active ingredient precipitation as a function of 
NOA449851, solvent and water concentration [% (w/w)]. Solvents used were 
triacetin ( ) and NMP ( ). 
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3.4. Raman spectroscopy 
 
Raman spectroscopy was used to investigate conformational morphology of in-vitro solidified 
implants. The analysis focused mainly on possible polymorph conformations of the active 
ingredient in the solid implants as well as detection of possible interactions between the 
active ingredient and the polymer matrix. The investigated solid implants were gendered from 
the formulations “PLA-AI(1:1)” (curve a), “Co-solvent (10 %) GF, PLA-AI(1:1)” (curve b), 
“Co-solvent (10 %) ethanol, PLA-AI(1:1)” (curve c), “Co-solvent (10 %) Miglyol, PLA-AI(1:1)” 
(curve d). 
 
Raman spectra of implants obtained after in-vitro solidification are illustrated in Figure 3.18 in 
a wavelength range from 300 cm-1 to 4000 cm-1. The intensity of the Raman signal of each 
component was not identical for every samples, as the composition of each implants was 
different. Various solvent mixtures were used, and the active ingredient content of each 
implant was different due to the various release properties of each implant. However, the 
signal for the amorphous conformation of the active ingredient, as determined in Chapter 2, 
was consistent in each solid implant (dotted line). Furthermore, the Raman bands position of 
all component remained unchanged, indicating no detectable interaction. Therefore, no 
polymorphic conformation change or interaction between the active ingredient and the 
polymer matrix were found. 
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Figure 3.18: Raman spectra plotted in the region between 4000 cm-1 and 300 cm-1 of the in-
vitro solidified implants from formulations “PLA-AI(1:1)” (a), “Co-solvent (10 %) 
GF, PLA-AI(1:1)” (b), “Co-solvent (10 %) ethanol, PLA-AI(1:1)” (c), “Co-solvent 
(10 %) Miglyol, PLA-AI(1:1)” (d). 
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4. Discussion 
4.1. Dissolution test method 
 
In order to investigate the in-vitro drug release from sustained release injectables formed 
in-situ, various dissolution tests were carried out. At the present time, no in-vitro method is 
described in the Pharmacopoeia for characterisation of such formulations. Therefore, a 
modified USP basket method was applied, using felt bags to prevent the liquid formulation 
from running out of the basket before solidification of the implant. This modified method has 
already been used previously for characterisation of release profiles from sustained release 
formulations formed in-situ and it showed sufficient discriminatory criteria to be further 
recommended [Matschke, 2002]. 
 
As the active ingredient NOA449851 is insoluble in water, it was important to determine an 
appropriate medium for the dissolution tests. In-vitro, the release rate depends on the active 
ingredient properties and on dissolution test conditions. These conditions can be modified to 
improve active ingredient solubility by adding alcohol or another organic solvent to the 
aqueous medium, or by increasing the agitation rate. Nevertheless, these methods lack 
physiological relevance. On the contrary, surfactants can be successfully added to the 
medium for dissolution tests without losing the physiological relevance, since the body has 
natural surfactants which help dissolving drugs with low water solubility [Noory et al., 2000; 
Shah et al., 1989].  
 
The surfactant Solutol HS 15® (polyethylene glycol-660-12-hydroxy stearate) was selected to 
increase the solubility of the active ingredient in water. Therefore, the solubility of 
NOA449851 was measured in aqueous medium containing Solutol HS 15® at concentrations 
varying from 0 % to 10 % (w/w). The addition of Solutol HS 15® led to a slight but sufficient 
increase of solubility of the active ingredient in water. In pure water, its concentration was 
below the detection limit of the HPLC method. A concentration of 0.04 % of active ingredient 
is reached in an aqueous medium containing 3 % Solutol HS 15®. A concentration of 5 % 
Solutol HS 15® in water raised the maximal concentration of NOA449851 up to 0.08 %. The 
active ingredient solubility in an aqueous medium with 10 % Solutol HS 15® was 0.22 %.  
 
The concentration of surfactant needed to be adjusted to maximise the sensitivity of the 
method without losing physiological relevance. One litre of an aqueous solution containing 
5 % Solutol HS 15® was found to be an optimal dissolution test medium for NOA449851. The 
medium was replaced with a new solution to guarantee sink conditions as soon as the active 
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ingredient concentration reached 0.01 %. Medium replacement is often used to study implant 
release characterisation when the dissolution testing lasts for several weeks. When the entire 
volume of dissolution medium is replaced with fresh solution, it is important that the dosage 
form remains intact so that no undissolved drug particles are lost [Rohrs et al., 2001]. 
 
4.2. Drug release profiles 
 
The in-vitro development studies were designed to ascertain the influence of critical 
parameters and variables on the final release characteristics of the formulation. The 
parameters  included were diverse polymer types, the concentration of the components of 
the formulations as well as the use of co-solvents.  
 
In the present experiments, the release profiles of NOA449851 from biodegradable 
PLA/PLGA polymer implants formed in-situ showed generally two distinct phases. The first 
phase, also called initial burst, is dependent on the solvent movements out of the implant 
formulations during the precipitation of the polymer. In addition, it is also related to the 
implant forming process. Directly after the injection into the basket of the dissolution 
apparatus, the solvents diffuse from the formulations into the aqueous dissolution medium, 
dragging the solved active ingredient with them. The burst is usually not desired because the 
drug which is released during this phase is not available for prolonged release. Even more 
important for potent substances or drugs with a narrow therapeutic window, this sudden 
release of a high drug dose may result in toxicity or other side effects. 
 
After injection of the formulation into the aqueous medium and after the solvent had diffused 
out of the formulation into the outer aqueous medium, the active ingredient is entrapped in 
the precipitated polymer matrix. The drug release after this time point, which is also called 
the linear phase, is attributed to a mixed drug diffusion and polymer erosion process 
[Miyajima et al., 1997; Shah et al., 1992]. 
 
The transition from the initial burst phase to the mixed diffusion and biodegradation 
controlled phase was indicated in the drug release profiles by the decline of the release 
curves. From these considerations can be deduced that a simple first order process was not 
sufficient to describe the release behavior of drugs from bulk degrading polymers. Therefore, 
a factor “b/a” was introduced for comparison of the various drug release profiles. A high “b/a” 
factor describes a profile with a substantial initial burst effect and a low release rate during 
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the linear phase. For a profile of zero order kinetic without any initial burst, the “b/a” factor 
would converge to the ideal value of 1.  
 
The mathematical results of all release profiles are listed in Table 3.11. The “b/a” factors can 
be divided in several groups, depending on the composition of the formulations. The “b/a” 
factor can be easily obtained from the graphical plots and allows rapid and objective 
comparisons of numerous release profiles. The formulation based on the solvent NMP 
reached a “b/a” factor of 67.0, while formulation based on glycerol formal reached a “b/a” 
factor of 30.1. For the formulations based on the solvent triacetin, and when the polymer to 
drug weight ratio was 1:1, all “b/a” factors were lower than 20. For all other polymer to drug 
ratios tested, the “b/a” factor was over 100, which is far away from the targeted drug release 
of zero order kinetic. There was no difference if the polymer or the active ingredient was in 
excess. Formulations with a polymer to drug weight ratio of 1:1 and containing co-solvents 
showed a variety of results. A “b/a” factor of 241.6 was obtained for the formulation 
containing the lipophilic co-solvent Miglyol 812. For the formulations with hydrophilic 
co-solvents, all “b/a” values were lower than 30, with an excellent result for the formulation 
containing absolute ethanol which reached the value of 1.9. Further formulations with ethanol 
as co-solvent were investigated, with polymer to drug weight ratios of 3:4 and 1:2. 
Substantial burst effects led to high “b/a” values of 129.7 and 505.3, respectively. 
 
4.2.1. Influence of solvent type 
 
In order to investigate the influence of the type of solvent on the drug release profile, three 
solvents were tested. Triacetin, NMP and glycerol formal were the excipients investigated as 
solvent in the sustained release formulations formed in-situ. It was found that the triacetin 
formulation “PLA-AI(1:1)” had a profile with a relative small initial burst and a great release 
rate during the linear phase. Formulations “NMP; PLA-AI(1:1)” and “GF; PLA-AI(1:1)” led to 
higher initial bursts, followed for the NMP based formulation by a linear phase with a lower 
release rate (Figures 3.2 and 3.3). 
 
The negative partition coefficient of NMP (log P = -0.38) indicates that this solvent is  highly 
water-miscible and therefore, after injection, diffused rapidly into the dissolution medium. 
This resulted in a high initial burst effect because the dissolved active ingredient is flushed 
out of the formulation simultaneously with the solvent. Apart from that, conditions leading to 
rapid phase separation, by decreasing the affinity between the solvent and the non solvent 
(here the dissolution medium) also promote the formation of a thick skin at the surface of the 
polymer-matrix [Graham et al., 1999]. It is then difficult for the active to diffuse through such 
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a dense barrier, and this may explain why the release rate during the second phase is 
reduced. 
 
Because triacetin is a short chain triglyceride, it is only sparingly miscible with water 
(log P = +0.25). Its use in the formulation decreased the affinity between the water and the 
polymer solution which resulted in a decrease in the water influx rate during implant 
formation. Conditions leading to a delayed precipitation promote more uniform sponge- like 
sublayers in the body of the implant. This is the case when triacetin is used as solvent. The 
final morphology of the implant had a direct influence on the resulting transport 
characteristics [Graham et al., 1999]. 
 
The drug release profiles illustrated in Figure 3.2 are therefore in accordance with the 
predictions of the different authors [McHugh et al., 1999; Graham et al., 1999; Brodbeck et 
al., 1999 (1), (2); Yewey et al., 1997]. NMP as a completely water miscible and strong 
solvent for the PLA polymers leads to a rapid implant solidification and consequently to a 
higher burst effect than the solvent triacetin. 
 
4.2.2. Different polymer types 
 
In order to study the influence of polymers with different biodegradation properties on the 
in-vitro release of NOA449851 from sustained release injectables formed in-situ, formulations 
based on PLA, 85/15 PLGA and 75/25 PLGA polymers were investigated. As reported in the 
literature, the hydrolysis of the polymers, mostly in presence of a minor amount of either 
lipophilic or hydrophilic drug, occurs in a period of about three months for 75/25 PLGA 
polymers, of about five months for 85/15 PLGA polymers and between six and twelve 
months for PLA polymers [Wang et al., 1997; Middleton et al., 2000]. The increase in lactic 
acid content decreases the degradation rate by reducing water uptake and making the ester 
bond less accessible to water, due to the hindrance by the bulky methyl group [Göpferich, 
1996].  
 
The polymer to drug weight ratio was 1:1 in the experiment represented in Figure 3.4, which 
is extremely high compared to the cited references. Surprisingly, no significant differences 
between the three types of polymer were observed. Due to the erosion properties of the 
different types of biodegradable polymers, it was expected that the release of active 
ingredient during the second phase, the mixed diffusion and erosion process, occurred faster 
when the glycolic unit ratio in the polymers became higher. The release rate of the active 
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ingredient during the linear phase was similar for all three formulations, varying from 
0.73 %/d for PLA, to 0.72 %/d for 85/15 PLGA and to 0.75 %/d for 75/25 PLGA. 
 
In order to investigate whether the identical release rates were determined by the high drug 
content which influenced the break down of the polymers, the dissolution tests were repeated 
with a lower amount of drug in the formulations. The high concentration of drug substance at 
the surface of the implant may have minimised the biodegradation effects of the different 
types of polymer and reduced the water penetration rate. Again, even with a polymer to drug 
weight ratio of 5:1 instead of 1:1, all three curves were very similar and no significant 
differences were observed during the linear phase (Figure 3.5).  
 
Obviously, the effects of the various biodegradation properties of PLA/PLGA polymers at the 
studied polymer to drug weight ratio of 5:1 and 1:1 on the release characteristics of 
NOA449851 were less important than expected. The experiments were stopped 40 days 
after injection into the dissolution apparatus. The erosion effects may have been more 
evident after a longer period.  
 
An additional experiment was carried out to study the effect of the polymer type on the drug 
release. The amount of active ingredient was further reduced to obtain a polymer to drug 
weight ratio of 100:1. As represented in Figure 3.6, the drug release was similar for all three 
formulations during the first half of the experiment. An initial burst effect as well as a second 
linear phase were observed for all three formulations. The second phase ended for the 
formulation based on 75/25 PLGA at day 20, followed by a fast and exponential drug release. 
For the formulations based on PLA and 85/15 PLGA, the second phase continued until the 
end of the dissolution test experiment. 
 
The profile of formulation “75/25 PLGA(100:1)“ showed a triphasic drug release, also referred 
to as the S release pattern phases. This has already been described for formulations based 
on biodegradable polymers, particularly concerning the release from microspheres [Wang et 
al., 1996; Cleland, 1997]. The release of the active ingredient is then controlled by erosion of 
the matrix and can be modified by choosing the appropriate chemical composition of the 
polymer. In the particular experiments, the effect of the polymer type can only be seen when 
the amount of active ingredient is decreased. The lipophilic properties of the active ingredient 
may reduce the penetration of water into the polymer matrix, leading to reduced erosion due 
to hydrolytic break of the ester bonds of the polymer. By reducing the loading of lipophilic 
drug in the implant, water can better enter the matrix and erode the polymer.  
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The conclusion of these series of experiments is that the drug release from sustained release 
injections formed in-situ was probably mainly due to diffusion phenomena. Only the third 
phase of the “75/25 PLGA(100:1)“ was effective matrix erosion controlled drug release. If 
erosion is slower than diffusion process, then the polymer controls the release by diffusion. 
Only if degradation is the fastest process, the drug release may be erosion controlled. Many 
systems made of degradable polymers are not truly degradation controlled drug delivery 
devices and their only advantage consists in the disappearance of the drug carrier through 
degradation, circumventing its removal [Göpferich, 1996].  
 
4.2.3. Active ingredient load  
 
The effect of active ingredient load was examined by comparing release profiles of 
formulations “PLA-AI(1:1)”, “PLA-AI(5:1)” and “PLA-AI(100:1)”, containing, respectively, 
17.00 %, 3.40 % and 0.17 % active ingredient. As the PLA content was maintained at 
17.00 %, the resulted polymer to drug weight ratios were 1:1, 5:1 and 100:1, respectively. 
Their in-vitro drug release profiles were compared with regard to the “b/a” factor. The “b/a” 
factor of formulation “PLA-AI(1:1)” was 19.5, while formulation “PLA-AI(5:1)” had a “b/a” 
factor of 296.2 and “PLA-AI(100:1)” of 329.3. The release patterns of the formulation with the 
polymer to drug weight ratio 1:1 was significantly closer to the targeted zero order release 
kinetic than the two other profiles.  
 
It is generally assumed that drug is released through the matrix by diffusion with a 
concentration gradient as driving force [McHugh et al., 1999; Graham et al., 1999; Dunn et 
al., 1996; Lambert et al., 1995]. If the release is mainly due to the Fickian‘s diffusion, then the 
driving force is generated by the concentration gradient. As the dissolution medium was 
changed to keep sink conditions, the formulation containing 17.00 % of drug had a bigger 
concentration gradient than the implant containing only 3.40 % of active ingredient. The 
diffusion phenomena during the linear phase was then much more important for formulation 
with the higher driving force and therefore the higher drug load. 
 
Another reason for these important differences in drug release profiles was that the amount 
of the solvent triacetin in formulation “PLA-AI(5:1)” and “PLA-AI(100:1)” was higher than in 
formulation “PLA-AI(1:1)” to compensate for the reduced active ingredient content. A higher 
amount of solvent led to a more pronounced initial burst because the fluid movement out of 
the implant was faster. Therefore the amount of active ingredient flushed out of the matrix 
together with the solvent was increased. 
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Eliaz et al., using 75/25 PLGA polymers dissolved in glycofurol as sustained release 
formulation, also observed a release rate which was highly dependent on drug loading. They 
suggested that, for low loading levels, the protein release was predominantly controlled by 
matrix degradation. For high protein loadings, the formation of large and interconnected 
pores throughout the matrix were responsible for the faster release [Eliaz et al., 2000 (1), (2); 
Eliaz et al., 1997]. The hypothesis of formation of pores within the polymer matrix leading to 
a faster release was already mentioned by Shah [Shah et al., 1993] and Chandrashekar 
[Chandrashekar et al., 1996]. It is also possible in the present study that channels were 
formed in the polymer matrix, leading to a higher drug release for formulation containing 
higher active ingredient concentrations.  
 
The effect of protein loading was also investigated by Yewey et al., by varying  bovine serum 
albumin (BSA) concentrations from 0.01 % to 20 %. In contrast to the results obtained above, 
as the protein load was increased, a smaller percentage of the total protein in the formulation 
was released. The authors suggested an increased protein-protein interaction within the 
polymer matrix [Yewey et al., 1997]. 
 
4.2.4. Polymer load 
 
In an attempt to modify the initial burst effect, release kinetics of drug from PLA formulations 
with different polymer loads were evaluated and followed over a period of 40 days. The 
release profiles of the formulations “PLA-AI(3:4)” and “PLA-AI(1:2)” containing, respectively, 
12.75 % and 8.50 % of PLA polymer both showed very large initial burst effects which 
represented a drug release during the first 6 days of 60.13 % and 72.89 %, respectively. As 
can be seen in Figure 3.7, the in-vitro initial burst was almost eliminated by increasing the 
polymer concentration to 17.00 % as in formulation “PLA-AI(1:1)”.  
 
At the initial phase, after injection of the polymer solution into an aqueous medium, the drug 
and the solvent diffuse out of the formulation into the surrounding medium. The higher the 
polymer concentration and therefore the viscosity are, the slower is the diffusion, which 
resulted in a lower burst. The influence of the polymer load on the in-vitro drug release is 
already widely described in the literature and appears to be a robust parameter. This effect 
has been described independent of the solvent used: NMP [Graham et al., 1999; Lambert et 
al., 1995], triacetin [Singh et al., 1997 (1); Chandrashekar et al., 1996; Shah et al., 1993] or 
glycofurol [Eliaz et al. 2000 (1); Eliaz et al. 1997]. It appears to be also independent if the 
polymer type used was PLA [Yewey et al., 1997], 75/25 PLGA [Eliaz et al. 2000 (1), (2)] or 
50/50 PLGA [Singh et al., 1997]. The influence of the polymer load on the initial drug release 
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was described for hydrophilic active ingredients [Graham et al., 1999] as well as for lipophilic 
active ingredients [Singh et al., 1997 (1), (2)]. 
 
4.2.5. Use of co-solvents 
 
As a further objective of the in-vitro experiments, the influence of co-solvents on the release 
behaviour was investigated. For these experiments various formulations were prepared, 
substituting a fraction of the main solvent triacetin with excipients of various properties. 
Miglyol 812 was used as lipophilic co-solvent, anhydrous glycerol, glycerol formal, NMP and 
ethanol were used as hydrophilic co-solvents. 
 
Miglyol 812, a mixture of medium chain triglicerides, was added to the formulation as 
lipophilic co-solvent, replacing 10.00 % of the main solvent triacetin. As investigated in 
Chapter 2, Section 3.1, only 5.6 % of active ingredient could be dissolved in Miglyol 812. 
Miglyol 812 can only solubilze the PLA/PLGA polymers up to 1 % [Matschke, 2002].  
 
As hydrophilic co-solvent, anhydrous glycerol was a candidate which was, like Miglyol 812, 
neither a good solvent for the active ingredient (Chapter 2) nor for the PLA polymers. 
Glycerol of anhydrous quality was used to prevent hydrolysis of the PLA polymers during 
storage. Two formulations were prepared, containing 5.00 % respectively 10.00 % of 
anhydrous glycerol. The poor miscibility of the co-solvent with triacetin resulted in the 
formation of emulsions, which were very viscous and therefore difficult to inject. The stability 
of the emulsions was also very critical, as it was mainly due to the high viscosity of the 
polymer phase. The addition of an emulsifier to stabilise the emulsion would have made a 
direct comparison impossible since two parameters would have been changed and the 
addition of tenside to polymer systems is known to increase the drug release rate [Graham et 
al., 1999; Yewey et al., 1997; Rohrs, 2001]. 
 
As further hydrophilic co-solvents, glycerol formal and NMP were tested. They showed good 
solubility properties for the active ingredient (Chapter 2) as well as for the PLA polymers 
[Matschke, 2002]. The formulations were clear solution of high viscosity.  
 
Ethanol was the fourth hydrophilic co-solvent investigated. Apart from the very high 
solubilizing power for NOA449851, it reduced the viscosity of the formulation, which was very 
advantageous for the injection procedure.  
 
 Chapter 3: In-vitro investigations  
 
 
82 
Solvents like PEG 300 and propylenglycol, which are generally well tolerated excipients for 
parenteral application, were not tested as co-solvent for the sustained release injectables 
formed in-situ.  
 
The effects of addition of co-solvent on the release profile were statistically relevant. 
Changes could be observed during the initial burst effect as well as during the linear phase. 
The addition of a lipophilic co-solvent like Miglyol 812 increased the initial burst (Figure 3.8) 
while the addition of hydrophilic co-solvents (anhydrous glycerol, NMP and ethanol) tended 
to minimise it (Figures 3.9, 3.11 and 3.12). 
 
The effects were dependent also on the amount of co-solvent used, since the initial burst 
effect of formulations containing 10.00 % anhydrous glycerol was smaller than the burst of 
formulations containing 5.00 % of this co-solvent (Figure 3.8).  
 
A slight increase of the release rate in the second phase was observed for the co-solvent 
glycerol anhydrous (0.84 %/d) while the release rate of the active ingredient was significantly 
accelerated with ethanol as hydrophilic co-solvent (1.25 %/d) in comparison with the 
formulation containing only triacetin as solvent (0.73 %/d). In contrary, the release rate during 
the linear phase was reduced for the formulation containing the lipophilic co-solvent Miglyol 
812 (0.15 %/d) and for the hydrophilic co-solvent glycerol formal (0.45 %/d).  
 
The lipophilic respectively the hydrophilic characteristics of the co-solvents had an obvious 
effect on the drug release from the implant. It can be assumed that the addition of 10.00 % of 
Miglyol 812 gave to the formulation a more lipophilic character and that the affinity of the 
active ingredient to the polymer system changed. On the other hand, the mixture of solvent 
and co-solvent had a different affinity to the dissolution medium and therefore different rate of 
fluid-convection and of the hardening process of the implant. As already seen in the drug 
release with NMP or glycerol formal as sole solvent (Figures 3.2 and 3.3), this parameter had 
a very strong influence on the hardening process of the implant, on the coagulation rate of 
the polymer and on the internal structure of the implant.  
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4.3. Phase diagrams 
 
The interactions between polymer, solvent and non-solvent were evaluated through the 
construction of ternary phase diagrams. Analysis of ternary phase diagrams indicated that 
the quantity of water needed to initiate PLA precipitation increased with polymer 
concentration of the initial mixture. However, as illustrated in Figure 3.14, the influence of 
polymer concentration was much more important for NMP based solutions than for triacetin 
based solutions.  
 
For Brodbeck et al., the nature of the solvent as well as the solvent/non-solvent miscibility 
are essential parameters for explaining the difference in the implant forming process. NMP is 
a strong solvent for PLA polymers and is completely miscible with water. These both factors 
accelerate the hardening process of the matrix, in contrast to solutions based on triacetin 
which is a solvent with lesser power and having a lower water miscibility [Brodbeck et al., 
1999 (1)]. As a result of the limited water miscibility of triacetin, the system shows, in Figure 
3.14, a significantly lower influence of the polymer concentration than for the NMP system.  
 
The interactions between polymer, solvent and non-solvent were further studied with a 
fraction of the main solvent triacetin substituted with co-solvents. The amount of water 
needed to add for PLA polymer precipitation was found to be also slightly dependent on the 
solvent mixture. Figure 3.15 illustrated that for Miglyol 812 containing mixtures, less water 
was needed to initiate polymer precipitation than for mixture containing only triacetin as 
solvent. The lipophilic co-solvent Miglyol 812 is not soluble in water and is also not a good 
solvent for the PLA polymers. However, for mixtures containing the hydrophilic co-solvents 
ethanol absolute and glycerol formal, more water was needed to initiate polymer precipitation 
than for the mixtures containing only triacetin as solvent. Co-solvent glycerol formal is a 
strong solvent for PLA polymers, while co-solvent ethanol absolute is weak solvent for the 
polymeric excipients, but completely water miscible.   
 
Interactions between active ingredient, solvent and non-solvent was also investigated for the 
two solvents triacetin and NMP. As for the PLA polymer system, the non-solvent was 
demineralised water. After injection of the formulation into the aqueous milieu not only the 
polymer but also the solved active ingredient precipitate to form the solid implant. As 
investigated in Chapter 2, the active ingredient was found not to be soluble in water. As 
illustrated in Figure 3.16, much more water was needed for NMP based mixtures than for 
triacetin based mixtures to observe drug precipitation. 
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4.4. Raman spectroscopy 
 
Many types of polymer based drug delivery systems are in current use, with the polymer 
acting either as carrier or as rate-controlling modulator of drug release. The physicochemical 
properties of both the polymer and the active ingredient are critical parameters to the 
performance of these delivery system by determining the nature of the release process.  
 
IR spectroscopy was not an adequate method for analysing the in-vitro solidified implants, as 
one of the limitation of use of this technique is the presence of water in the samples. Water is 
a very strong absorber and its total remove from the implants after solidification was 
technical not feasible. Therefore, Raman spectroscopy was applied for characterisation of 
the solid state of the implants. This method does not require specific preparation and also 
does not affect the morphological properties of the components in the implant. Raman 
spectroscopy is a technique which can be employed to monitor changes in the 
physicochemical properties of such systems by non-invasive analysis. 
 
Strength and specificity of interactions between a drug and a polymer plays an important role 
in the dissolution rate of the drug. It is important to determine the molecular state of the drug 
within the polymer matrix, and how the drug interacts with the polymer matrix. Raman 
spectroscopy has already been successfully used for investigations of interactions between 
drug and polymer matrix [Taylor et al., 1997; Watts et al., 1991; Broman et al., 2001; 
Breitenbach et al., 1999; Tudor et al., 1990]. 
 
The difference spectra of the active ingredient loaded implants did not reveal any discernable 
modification as compared with their corresponding Raman patterns, as illustrated in Figure 
3.18. 
 
In the solid state of the implant, the active ingredient has always the same conformation, 
independently of the solvent or co-solvent used. It was concluded that no polymorphic form 
was present in detectable amounts in these samples. Based on Raman and X-ray diffraction 
patterns as described in Chapter 2, the active ingredient is in the amorphous conformation in 
all investigated implants. The hypothesis that the active ingredient dissolved in different 
solvent mixtures could have taken, after precipitation, different polymorphic conformation 
with various solubility properties was therefore not corroborated. 
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Also the PLA polymer had identical parameters for all investigated implants and did not show 
any influence due to the solvent composition. No interaction between polymer matrix and 
active ingredient was observed.  
 
5. Conclusions 
 
A dissolution test method was used to compare dissolution profiles of various sustained 
release injectables formed in-situ. The changes in the composition of the formulations 
concerned type of solvent, type of polymer, amount of polymer and of active ingredient as 
well as use of co-solvents. The comparison of the dissolution profiles showed little influence 
of the polymer type on the drug release during the dissolution test period of 40 days. Only 
when the content of the lipophilic active ingredient was reduced to reach a polymer to drug 
ratio of 100:1, drug release was dependent on the hydrolysis rate properties of the various 
polymer type used. The biodegradable polymers are known to have different hydrolysis 
kinetics properties and it was concluded that the drug release was mainly regulated, for 
formulations with polymer to drug ratios of 1:1 or 5:1 by a diffusion-controlled process rather 
than by an erosion-controlled process. The amount of polymer admixed to the formulation 
highly influenced the release profiles. The high viscosity of the formulations containing a high 
amount of polymer reduced the convection of liquids and solvents, with a probable influence 
on the rate of the hardening process of the implant. The initial burst effect was mainly 
influenced by this factor. A change in solvents or even the substitution of a fraction of the 
solvent with a co-solvent led to significant differences in drug release profiles. 
Physicochemical properties of the solvent and co-solvents like log partition coefficient, 
miscibility with the aqueous outer medium and viscosity are determining factors for the 
diverse movements of the fluids and for the implant forming process. The speed of hardening 
conferred to the implant the definitive matrix structure and release characteristics. The focus 
on bio-relevancy should be increased, with major interest in in-vivo-in-vitro correlation and 
therefore, in-vivo tests were needed. 
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Chapter 4 
 
Injectability properties and pharmacokinetic data of 
sustained release injectables formed in-situ tested in-vivo 
 
 
1. Objectives and introduction 
 
One of the major tasks during development of sustained release injectables formed in-situ is 
to determine the active ingredient release patterns from the implants. Ideally, in-vitro drug 
dissolutions reflect properties of the in-vivo dissolution process. However, since this 
correlation is mostly unclear, it was the objective of this chapter to test the formulations in the 
target animal to assess the effective active ingredient release profiles. In addition, the 
pharmacokinetic properties and local tolerability of the injectables were investigated in detail. 
 
Therefore, six formulations investigated in-vitro for drug release were selected to be applied 
to experimental animals. After subcutaneous administration in Beagle dogs, the blood 
concentrations of the active ingredient NOA449851 were measured during several months. 
The pharmacokinetic data were used for further characterisation of the subcutaneous 
implants. To test local tolerability, the related placebos were also injected to the same 
experimental animal and possible reactions were recorded with visual and palpatory 
examination.  
 
As the formulations were highly viscous and therefore difficult to inject with standard needles, 
the rheological properties of the formulations were measured using a cone-plate rheometer 
for shear rates in a range from 1 s-1 to 100 s-1. Additionally, a texture analyser apparatus was 
used for determining the force to be applied on the syringe as well as the total work required 
for the injection of the formulations through three different needle sizes within predetermined 
time frames. 
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2. Materials and methods 
2.1. Materials 
 
The drug substance NOA449851 was manufactured by CarboGen Laboratories, Aarau, CH. 
The PLA polymers (inherent viscosity: 0.68 dl/g in trichloromethane at 30°C) were purchased 
from Birmingham Polymers Inc., Birmingham, AL, USA. Triacetin, glycerol formal and 
anhydrous glycerol were obtained from Fluka AG, Buchs, CH. The solvents ethanol, 
acetonitrile, methanol and water for chromatography were purchased from Merck Inc., 
Darmstadt, D. All solvents were at least of reagent analytical grade. 
 
2.2. Methods 
 
2.2.1. Preparation of formulations and placebos 
 
The sustained release injectables formed in-situ were prepared as already described in 
Chapter 3, Section 2.2.1.1. To assure sterility of the formulations, they were manufactured 
under aseptic conditions in a laminar flow bench (VS 120 AFX, Skan AG, Allschwil, CH). All 
solvents were filtered through sterile filters with 0.22 µm pore size, and all beakers and 
spatula were sterilized in the autoclave (Melag Autoklav, Typ 23, Berlin, D) before 
manufacturing.  
 
All formulations contained 17.00 % (w/w) of the active ingredient NOA449851 beside PLA 
polymers and triacetin. The formulations differed in concentration of the PLA polymers 
(17.00 % (w/w) or 12.75 % (w/w)) as well as in the composition of the solvent mixture: a 
fraction of the main solvent triacetin was substituted with hydrophilic co-solvents such as 
ethanol, glycerol formal or anhydrous glycerol. In the placebos, the active ingredient was 
replaced by the equivalent amount of the solvent triacetin. The exact compositions of the 
formulations tested in-vivo are listed in Table 4.1. 
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Table 4.1: Composition [% (w/w)] of the sustained release injectables formed in-situ for in-vivo 
experiments in dogs.  
 
Formulation Component Content in formulation Content in placebo 
  
[% (w/w)] [% (w/w)] 
A 
NOA449851 
PLA 
triacetin 
17.00 
17.00 
66.00 
- 
17.00 
83.00 
B 
NOA449851 
PLA 
triacetin 
17.00 
12.75 
70.25 
- 
12.75 
87.25 
C 
NOA449851 
PLA 
ethanol 
triacetin 
17.00 
17.00 
10.00 
56.00 
- 
17.00 
10.00 
73.00 
D 
NOA449851 
PLA 
ethanol 
triacetin 
17.00 
12.75 
10.00 
60.25 
- 
12.75 
10.00 
77.25 
E 
NOA449851 
PLA 
glycerol formal 
triacetin 
17.00 
17.00 
10.00 
56.00 
- 
17.00 
10.00 
73.00 
F 
NOA449851 
PLA 
anhydrous glycerol 
triacetin 
17.00 
17.00 
10.00 
56.00 
- 
17.00 
10.00 
73.00 
 
 
2.2.2. Viscosity of formulations and placebos 
 
The high viscosity of the sustained release injectables formed in-situ is a challenging 
parameter to be adapted for applicability of the formulation as well as for acceptance of the 
patient. Therefore, the viscosity of the six formulations and placebos administered to 
experimental animals was determined using a cone-plate rheometer (StressTech 
Rheometer, Reologica, Lund, Sweden). 
 
Measurements were carried out at shear rates in a range from 1 s-1 to 100 s-1 and at a 
constant temperature of 20°C. The viscosity of formulations and of placebo solutions was 
recorded for the shear rates 1 s-1, 5.5 s-1, 30 s-1 and 100 s-1. 
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2.2.3. Syringeability of formulations and placebos 
 
The force necessary to apply on the plunger of the syringe for injection of the formulation 
through a needle with a specific size was determined using a TA-XT2 texture analyser 
apparatus in compression mode (Stable Micro System, Surrey, UK). The formulations as well 
as the placebos were loaded into plastic syringes (Braun Inc., Melsungen, D) with a 16 G, a 
18 G or a 19 G needle attached (Becton and Dickenson, Basel, CH). The force was applied 
to the syringe plunger by using the arm of the texture analyser. The piston moved during 
5 seconds at a rate of 3 mm/s into the syringe. The pressure for delivery of the formulation 
was measured five times for every sample. The force applied versus injection time was 
graphically plotted and the area under the force-time curve was integrated to obtain the total 
work.  
 
2.2.4. Experimental animals 
 
A total of twelve healthy Beagle dogs of various age, breed, body weight and sex were 
selected. They were supplied by the CRA dog facilities of Novartis Animal Health Inc.. Dogs 
were identified by an individual collar number as well as a subcutaneous tag (“RID” RF 
Identification Technology by Data Mars® SA, CH-6814 Cadempino-Lugano, CH). The study 
was reviewed by an ethic committee according to the Principles of Laboratory Animal Care 
(NIH publication no. 86-23, revised 1985) and the Swiss regulation for animal experiments 
(Schweizerisches Tierschutzgesetz). 
 
2.2.5. Dose and method of administration 
 
Each formulation was tested in two dogs, each dog receiving one injection with the active 
ingredient and the corresponding placebo. The NOA449851-containing injectables formed 
in-situ were administered subcutaneously behind the shoulder and over the ribs of the left 
side, while the related placebo solution was injected on the right side of the same animal. 
The supervising veterinarian administered all injections. A 18 G or 16 G needle was used for 
injection to the experimental animals, depending on the viscosity of the formulation. 
 
The total injection volume per formulation was 2 ml, leading to a total amount of 400 mg 
NOA449851 per dog, corresponding to a dose of 40 - 44 mg/kg of active ingredient, 
depending on the body weight of the selected dog. 
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2.2.6. Clinical observation 
 
At the beginning of the study all dogs were examined by a veterinarian. Only healthy dogs 
were included in the trial. The dogs were observed weekly with respect to their general 
health, behavior and appetite by the maintenance staff. During the whole duration of the 
experiment and especially on the day of injection, the dogs were monitored by the 
veterinarian, with special attention to possible general side effects and to local reactions at 
the injection site. Possible general side effects were described by quality and severity of 
respective reactions. Localized reactions at the injection site were measured by visual and 
palpatory examination. All qualitative characteristics, such as signs of inflammation, 
hyperthermia, painfulness, size and persistence of local changes, were recorded. 
 
2.2.7. Collection of blood specimens 
 
Blood samples were collected from the vena jugularis of each dog into sterile tubes 
(S-Monovette®, Medi-prax GmbH, München, D) of 2.7 ml volume containing EDTA as 
anticoagulant. Blood was collected at the following nominal time points: at pre-test and at  
2 h, 8 h, 24 h, 48 h after administration of test items and continued weekly until 462 days for 
dogs receiving the formulations A and C, until 468 days for formulations B, 189 days for 
formulation D and 426 days for formulations E and F. The blood samples were kept frozen 
until HPLC-MS analysis. 
 
2.2.8. Analytical method for S-1238 
 
S-1238 is the major homologue and represents approximately 80 % of the active ingredient 
NOA449851. Besides S-1238, the active ingredient also contains approximately 20 % of the 
component S-1262. Only S-1238 was quantitatively analysed in the blood samples, by 
comparison with an internal standard solution of NOA409797. 
2.2.8.1. Extraction method 
 
After mixing 0.5 ml of blood sample with 50 µl internal standard solution (2500 ng/ml 
NOA409797 in acetonitrile), 0.5 ml water and 1.0 ml acetonitrile, the samples were 
centrifuged, the supernatant solution was extracted and washed, using a Bond Elut cartridge 
(Varian Inc., California, USA). Then, 2.0 ml acetonitrile were used for the elution before 
evaporation to dryness. The residues were dissolved in 125 µl of a mixture acetonitrile/water 
(75:25) and quantified by HPLC-MS.  
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2.2.8.2. HPLC-MS method 
 
A LC-MS 1100 apparatus (Agilent, Basel, CH) was used for the quantitative analysis of the 
extracted samples. The column (Nucleosil 100-3, C18, 70/2, Macherey-Nagel, Düren, D) was 
maintained at a temperature of 40°C. The mobile phase consisted of a constant mixture of 
water, methanol and acetonitrile. The flow rate was kept at 0.5 ml/min during the whole 
analyze run. The injection volume of the samples was 10 µl. The samples were detected at a 
wavelength of 247 nm.  
 
The positive ion mode of API-ES electrospray was used for the measurements. The 
parameters controlling the electrospray chamber were determined as follow: the fragmentor 
voltage was set at 200 V, the capillary voltage at 4500 V, the nebulizer pressure at 40 psi. 
The drying gas nitrogen was set to a rate of 10 l/min and at a temperature of 350°C.  
 
The detected blood concentrations of S-1238, the major homologue of NOA449851, were 
graphically plotted over time for each dog separately. 
 
3. Results 
 
In order to determine the release characteristics of the active ingredient NOA449851 from 
sustained release injectables formed in-situ, in-vivo trials in Beagle dogs were initiated. Six 
formulations and their respective placebos were administered subcutaneously in twelve 
healthy dogs, and tolerability and blood profiles were followed during several months. 
 
3.1. Viscosity of formulations and placebos 
 
The viscosity of all formulations and placebos applied to the experimental animals was 
determined using a cone-plate rheometer. The viscosity of the different formulations varied in 
a large range from 0.4 Pa*s (placebo D at shear rate 1 s-1) to 118 Pa*s (formulation F at 
shear rate 1 s-1). The viscosity of the placebos was significantly lower than the one of 
formulations with active ingredient. This can be explained by the substitution of the active 
ingredient with the equivalent amount of the solvent triacetin in the placebos.  
 
The amount of polymer greatly influenced the viscosity of the formulations. For example, the 
viscosity of formulation A with 17.00 % of PLA polymer was 49.0 Pa*s at shear rate 1 s-1, 
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while formulation B with only 12.75 % of PLA polymer had a viscosity of 12.3 Pa*s at the 
same shear rate. Similarly, the viscosity of formulation C with 17.00 % of PLA polymer 
dissolved in a solvent mixture consisting of triacetin and ethanol was 5.5 Pa*s at shear rate 
1 s-1 while its related formulation D with only 12.75 % of PLA polymer had a reduced 
viscosity of 2.2 Pa*s at the same measurement conditions. The substitution of the solvent 
triacetin with hydrophilic co-solvents also modified the viscosity. Ethanol and glycerol formal 
tended to reduce the viscosity of the formulations, while anhydrous glycerol increased it 
dramatically. Formulations C and E had a viscosity of 5.5 Pa*s and 30.3 Pa*s at shear rate 1 
s-1, as formulation F had a viscosity of 118 Pa*s at the same measurements conditions. 
 
All placebo PLA polymers solutions showed Newtonian rheological behavior, since the 
viscosity seemed independent of the shear rate. Also the active ingredient loaded 
formulations B, C and D showed the ideal Newtonian behavior, whereas formulations A, E 
and F decreased in viscosity at increased shear rates. This type of fluid comportment is 
referred to as shear thinning or pseudoplastic flow behavior.  
 
The measured viscosity at the four pre-selected shear rate 1 s-1, 5.5 s-1, 30 s-1 and 100 s-1 
are listed in Table 4.2. 
 
 
Table 4.2: Viscosity of the in-vivo tested formulations and their respective placebos at four 
different shear rates.  
 
Viscosity [Pa*s] at shear rate: 
 
 
Formulation 
1 s-1 5.5 s-1 30 s-1 100 s-1 
formulation A 49.0 49.5 46.1 17.6 
placebo A 7.2 7.3 7.4 7.2 
formulation B 12.3 12.9 12.9 12.0 
placebo B 2.3 2.3 2.3 2.3 
formulation C 5.5 5.7 5.8 5.6 
placebo C 1.4 1.4 1.5 1.5 
formulation D 2.2 2.3 2.3 2.2 
placebo D 0.4 0.5 0.5 0.5 
formulation E 30.3 31.7 30.9 19.4 
placebo E 5.3 5.5 5.5 5.4 
formulation F 118 113 53.4 12.4 
placebo F 12.4 12.6 12.2 11.1 
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3.2. Injectability of formulations and placebos 
 
Formulations and placebos solutions were filled into syringes with a 16 G, a 18 G or a 19 G 
needle attached. The parameters for injections with the texture analyser apparatus were 
defined as follows: the arm pushed the plunger into the syringe at a rate of 3 mm/s during 
5 seconds. 
 
The texture analyser allowed to determine different parameters such as the maximal force 
during injection [N] as well as the total work [N*s]. The maximal force measured with the 
texture analyser increased with the decrease of diameter of the needle. It varied in a range 
from 2.0 N to 103.8 N for 16 G needles, from 4.9 N to 172.5 N for 18 G needles and from 
6.5 N to 212.3 N for 19 G needles. The maximal force average (n = 5 ± S.D.) applied on the 
plunger of the syringe during injection procedure for each needle and formulation is depicted 
in Figure 4.1. 
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Figure 4.1: Maximal force average [N] measured with the texture analyser apparatus during 
injection of the formulations and placebos investigated in-vivo through 16 G ( ), 
18 G ( ) and 19 G ( ) needles (n = 5 ± S.D.). 
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The total work to be applied on the syringe plunger for delivery of the formulation was also 
determined by integrating the area under the force-time curve. As the force was not constant 
during injection procedure, the total work was not directly proportional to the maximal force. 
All the results are depicted in Figure 4.2. 
 
The total work required from the texture analyser apparatus for pushing the plunge of the 
syringe during 5 seconds at a rate of 3 mm/s into the syringe varied in a range from 9.9 N*s 
to 421.3 N*s for 16 G needles, from 24.5 N*s to 613.5 N*s for 18 G needles and from 
31.8 N*s to 764.2 N*s for 19 G needles. 
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Figure 4.2: Total work required in average [N*s] for pushing the plunge during 5 seconds at a 
rate of 3 mm/s into the syringe, to which a 16 G ( ), 18 G ( ) and 19 G ( ) needle 
was attached (n = 5, ± S.D.). 
 
 
The force applied to the plunger of the syringe did not remain constant but tended to 
increase during injection procedure. The less viscous the formulation, the sooner the arm of 
the texture analyser apparatus reached the maximal force to apply to the plunger. For the 
remaining distance to push, the force was maintained constant. An example of graphic of the 
injection force over the time for a relatively low viscous formulation is shown in Figure 4.3. 
The injected solution was the placebo solution D through a 19 G needle. The maximum force 
was reached within the first second of injection procedure. 
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Figure 4.3: Force [N] to be applied on the syringe piston against time measured with the texture 
analyser for the placebo solution D through a 19 G needle as an example of a 
relatively low viscous formulation. 
 
 
In case of highly viscous formulations, the maximal force is reached after a longer period of 
time. Figure 4.4 illustrates the plot “Force versus Time” of the injection of formulation A 
through a 18 G needle as an example of a highly viscous solution. The maximum force is 
reached with a delay of about 3 seconds. 
 
 
 
Figure 4.4: Force [N] to apply on the syringe piston against time measured with the texture 
analyser for the formulation A through a 18 G needle as an example of a relative 
highly viscous formulation. 
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For extremely highly viscous solutions such as formulations A, E or F, the force applied to 
the plunger when a needle with a reduced internal diameter (19 G) was attached did not 
result in the injection of the formulation through the needle, but rather in deformation of the 
plastic syringe due to the increase of the internal pressure. 
 
In practice, a comfortable injection should not need more than 5 N for its application. No 
formulation was injectable with less than 8.5 N, by using the selected needles diameters. 
Only placebo solutions C and D were close to this value by using the largest investigated 
needle diameter (16 G).  
 
3.3. Local and systemic tolerability 
 
Each dog received 2 ml of formulation on the left shoulder and 2 ml of the respective placebo 
on the right side. Minor localized reactions at the injection site were observed. It consisted in 
slight and painless oedema which spontaneously shrinked within 1-2 days after the 
subcutaneous application. No systemic side effects were noticed in any dog. 
 
3.4. Blood levels profiles 
 
Six formulations investigated in Chapter 3 for in-vitro dissolution were selected for in-vivo 
trials to Beagle dogs. After subcutaneous injection of the formulations, the blood 
concentrations were determined over a period of several months. There were two major 
criteria to assess the results. First, the magnitude of the initial burst and second, the duration 
and consistency of the drug release above the therapeutic concentration estimated at 
10 ng/ml. 
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Blood concentrations of S-1238 after application of formulation A to dogs # 2014 and # 2026 
versus time are represented in Figure 4.5. Blood levels were measured during a period of 
462 days. They reached a maximal blood concentration of 89.2 ng/ml and of 87.6 ng/ml, 
respectively during the first two days. A second burst was observed for dog # 2026 at day 52, 
leading to a blood concentration of 69 ng/ml. Blood levels almost one year (350 days) after 
application were 3.5 ng/ml and 1.8 ng/ml, respectively. However, as illustrated in the chart, 
there is a big difference in the blood concentration profiles of both dogs which have received 
the formulation A during the first 200 days of treatment. 
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Figure 4.5: Pharmacokinetics of S-1238 [ng/ml], the major homologue of NOA449851, after 
subcutaneous injection of formulation A to dogs # 2014 ( ) and # 2026 ( ), 
measured over a period of 462 days. 
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Formulation B, which contained a reduced amount of PLA polymers in comparison to 
formulation A, was applied to dogs # 2030 and # 2032. Maximal blood concentrations were 
reached after 2 and 13 days, with concentrations of 92.7 ng/ml and 117.2 ng/ml, respectively. 
After almost one year (370 days), blood concentrations were found to be 9.1 ng/ml and 
9.7 ng/ml, respectively. S-1238 blood profiles of both dogs which received formulation B are 
represented in Figure 4.6. 
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Figure 4.6: Pharmacokinetics of S-1238 [ng/ml], the major homologue of NOA449851, after 
subcutaneous injection of formulation B to dogs # 2030 ( ) and # 2032 ( ), 
measured over a period of 468 days. 
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Dogs # 2063 and # 2028 each received subcutaneously 2 ml of the formulation C, containing 
ethanol as co-solvent. The maximal blood levels S-1238 were measured 3 and 4 days after 
administration at blood concentrations of 44.2 ng/ml and 47.5 ng/ml, respectively. For dog # 
2063, an additional and unexplained burst was observed after 158 days, reaching a blood 
concentration of 38 ng/ml. After almost one year (364 days), blood concentration was found 
to be 9.5 ng/ml for dog # 2063 and 1.5 ng/ml for dog # 2028. The blood level profiles of the 
experimental animals to which formulation C was applied are represented in Figure 4.7.  
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Figure 4.7: Pharmacokinetics of S-1238 [ng/ml], the major homologue of NOA449851, after 
subcutaneous injection of formulation C to dogs # 2063 ( ) and # 2028 ( ), 
measured over a period of 462 days.  
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In Figure 4.8, the blood profiles of both experiment animals (dogs # 957 and # 973) after 
administration of 2 ml of the formulation D are illustrated. The initial burst was observed at 
day 1 and 2, respectively, and blood levels reached concentrations up to 61.2 ng/ml and 
48.9 ng/ml. After 49 and 91 days, respectively, blood levels decreased to concentrations 
lower than 10 ng/ml. 
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Figure 4.8: Pharmacokinetics of S-1238 [ng/ml], the major homologue of NOA449851, after 
subcutaneous injection of formulation D to dogs # 957 ( ) and # 973 ( ), measured 
over a period of 189 days. 
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Formulation E, which contained glycerol formal as co-solvent was applied to dogs # 2009 
and # 2010. Maximum blood levels were reached at day 2 and 6, with blood concentrations 
of 35.6 ng/ml and 37.4 ng/ml, respectively. Blood levels almost one year (370 days) after 
application were 2.8 ng/ml and 3.3 ng/ml. Figure 4.9 illustrates the pharmacokinetics after 
injection of formulation E . 
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Figure 4.9: Pharmacokinetics of S-1238 [ng/ml], the major homologue of NOA449851, after 
subcutaneous injection of formulation E to dogs # 2009 ( ) and # 2010 ( ), 
measured over a period of 426 days.  
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Formulation F, containing anhydrous glycerol as co-solvent, was applied to dogs # 2005 and 
# 2007. Maximal blood concentration were obtained in both cases two days after 
subcutaneous administration and reached concentrations of 35.0 ng/ml and 40.6 ng/ml. 
Blood levels almost one year after application (370 days) reached concentrations of 
2.0 ng/ml and 2.6 ng/ml, respectively. They passed the critical blood concentration of 
10 ng/ml 23 days, respectively 30 days after injection. Blood levels of both experimental 
animals are illustrated in Figure 4.10. 
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Figure 4.10: Pharmacokinetics of S-1238 [ng/ml], the major homologue of NOA449851, after 
subcutaneous injection of formulation F to dogs # 2005 ( ) and # 2007 ( ), 
measured over a period of 426 days. 
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3.5. Assessment of pharmacokinetic parameters 
 
Blood levels were collected at selected time points and release characteristics of the 
formulations were determined based on these analytical results. Pharmacokinetic 
parameters such as time at maximal blood concentration (Tmax), maximal blood concentration 
(Cmax) and area under the concentration-time curve AUC(0-x d) are summarized in Table 4.3. 
Each dog received 400 mg of NOA449851, representing an amount of 320 mg of its major 
homologue S-1238. 
 
The time at maximal blood concentration varied between 1 and 13 days after the 
subcutaneous application of the different formulations, but was most of the time between 2 
and 4 days. The maximal blood concentration (Cmax) was dependent on the composition of 
the formulation. It was higher for formulations with a concentration of polymers of 12.75 % 
(w/w) than for the related formulation containing 17.00 % (w/w) of polymers. The maximal 
blood concentrations for experimental animals to which formulation A (containing 17.00 % 
(w/w) PLA) was applied were 89.2 ng/ml (dog # 2014) and 87.6 ng/ml (dog # 2026). The 
dogs to which the related formulation B (containing 12.75 % (w/w) PLA) was injected had 
higher maximal blood concentrations of 92.7 ng/ml (dog # 2030) and 117.2 ng/ml 
(dog # 2032).  
 
A similar comparison can be made for formulations C and D, containing both a solvent 
mixture consisting of triacetin and ethanol. The maximal blood concentrations after 
application of formulation C (containing 17.00 % (w/w) PLA) were 44.2 ng/ml (dog # 2063) 
and 47.5 ng/ml (dog # 2028), while dogs to which formulation D (containing 12.75 % (w/w) 
PLA) was injected had maximal blood concentrations of 61.2 ng/ml (dog # 957) and 
48.9 ng/ml (dog # 973). 
 
The substitution of a fraction of the solvent triacetin with various co-solvents resulted in the 
decrease of the maximal blood concentrations. Formulation A, containing only triacetin as 
solvent, lead to maximal blood concentrations of 89.2 ng/ml (dog # 2014) and 87.6 ng/ml 
(dog # 2026). With the same amount of polymer (17.00 % w/w) and of active ingredient 
(17.00 % w/w) and the substitution of 10.00 % of the solvent triacetin with various 
co-solvents, the maximum blood concentration was reduced to 44.2 ng/ml (dog # 2063) and 
47.5 ng/ml (dog # 2028) for the formulation containing the co-solvent ethanol (formulation D), 
35.6 ng/ml (dog # 2009) and 37.4 ng/ml (dog # 2010) for the formulation containing the 
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co-solvent glycerol formal (formulation E), and 35.0 ng/ml (dog # 2005) and 40.6 ng/ml 
(dog # 2007) for the formulation with the co-solvent anhydrous glycerol (formulation F). 
 
 
Table 4.3: Overview of pharmacokinetic parameters of the in-vivo trials: time at maximal blood 
concentration (Tmax), maximal blood concentration (Cmax) and AUC(0-x d).  
 
Formulation Dog # Weight of dog (beginning) 
Weight of dog 
(end) Tmax Cmax AUC(0-x d) 
  [kg] [kg] [d] [ng/ml] [ (ng/ml)d] 
A 2014 
2026 
9.4 
10.4 
11.0 
12.0 
1 
2 
89.2 
87.6 
AUC(0-462 d): 2576 
AUC(0-462 d): 7210 
B 2030 
2032 
8.6 
8.9 
8.6 
8.7 
2 
13 
92.7 
117.2 
AUC(0-468 d): 10034 
AUC(0-468 d): 7240 
C 2063 
2028 
11.5 
10.0 
12.0 
11.0 
3 
4 
44.2 
47.5 
AUC(0-462 d): 3981 
AUC(0-462 d): 1807 
D 957 
973 
10.0 
11.0 
10.6 
10.5 
2 
1 
61.2 
48.9 
AUC(0-189 d): 1271 
AUC(0-189 d): 1664 
E 2009 
2010 
9.4 
9.8 
10.2 
10.0 
2 
6 
35.6 
37.4 
AUC(0-426 d): 1817 
AUC(0-426 d): 2597 
F 2005 
2007 
12.0 
9.1 
13.4 
10.6 
2 
2 
35.0 
40.6 
AUC(0-426 d): 1367 
AUC(0-426 d): 1458 
 
 
The pharmacokinetic parameters can be used to further calculate the release characteristics 
of the implants. The overall mean concentration (ng/ml) is calculated with the AUC(0-x d) 
divided by the time period of the experiment (AUC(0-x d)/t). Further, the fraction of drug release 
from the implants was evaluated using the AUC(0-x d), multiplied with the clearance and the 
weight of the experimental animal. In Table 4.4 the release is represented in weight [mg] and 
in percentage [%] of the total active ingredient integrated in the formulation. The clearance of 
the active compound for dogs was previously determined to be 3 L/kg*d (unpublished 
internal data). 
 
The fraction of drug released after application of formulation A during the duration of the 
animal trials (462 days) represented 25 % (85 mg) and 76 % (259 mg) of the total active 
ingredient integrated in the implant for the dogs # 2014 and # 2026. A fraction of 89 % 
(301 mg) and 64 % (217 mg) was found to be released from the implants for the dogs # 2030 
and # 2032, 468 days after application of the formulation B. The fraction of active ingredient 
released till day 462 from the implant emerged form the formulation C was 42 % (143 mg) 
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and 18 % (60 mg) for the dogs # 2063 and # 2028, respectively. After 189 days following the 
injection of formulation D, the fraction of active ingredient released was 11 % (38 mg) for dog 
# 957 and 15 % (50 mg) for dog # 973. The fraction of drug released 426 days after 
application of formulation E was 16 % (55 mg) and 23 % (78 mg) for dogs # 2009 and # 
2010, respectively. After 426 days of treatment with formulation F, 12 % (41 mg) of the active 
ingredient were released in dog # 2005 and 13 % (44 mg) in dog # 2007.  
 
 
Table 4.4: Overall mean concentration C [ng/ml] as well as amount of drug released ([mg] and 
[%]) during the in-vivo experiment. 
 
Formulation Dog # AUC(0-x d) AUC(0-x d) /t AUC(0-x d) x Cl x weight 
AUC(0-x d) x Cl x 
weight 
  [(ng/ml)d] [ng/ml] [mg] [%] 
A 2014 
2026 
AUC(0-462 d): 2576 
AUC(0-462 d): 7210 
5.6 
15.6 
85 
259 
25 
76 
B 2030 
2032 
AUC(0-468 d):10034 
AUC(0-468 d): 7240 
21.4 
15.5 
301 
217 
89 
64 
C 2063 
2028 
AUC(0-462 d): 3981 
AUC(0-462 d): 1807 
8.6 
3.9 
143 
60 
42 
18 
D 957 
973 
AUC(0-189 d): 1271 
AUC(0-189 d): 1664 
6.7 
8.8 
38 
50 
11 
15 
E 2009 
2010 
AUC(0-426 d): 1817 
AUC(0-426 d): 2597 
4.3 
6.1 
55 
78 
16 
23 
F 2005 
2007 
AUC(0-426 d): 1367 
AUC(0-426 d): 1458 
3.2 
3.4 
41 
44 
12 
13 
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4. Discussion 
4.1. Viscosity and injectability of formulations and placebos 
 
4.1.1. Rheology 
 
The PLA polymer solutions gave wide ranges of viscosity and appeared to be either 
Newtonian or non-Newtonian. All formulations with a viscosity lower than 20 Pa*s showed 
Newtonian flow behavior. This was valid for all placebo polymer solutions as well as active 
ingredient loaded formulations B, C and D. However, active ingredient loaded formulations A, 
E and F showed pseudoplastic flow behavior, with a significant decrease of viscosity at 
higher shear rates. In the practice, it is not possible to take advantage of the pseudoplasic 
flow behavior of formulations A, E and F, because, at the moment, it exists no application 
device capable of generating high shear rates to lower the viscosity at injection time. 
 
The data in Table 4.2 show that the viscosity of the formulations was reduced by decreasing 
the amount of PLA polymers from 17.00 % (w/w) to 12.75 % (w/w) (formulations B versus A 
and formulation D versus C). As the PLA polymers form the matrix of the implant and leads 
to the sustained release effect of the active ingredient, reduction of the polymer 
concentration is restricted.  
 
Another way for lowering the viscosity of the formulations was to reduce the active ingredient 
concentration. As illustrated in the experiment, the placebo solutions were less viscous than 
the related formulations with active ingredient. For evident reasons, the drug content in the 
formulation should be sufficient to provide long release of an adequate amount of active 
ingredient.  
 
A further alternative to reduce viscosity and therefore improve syringeability is to use a 
co-solvent which is less viscous than the main solvent triacetin. As successful examples, 
both formulations containing ethanol as co-solvent (formulations C and D) were significantly 
less viscous and easier to inject than the related formulations without co-solvent (formulation 
A and B).  
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4.1.2. Injection procedure to dogs 
 
The largest needle with respect to length and diameter, that can be used for a given 
indication is determined by a number of parameters including the fluidic requirements of the 
formulation, the application way (i.m., s.c. or i.v.), the frequency of injection, the seriousness 
of the disease, the target population and the availability of alternative therapies. The 
acceptability of the injection system is important for human patient as well as for companion 
animal patients.  
 
The high viscosity of the formulations is inconvenient for the injection procedure. To prevent 
a long injection time and to reduce the necessary force to be applied on the syringe plunge, 
18 G needles had to be used. For formulations containing glycerol formal or anhydrous 
glycerol, the even larger 16 G needles were necessary, resulting in a pain reaction during 
subcutaneous insertion of the needles into the skin. However, the injection of the 
formulations themselves did not seem to be painful to the dogs. 
 
A force of maximum 5 N is needed for a comfortable injection. Combined with the fact that in 
practice 19 G needles as maximum size for subcutaneous injections to dogs is acceptable, it 
can be concluded that the high viscosity of the sustained release injectables formed in-situ is 
a serious issue for further development of this technology. No formulation could fulfill both 
requirements. Only the placebo solutions C and D were close to these desired specifications. 
Development of an applicator suitable to inject subcutaneously highly viscous formulations 
would overcome these issues. At present time, there is no such applicator to be found on the 
market. A novel injection system which has the potential to enhance the delivery of complex 
formulations such as viscous and particulate material is described by Maynard et al. 
[Maynard et al., 2003]. 
 
4.2. Tolerability 
 
All formulations, placebos as well as formulations with active ingredient, were well tolerated 
by the experimental animals. The excipients used in the formulations like triacetin, PLA, and 
anhydrous glycerol are known to be generally well tolerated after subcutaneous injection 
[Bertholom et al., 2000; Bartsch et al., 1976; Bailey et al., 1991]. Glycerol formal and ethanol 
are more critical substances [Bertholom et al., 2000], but at concentrations of 10.00 % as in 
formulations C, D and E, no side effects were observed.  
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Clinical tolerability is a parameter which is regularly checked in the experiments cited in the 
literature. Authors using the solvents NMP and DMSO mentioned inflammation or tissue 
irritation [Kranz et al., 2001; Royals et al., 1999; Yewey et al., 1997]. Encapsulation with 
connective tissues of implant is cited also several times, however without causing any 
problems for acceptability [Eliaz et al., 2002; Royals et al., 1999]. The encapsulation of the 
subcutaneous implant can lead to modifications in the active ingredient release rate and 
extent. The capsule builds an additional barrier for water to enter the implant and therefore 
for biodegradation of the polymers, as well as for the active to be released from the implant 
into the subcutaneous milieu and therefore the systemic circulation. 
 
Sustained release injectables implants formed in-situ with the solvent triacetin were also 
tested in-vivo for tolerability: very slight irritations were observed after i.m. or s.c. application 
in rats of 0.2 ml of a 5 % 50/50 PLGA solution in triacetin [Shah et al., 1993]. 
 
In the present experiments, all injections resulted in a mild swelling surrounding the injection 
site due to the injected volume. No skin changes were noted on top of these swellings and 
there were no clinical signs of irritation or pain. Formulations with active ingredient as well as 
the related placebos were also very well tolerated by the experimental animals. 
 
The placebo implants disintegrated quite rapidly and were no more noticeable at the injection 
site 30 days after application. The implants containing active ingredient were more 
voluminous than the placebos and were resorbed more slowly. Interestingly, the opposite 
was observed by Eliaz for 75/25 PLGA implants containing plasmid DNA as active ingredient 
[Eliaz et al., 2002]. In this in-vivo experiment, the 75/25 PLGA polymers of the implants 
containing the plasmid DNA disintegrated more rapidly than the polymers of the related 
placebo implants. Even if these observations seem contradictory, there is evidence that the 
erosion of the polymers is influenced by the substances contained in the implant [Vert et al., 
1998]. The bioerosion of the polymers is due to the hydrolysis of ester bonds and is therefore 
dependent on the amount of water penetrating the implant matrix. The physicochemical 
characteristics of the active ingredient may influence water permeation. A lipophilic 
substance such as NOA449851 is an hindrance for the water to enter the polymer matrix, 
whereby a more hydrophilic substance like a plasmid DNA may enhance water diffusion and 
therefore increase the rate of the polymer erosion. This may be the explanation for these 
seemingly contradictory observations. 
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4.3. Blood level profiles 
 
The present in-vivo trials are carried out in an early clinical stage and should be considered 
as an explorative pilot study. To obtain more robust results, it would be necessary to carry 
out confirmatory trials in accordance with the current guideline for Good Clinical Practice. 
The appropriate minimal number of animals per group should be carefully estimated to 
produce robust data, including factors such as variance of responses and high inter-animal 
variations. However, the collected data give good indications with regard to tendency of drug 
release from the sustained release injectables formed in-situ and allow a first assessment of 
the properties of the different formulations. 
 
Because of a very high risk of local and systemic toxicity, it was not considered ethical to 
inject a triacetin solution containing the same amount of active ingredient but without the PLA 
polymers. Without PLA polymers, no sustained release effect would be generated and the 
amount of active ingredient would  probably be released in a short period of time, leading to 
acute high blood concentrations and possibly systemic side effects. Therefore, no control 
tests were carried out to measure the effective impact of PLA polymers on the sustained 
drug release.  
 
Based on the in-vitro results obtained from formulations with different polymer types (PLA, 
85/15 PLGA and 75/25 PLGA), only formulations containing PLA polymers were tested. The 
in-vitro dissolution tests showed that formulations with high drug loads had very similar drug 
release profiles, independently of polymer type (Chapter 3, Figures 3.3 and 3.4). This was 
attributed to the drug release mechanism which seemed to be mainly drug diffusion 
controlled and not polymer erosion controlled. The goal of these experiments was to reach 
in-vivo a sustained release of the active ingredient at therapeutic levels over the longest 
possible time period. Therefore, the polymer type selected for the in-vivo trials was the one 
with the lowest degradation rate: the PLA polymer [Middleton et al., 2000]. 
 
The in-vivo trials were stopped after the active ingredient blood concentrations decreased 
and remained below the therapeutic level of 10 ng/ml. The fractions of drug released, 
estimated from the total AUC, multiplied with the clearance and the weight of the 
experimental animal were surprisingly low (Table 4.4). It represented 25 % (85 mg) and 76 % 
(259 mg) of the total injected active ingredient for the dogs # 2014 and # 2026, 462 days 
after application of the formulation A, and 89 % (301 mg) and 64 % (217 mg) for the dogs # 
2030 and # 2032, 468 days after application of the formulation B. The fraction of drug 
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released after application of formulation C was 42 % (143 mg) and 18 % (60 mg) for the dogs 
# 2063 and # 2028, respectively. After 189 days treatment with formulation D, the fraction of 
active ingredient released was only 11 % (38 mg) for dog # 957 and 15 % (50 mg) for dog # 
973. The fraction of drug released after application of formulation E was 16 % (55 mg) and 
23 % (78 mg) for the dogs # 2009 and # 2010, respectively. The values were even lower 426 
days after the injection of formulation F, with only 12 % (41 mg) of the active ingredient 
released in dog # 2005 and 13 % (44 mg) in dog # 2007. 
 
The low fraction of active ingredient released during the in-vivo experiments may indicate a 
too high concentration of the PLA polymer in the formulations: the formulations B with a 
reduced amount of polymer had over 60 % of the drug released for both experimental 
animals 468 days after application. It could also be an indication that the implant matrix 
should not consist of PLA polymers but of faster degrading polymers such as 85/15 PLGA or 
75/25 PLGA. The small fraction of active ingredient released in-vivo after long period of time 
may also be explained by the possible encapsulation of the solid subcutaneous implant. As 
already mentioned, this may build an additional barrier which inhibits water permeation into 
the implant matrix and therefore prevents hydrolysis of the polymeric ester bounds and 
concomitantly complicates drug diffusion into the subcutaneous milieu.  
 
In some cases, very high inter-animal variations in the blood drug concentration were noticed 
for dogs which had received the same formulation. The pharmacokinetic data represented in 
Table 4.3, and particularly the AUC values, illustrate these differences. This was the case for 
the experimental animals to which formulations A and C were applied, as illustrated in 
Figures 4.5 and 4.7. The injection of these formulations led in one of the experimental animal 
per group to an unexplained spontaneous burst at 60, respectively 150 days after 
application. This effect of spontaneous late burst has also been observed in published 
literature [Ravivarapu et al., 2000 (3)]. For explorative trials, two dogs per group allow some 
correlation with in-vitro findings. However, the number of animals per group must be higher in 
future confirmatory experiments. 
 
The amount of active ingredient injected was 400 mg for all dogs. As they have body weight 
ranging from 8.6 kg to 13.4 kg, all dogs should have similar AUC values. In Table 4.3, the 
values of the AUC showed evident differences. These differences may be the consequence 
of encapsulation of the subcutaneous implant. It has been reported in previous papers that 
connective tissue was found around the implant [Jain et al., 1999; Royals et al., 1999; Eliaz 
et al., 2002]. This can build a barrier for the active ingredient and inhibit its diffusion into the 
body. As an other explanation, the active ingredient may have degraded within the implant 
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[Burgess et al., 2002]. According to stability investigations of the active ingredient in the liquid 
formulations A, B and C (Chapter 6, Figure 6.4), the refund of the drug NOA449851 was 
between 92.89 % and 95.46 % after six months storage at 40°C. Therefore, the degradation 
of the active ingredient within the polymer matrix seems not to explain alone the low fraction 
of drug released. 
 
Attention was paid to test in-vivo formulations which were already investigated in-vitro with 
dissolution tests. The trends of the release profiles were therefore already known. This is 
further elaborated as part of a correlation between the in-vivo and the in-vitro data in Chapter 
5. 
 
4.3.1. Influence of polymer concentration in the formulation 
 
A reduction of the PLA polymer concentration in the formulation lowered the viscosity and 
therefore improved its injectability. For this reason, such formulations were tested, despite 
in-vitro release profiles showing a dramatic increase in the initial burst effect (Chapter 3, 
Figures 3.6 and 3.11).  
 
A comparison can be made between formulation A, containing 17.00 % (w/w) PLA polymers 
and formulation B, containing only 12.75 % (w/w) PLA polymers. According to the in-vitro 
dissolution tests, an important intensification of the initial burst effect was expected for the 
formulation with a reduced amount of polymer. Surprisingly, the differences of blood 
concentrations during the first days of the in-vivo trial between the animals receiving the 
formulation A and formulation B were not so evident. The maximal blood concentrations for 
dogs which received formulation A with 17.00 % (w/w) PLA polymers were 89.2 ng/ml (dog # 
2014) and 87.6 ng/ml (dog # 2026); dogs which received formulation B with 12.75 % (w/w) 
PLA polymers reached maximal blood concentrations of 92.7 ng/ml (dog # 2030) and 
117.2 ng/ml (dog # 2032). The formulations containing less polymer led to a slightly 
increased initial burst effect during the in-vivo testing. 
 
Similarly, a comparison can be made between formulations C and D. The PLA polymer 
concentration was 17.00 % (w/w) for formulation C and 12.75 % (w/w) for formulation D. In 
this case, the solvent of the formulations was a mixture of triacetin and ethanol. The maximal 
blood concentrations for dogs which received formulation C with 17.00 % (w/w) PLA 
polymers were 44.2 ng/ml (dog # 2063) and 47.5 ng/ml (dog # 2028); dogs which received 
the formulation D with 12.75 % (w/w) PLA polymers reached maximal blood concentrations 
of 61.2 ng/ml (dog # 957) and 48.9 ng/ml (dog # 973). Here again, reduction of PLA polymer 
 Chapter 4: Injectability and pharmacokinetic data 
 
 
113 
content in the formulations increased slightly the initial burst, but not in the same proportions 
as in the in-vitro dissolution tests carried out with the same formulations (Chapter 3, Figure 
3.11). 
 
The effects of polymer concentrations on the in-vivo drug release and particularly on the 
magnitude of the initial burst have already been widely discussed in various papers. In an 
experiment using the lipophilic drug naltrexone base in rats, Shively et al. [Shively et al., 
1995] described the in-vivo initial release being highly dependent on the polymer 
concentration. The percent of active ingredient released from a formulation containing 57 % 
75/25 PLGA polymers was significantly lower than that observed for a formulation containing 
35 % of the same polymer. No explanation about the prolonged release was possible as the 
blood concentrations were only monitored for four hours following injection [Shively et al., 
1995]. 
 
Eliaz et al. described in diverse papers the effect of different polymer concentrations on the 
release of water soluble TNF receptors p55-R from sustained release injectables formed 
in-situ. The formulation containing 10 % of the 75/25 PLGA polymer had a higher initial burst 
effect than the formulation containing 20 % of the polymer. However, following the initial 
burst, the sp55-R serum concentration at 6 hours after injection was similar for both polymer 
concentrations [Eliaz et al., 2000 (1); Eliaz et al., 1997]. 
 
In the experiments described by Ravivarapu et al., in which formulations containing the water 
soluble active ingredient leuprolide acetate were investigated, the efficacy on testosterone 
level in rats was tested. The polymer concentrations ranged from 40 % to 50 % (w/w). No 
significant effect of polymer concentration on formulation efficacy could be noted, except for 
one day (day 9) when the testosterone level was statistically higher for animals having 
received the formulation with the highest polymer concentration. However, it was concluded 
that the whole range of polymer concentrations tested was suitable for producing efficacious 
formulations for a period of 100 days [Ravivarapu et al., 2000 (1)]. 
 
4.3.2. Influence of hydrophilic co-solvents 
 
The initial burst effects are often mentioned by authors who have performed in-vivo 
experiments with sustained release injectables formed in-situ [Ravivarapu et al., 2000 (2); 
Yewey et al., 1997; Chandrashekar et al., 1996; Dunn et al., 1996; Randomsky et al., 1993]. 
The two main reasons to prevent an initial burst is that the released active ingredient is no 
longer available for the prolonged release and that the early concentrations can reach toxic 
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blood levels and generate systemic side effects. Therefore, a major objective of this 
formulation development was to determine and test parameters capable to reduce the 
magnitude of the initial burst effect. 
 
The use of various hydrophilic co-solvents resulted in the decrease of the initial burst effect. 
Maximum blood concentrations of the formulations containing only triacetin as solvent 
(formulation A) were 89.2 ng/ml (dog # 2014) and 87.6 ng/ml (dog # 2026). With the same 
amount of polymer and active ingredient, but substitution of 10 % triacetin with hydrophilic 
co-solvents, the maximum blood concentration was decreased as follows: to 44.2 ng/ml 
(dog # 2063) and 47.5 ng/ml (dog # 2028) for the formulation containing the co-solvent 
ethanol (formulation D), to 35.6 ng/ml (dog # 2009) and 37.4 ng/ml (dog # 2010) for the one 
containing glycerol formal (formulation E), and to 35.0 ng/ml (dog # 2005) and 40.6 ng/ml 
(dog # 2007) for the formulation with the co-solvent anhydrous glycerol (formulation F). 
 
This effect was also observed for formulations B and D which both contained a reduced 
amount of PLA polymers (12.75 % w/w). Formulation B, with triacetin as unique solvent, had 
an initial drug concentration of 92.7 ng/ml (dog # 2030) and 117.2 ng/ml (dog # 2032) while 
formulation D, with ethanol as co-solvent, had a reduced burst with a maximal blood 
concentration of 61.2 ng/ml (dog # 957) and 48.9 ng/ml (dog # 973). 
 
The reduction of magnitude of initial burst by the substitution of the main solvent triacetin with 
hydrophilic co-solvents was already observed during the in-vitro dissolution tests (Chapter 3, 
Figures 3.8, 3.9 and 3.10). The hydrophilic co-solvent may affect the convections of water 
into the implants and out of the polymer matrix, altering the implant forming process. 
Attempts to make a mathematical correlation between in-vitro and in-vivo data of drug 
release from sustained release injectables formed in-situ can be found in Chapter 5. 
 
The ideal blood profile with a sustained release injectable formed in-situ is a zero order 
kinetic during several months. Formulations containing glycerol formal (formulation E) and 
anhydrous glycerol (formulation F) clearly showed a continuous decrease in the blood level 
concentration over time. These formulations are therefore no good candidates for such 
application. In addition, due to the high viscosity, both formulations were very difficult to inject 
with a normal syringe. 
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5. Conclusion 
 
A total of twelve healthy Beagle dogs were used for the in-vivo studies, with two dogs 
assigned to each formulation. Six different formulations were tested, each dog receiving both 
an active ingredient loaded formulation and the related placebo injection.  
 
The rheological properties as well as the syringeability of each formulation tested in-vivo 
were evaluated using a cone-plate viscosimeter and a texture analyser apparatus. All PLA 
placebo solutions showed Newtonian flow behaviour whereas some highly viscous active 
ingredient loaded formulations had pseudoplastic rheological properties. Injection through 
normal needles of these formulations with high viscosity required excessive pressure on the 
syringe plunger. The high viscosity of the sustained release injectables formed in-situ is a 
serious issue for further development of this technology. However, the viscosity of the 
formulation was reduced when the concentration of PLA polymers was lowered as well as 
when the main solvent triacetin was substituted to a fraction by co-solvents such as ethanol.  
 
All PLA placebo solutions and all formulations applied subcutaneously were very well 
tolerated by the experimental animals with only a slight and painless swelling at the injection 
site for a few days. The blood profiles showed a release of the active ingredient over a 
prolonged period for all formulations. The magnitude of the initial burst was slightly increased 
by the reduction of the amount of PLA polymers in the formulation. However, a significant 
decrease of the initial burst was observed for all formulations containing hydrophilic 
co-solvents such as ethanol, glycerol formal or anhydrous glycerol. The fractions of active 
ingredient released were in general very low and may have indicated a too high 
concentration of PLA polymer in the formulations. As alternative to increase the fraction of 
drug released over the whole duration of the treatment, faster degrading polymer types such 
as 85/15 PLGA or 75/25 PLGA could be used instead of the selected PLA polymers.  
 
The present in-vivo trials were carried out in an early clinical stage and should be considered 
as an explorative pilot study. In some cases, very high inter-animal variations in the blood 
drug concentration were measured for dogs which received identical formulations. It would 
be necessary to carry out confirmatory trials in accordance with the current guideline for 
Good Clinical Practice and carefully estimated the appropriate number of animals per group 
to produce more robust data. 
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Chapter 5 
 
In-vitro in-vivo correlation (IVIVC) for sustained release 
injectables formed in-situ the active ingredient NOA449851 
 
 
1. Introduction and objectives 
 
Scientifically based methods to predict the in-vivo drug release performance of 
pharmaceutical dosage forms are beneficial in order to minimize animal experiments, reduce 
drug development duration and allow a quality control of the release properties of the dosage 
forms. Various physicochemical, biopharmaceutical and physiological factors need to be 
considered to achieve a successful correlation between in-vitro data and in-vivo parameters. 
Guidance for IVIVC models are proposed for oral [Guidance for industry, 1997; EMEA, 1999, 
USP 28, 2005 <1088>], parenteral [Burgess et al., 2004; USP 28, 2005 <1088>] and 
transdermal dosage forms [EMEA, 1999, USP 28, 2005 <1088>]. IVIVC models are divided 
into three categories known as levels A, B and C. Level A correlations apply to models than 
can predict the entire in-vivo time course from in-vitro data. They represent point-to-point 
correlations between in-vivo absorption profiles and in-vitro release profiles. Level B 
correlations are based on statistical moment analysis and compare mean in-vitro dissolution 
time of the formulation with mean residence time in the body. Level C correlations establish a 
single point relationship between an in-vitro dissolution parameter and a pharmacokinetic 
parameter [Guidance for industry IVIVC; EMEA, 1999; Burgess et al., 2004]. 
 
The active ingredient release from sustained release injectables formed in-situ is a complex 
process determined mainly by properties of the formulation as well as by the 
physicochemical characteristics of the active ingredient. After an initial burst phase related to 
solvent diffusion into the surrounding milieu and solidification of the subcutaneous implant, 
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the drug is released at slower rates, mainly by diffusion through the polymeric matrix coupled 
with erosion of the biodegradable polymers. 
 
The objective of this chapter is to find a correlation between in-vitro release properties of 
active ingredient NOA449851 from sustained release injectables formed in-situ obtained with 
dissolution tests (Chapter 3) and in-vivo drug release data obtained after subcutaneous 
application of the same formulations to experimental animals (Chapter 4). 
 
2. Materials and methods 
2.1. Materials 
 
In-vitro release profiles and in-vivo pharmacokinetic data were obtained from experiments 
described in Chapter 3 and 4, respectively. More information on the materials used for 
manufacturing of the formulations and for analytics can be found in Section 2.1 of the related 
chapters. 
 
2.2. Methods 
2.2.1. Selection of formulations 
 
IVIVC was performed for the six sustained release injectables formed in-situ tested in-vivo 
(Chapter 4) as their in-vitro drug release characteristics were previously evaluated with 
dissolution tests (Chapter 3). Compositions of the six evaluated formulations are summarized 
in Table 5.1. All formulations contained 17.00 % (w/w) of the active ingredient NOA449851 
beside PLA polymers and triacetin. The formulations differed in concentration of the PLA 
polymers (17.00 % (w/w) or 12.75 % (w/w)) as well as in composition of the solvent mixture: 
a fraction of the main solvent triacetin was substituted with co-solvents such as ethanol, 
glycerol formal or anhydrous glycerol. Furthermore, the different used nomenclatures for 
formulations in Chapters 3 and 4 are mentioned in Table 5.1, as well as the Figures in which 
the related drug release profile is represented. In this chapter, the same nomenclature for the 
formulations will be used as in Chapter 4 (formulations A to F). Preparation method of 
formulations can be found in Chapter 3, Section 2.2.1.1.  
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Table 5.1: Compositions [% (w/w)] of sustained release injectables formed in-situ used for 
determination of IVIVC. It is also indicated which Figure shows the corresponding 
in-vitro drug release profile and the in-vivo profile.  
 
Nomenclature 
of formulation 
in Chapters 4 
and 5 
Nomenclature of 
formulation in 
Chapter 3 
Components Content of 
components 
In-vitro 
release 
profile 
In-vivo 
release 
profile 
   [% (w/w)]   
A PLA-AI(1:1) 
NOA449851 
PLA 
triacetin 
17.00 
17.00 
66.00 
Chapter 3, 
Figure 3.6 
Chapter 4, 
Figure 4.5 
B PLA-AI(3:4) 
NOA449851 
PLA 
triacetin 
17.00 
12.75 
70.25 
Chapter 3, 
Figure 3.6 
Chapter 4, 
Figure 4.6 
C 
Co-solvent (10 %) 
ethanol, PLA-
AI(1:1) 
NOA449851 
PLA 
ethanol absolute 
triacetin 
17.00 
17.00 
10.00 
56.00 
Chapter 3, 
Figure 
3.10 
Chapter 4, 
Figure 4.7 
D 
Co-solvent (10 %) 
ethanol, PLA-
AI(3:4) 
NOA449851 
PLA 
ethanol absolute 
triacetin 
17.00 
12.75 
10.00 
60.25 
Chapter 3, 
Figure 
3.11 
Chapter 4, 
Figure 4.8 
E 
Co-solvent (10 %) 
glycerol formal 
PLA-AI(1:1) 
NOA449851 
PLA 
glycerol formal 
triacetin 
17.00 
17.00 
10.00 
56.00 
Chapter 3, 
Figure 3.9 
Chapter 4, 
Figure 4.9 
F 
Co-solvent (10 %) 
glycerol, PLA-
AI(1:1) 
NOA449851 
PLA 
anhydrous glycerol 
triacetin 
17.00 
17.00 
10.00 
56.00 
Chapter 3, 
Figure 3.8 
Chapter 4, 
Figure 
4.10 
 
 
2.2.2. Correlation approaches 
 
IVIVC is a mathematical relationship between in-vitro and in-vivo data. Plasma concentration 
data cannot be directly correlated with in-vitro dissolution data and need first to be translated 
into suitable dimensions to be able to assess whether there is a correlation. Therefore, the 
fraction of drug released in-vivo was evaluated using the corresponding AUC values. The 
fraction of drug released in-vivo for a given time period was calculated with a model-
independent evaluation, based on mean AUC[0,t] for the determined period of time, related to 
the predicted AUC[o,∞] to infinite time, as represented in equation 5.1,  
 
Equation 5.1:  ( ) [ ]
[ ]
%100%__
,
,0
⋅=
∞o
t
AUC
AUC
treleasedFraction  
 
where AUC[o,t] is the area under the curve from injection time to time point t and AUC[o,∞], the 
area under the curve from injection time to infinite time, as extrapolated from the model-
independent evaluation. 
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2.2.2.1. Development of level C correlation model 
 
Level C correlation establishes a single point relationship between a dissolution parameter 
obtained with an in-vitro experiment and a pharmacokinetic parameter. Here, the 
pharmacokinetic parameters are the maximal blood concentration Cmax and the evaluated 
percentages of drug released at three predetermined time points. Level C IVIVC does not 
reflect the complete shape of the plasma level and is generally not useful for supporting 
major variations in composition or manufacturing process of the product. However, it can 
provide useful information during formulation development and can be used in setting 
release specifications. 
 
Level C IVIVC modeling was first attempted using Cmax values as pharmacokinetic 
parameter, form which it is claimed to be related with the cumulative percentage of drug 
released in-vitro during dissolution test until the time point Tmax. The correlation points for the 
six formulations were represented in a scatter plot, with the Cmax value reported on the Y-axis 
and the percentage of drug released in-vitro at Tmax reported on the X-axis. 
 
Further level C IVIVC models were attempted for three predetermined time points. The 
selected time points were set at 2, 7 and 14 days, to investigate the initial burst effect of 
sustained release injectables formed in-situ. Regression lines and related correlation 
coefficients were calculated from the various scatter plots.  
 
2.2.2.2. Development of level A correlation model 
 
Level A IVIVC represents a point-to-point relationship between in-vitro cumulative dissolution 
curves of the product and in-vivo dissolution profiles generated by pretreatment of the 
plasma level data.  
 
For a given sustained release injectable formed in-situ formulation, the average cumulative 
percentages of drug released in-vitro during dissolution test were reported as a function of 
the mean evaluated percentage of active ingredient released in-vivo at the same time point. 
Correlation was possible only for the first 40 days of the experiments, as the in-vitro 
dissolution tests carried out in Chapter 3 were stopped after this period of time. The 
correlation profiles were reported graphically on a chart where the percentage of drug 
released in-vitro was represented on the X-axis and the corresponding evaluated in-vivo drug 
released on the Y-axis.  
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3. Results 
3.1. Level C correlations  
3.1.1. Level C correlations using Cmax 
 
Level C IVIVC was performed using the average Cmax values of in-vivo drug release profiles, 
as function of the average percentage of drug released in-vitro at the time point Tmax.  
 
For each formulation, maximal drug concentration in the in-vivo release profile was reported 
on the Y-axis, while percentage of drug released at this time point (Tmax) during in-vitro 
dissolution test was represented on the X-axis. Correlation points were reported as scatter 
plot in chart of Figure 5.1. 
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Figure 5.1: Level C IVIVC for formulations A to F, using Cmax-values. Labels A, B, C, D, E and F 
indicate the related formulations. 
 
 
No significant correlation could be found for level C IVIVC using Cmax values as 
pharmacokinetic parameter. Specifically correlation point of formulation A differs highly from 
the other formulation correlations data.  
 
However, excluding formulation A, a clear trend could be observed, in which the in-vitro drug 
release performances from the different formulations were positively and linearly correlated 
to the obtained in-vivo Cmax values. The higher the value of Cmax, the higher the in-vitro drug 
release in the dissolution test at this time point.  
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3.1.2. Level C correlation for time point t = 2 days 
 
Level C IVIVC of NOA449851 for time point t = 2 days is shown in a scatter plot in Figure 5.2, 
for the four formulations containing 17.00 % of PLA polymer (formulations A, C, E and F). 
The percentage of drug released in-vitro two days after injection is presented on the X-axis 
and the evaluated percentage of drug released in-vivo two days after subcutaneous 
application is reported on the Y-axis. Based on relationships of the various formulations for 
this time point, a linear regression level C IVIVC model was constructed. The equation of the 
regression line and the correlation coefficient are indicated in Figure 5.2.  
 
The slope of the linear regression obtained from these data is significantly different from 0 
(p-value = 0.0362). The good correlation coefficient indicates a strong predictability. 
However, the negative slope of the regression line is surprising, as it suggest an inverse 
proportional correlation of the drug release for the investigated range. 
 
 
 
Regression line: 
 y = - 2.4 x + 22.6 
 
 
Correlation coefficient: 
 - 0.9638 
 
 
p-value: 
 0.0362 
 
 
 
 
 
Figure 5.2: Percentage of active ingredient released in-vivo from formulations A, C, E and F 
versus in-vitro release, two days after injection. Regression line, related equation 
and correlation coefficient are indicated. The labels A, C, E and F indicate the 
related formulations. 
 
 
By using all formulations (formulations A to F) for level C IVIVC at time point t = 2 days, no 
significant correlation could be found. The results for the correlation of the formulations 
containing a reduced amount of polymer (formulations B and D with 12.75 % of PLA 
polymers) differed significantly from the results of formulations containing 17.00 % of PLA 
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polymers (formulations A, C, E and F). The slope of the regression line obtained from this 
data set was not significantly different from 0 (p-value = 0.1589). The correlation coefficient 
of -0.65 indicated a bad predictability. However, similarly to level C correlation at time 
t = 2 days for formulations A, C, E and F, the slope of the regression line is negative. 
 
Correlation for formulations B and D differed highly compared to the other formulations 
investigated. After two days, none of the formulations released more than 10 % in-vivo, and 
all formulations containing 17.00 % PLA polymers released between 6 % and 8 % in-vitro. 
Formulations B and D however, had both extensive in-vitro release, representing 39 % and 
13 % of the total amount of active ingredient integrated in the formulation, respectively. 
 
 
 
Regression line:  
y = - 0.1 x + 66  
 
 
Correlation coefficient: 
- 0.65 
 
 
p-value: 
0.1587 
 
 
 
 
 
 
Figure 5.3: Percentage of active ingredient released in-vivo from formulations A to F versus  
in-vitro release, two days after injection. Regression line, related equation and 
correlation coefficient are indicated. The labels A, B, C, D, E and F indicate the 
related formulations. 
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3.1.3. Level C correlation for time point t = 7 days 
 
A level C IVIVC is presented as scatter plot in Figure 5.4 for the time point t = 7 days. For 
each formulation containing 17.00 % of PLA polymer, percentage of drug released in-vitro 
after seven days of the dissolution test is presented on the X-axis, while the percentage of 
drug released in-vivo seven days after subcutaneous application is reported on the Y-axis. 
According to the obtained relationship of drug released from formulations A, C, E and F for 
this time point, a linear regression was calculated. The equation of the regression line and its 
correlation coefficient are also indicated in Figure 5.4.  
  
The slope of the linear regression obtained from this data set was not significantly different 
from 0 (p-value = 0.2047). This can be due to the small number of data used for this 
correlation calculation. The inverse proportional correlation observed in Figure 5.2 between 
in-vitro and in-vivo performance was again observed after seven days of treatment with a 
negative slope of the regression line. However, no significant correlation could be determined 
between the various formulations after seven days of treatment compared to two days of 
treatment. 
 
 
 
Regression line:  
y = - 2.1 x + 51.4  
 
 
Correlation coefficient:  
- 0.7952 
 
 
p-value:  
0.2047 
 
 
 
 
Figure 5.4: Percentage of active ingredient released in-vivo from formulations A, C, E and F 
versus in-vitro release, seven days after injection. Regression line, related equation 
and correlation coefficient are indicated. The labels A, C, E and F indicate the 
related formulations. 
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Level C correlation at time point t = 7 days, including all formulations (formulations A to F) did 
not show any significant correlation (chart not shown). The slope of the linear regression was 
not significantly different from 0 (p-value = 0.1551). Equation of regression line was  
- 0.3 x + 27.9 and correlation coefficient - 0.66. 
 
3.1.4. Level C correlation for time point t = 14 days 
 
Level C IVIVC for formulations A, C, D and F at time point t = 14 days is represented in a 
scatter plot in Figure 5.5. Linear regression level C IVIVC model was calculated from the 
relationships between in-vitro and in-vivo performances of the investigated formulations for 
this time point. The equation of the regression line and the correlation coefficient are 
indicated in Figure 5.5.  
 
Similarly to IVIVC level C model at time points t = 7 day, the slope of the linear regression 
obtained from the data set for t = 14 days was not significantly different from 0  
(p-value = 0.2860). Correlation coefficient of the linear regression with the value - 0.7141 
indicates an insufficient relationship between investigated formulations with regard to 
percentage of drug released during in-vitro dissolution test and in-vivo trials. Similarly to level 
C correlation at time point t = 2 and 7 days, slope of regression line was negative. From 
these considerations, no significant level C correlation could be assessed between the 
various formulations after two weeks treatment.  
 
 
Regression line: 
y = - 2.4 x + 84.7 
 
 
Correlation coefficient : 
- 0.7141 
 
 
P-value:  
0.2860 
 
 
 
 
 
Figure 5.5: Percentage of active ingredient released in-vivo from formulations A, C, E and F 
versus in-vitro release, two weeks after injection. Regression line, related equation 
and correlation coefficient are indicated. The labels A, C, E and F indicate the 
related formulations. 
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Level C correlation at time point t = 14 days for all formulations (formulations A to F) did not 
show any significant correlation (chart not shown). The slope of the linear regression was not 
significantly different from 0 (p-value = 0.2566). Equation of regression line was  
- 0.4 x + 44.8 and correlation coefficient - 0.55. 
 
3.2  Level A evaluation model 
 
Level A correlation profiles represent percentage of drug released in-vitro as a function of 
percentage of in-vivo drug released at the same time point. Predictability of the performed 
dissolution tests can therefore be evaluated for each time point. The correlation profiles of 
each formulation is presented in Figure 5.6 as a solid line for a test period of 40 days. None 
of the correlation profiles is linear, however, some trends could be observed, as described 
below. 
 
Figure 5.6: Correlation profiles level A for formulations A to F, for a drug release period of 40 
days. The cumulative drug released in-vivo is reported for the cumulative drug 
release in-vitro for each time point. 
 
 
Formulation A is based on the sole solvent triacetin and has a weight polymer to drug ratio of 
1:1. The in-vitro as well as the in-vivo drug release profiles are characterized by two 
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distinguished phases (Figure 3.6, Chapter 3 and Figure 4.5, Chapter 4). First, there is a 
phase during which the drug is rapidly released, the initial burst, followed by a second linear 
phase with lower and more constant drug release rates. Level A IVIVC for formulation A is 
presented by an almost linear curve. According to the obtained correlation profile, it seems 
that during the first 40 days of the experiment, the in-vitro drug release could be found 
presented in average twice the in-vivo drug release. The two phases of the drug release 
profiles from the sustained release injectables formed in-situ were found to occur 
concomitantly in both drug release tests performed with formulation A, with an overall greater 
magnitude for in-vitro dissolution test.  
 
Similarly to formulation A, formulation B contained only triacetin as solvent. However, 
polymer concentration in formulation B was reduced from 17.00 % (w/w) to 12.75 % (w/w), 
resulting in a weight polymer to drug ratio of 3:4. As reported before, initial burst from 
formulation B was increased for both in-vitro and in-vivo drug release experiments in 
comparison to formulation A, which contained higher polymer concentration (Figure 3.6, 
Chapter 3 and Figure 4.6, Chapter 4). Level A correlation profile of formulation B exhibits two 
distinguished phases: first, a phase with a much faster drug release in-vitro than in-vivo 
followed by a reversed tendency, where the in-vivo release occurred at higher rates than 
in-vitro. During the first phase of the release, already 60 % of the active ingredient was 
released in-vitro, while only 10 % of the drug was released in-vivo. During the second phase, 
the drug release was clearly faster for the in-vivo drug performance than for the in-vitro drug 
release. Level A correlation profile for formulation B indicates a poor predictability of the 
in-vitro dissolution test for in-vivo drug release performances. The increased initial burst 
resulting from the reduction of the polymer amount was obviously more pronounced in the 
in-vitro dissolution tests than in the in-vivo experiments.  
 
The overall percentage of drug released during the 40 days of the experiment was greater for 
formulation B than for formulation A, for both in-vitro and in-vivo experiments. This was 
reported to the reduced amount of polymer and the consequently increased initial burst 
release. 
 
Similarly to formulation A, formulation C had a weight polymer to drug ratio of 1:1, but 
contained, in addition to the main solvent triacetin, 10.00 % of co-solvent ethanol. Drug 
release  from formulation C, for in-vitro and in-vivo experiments, showed a reduced initial 
burst compared to formulation A (Figure 3.10, Chapter 3 and Figure 4.7, Chapter 4). 
Correlation curve of formulation C exhibits a sigmoid profile. At the very beginning, in-vitro 
drug release occurs at a faster rate than in-vivo drug release. Then, during the second phase 
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the in-vivo drug release was greater than the concomitant in-vitro performance. Finally, and 
until the end of the 40 days of the experiment, the slope of the correlation curve is reduced 
and suggest similar releasing rates for both, in-vitro and in-vivo conditions. 
 
Like formulation B, formulation D had a weight polymer to drug ratio of 3:4, and similarly to 
formulation C, it contained, in addition to the main solvent triacetin, 10.00 % of co-solvent 
ethanol. Drug release performance from formulation D showed, for in-vitro as well as in-vivo 
experiments, a reduced initial burst compared to formulation B due to the addition of the 
co-solvent ethanol, and an increased initial release compared to formulation C due to the 
reduced amount of PLA polymers (Figure 3.10, Chapter 3 and Figure 4.7, Chapter 4).  
 
Correlation profile of formulation D suggested a good predictability of the drug release 
performance. The fraction of drug released during the first two weeks of the experiments was 
slightly higher for in-vitro experiment than for in-vivo experiment. For the second half of the 
test, the inverse tendency was observed, with an increased in-vivo release compared to the 
in-vitro performance. This profile is similar, but in a less accentuate way, to the correlation 
profile of formulation B, which also contained a polymer to drug ratio of 3:4. 
 
Like formulations C, formulations E and F had weight polymer to drug ratios of 1:1 and 
10.00 % co-solvent above the main solvent triacetin. Glycerol formal is used as co-solvent for 
formulation E and anhydrous glycerol for formulation F. In-vitro as well as in-vivo drug 
release tests for formulation E (Figure 3.9, Chapter 3 and Figure 4.9, Chapter 4) and for 
formulation F (Figure 3.8, Chapter 3 and Figure 4.10, Chapter 4) showed reduced initial burst 
release, compared to formulation A, which contained no co-solvent but only triacetin as 
polymer solvent. Correlation profiles of formulations E and F were similar to correlation 
profile of formulation C. At the very beginning, level A correlation curves showed a faster 
drug release in-vitro than in-vivo. Then, during the second phase, the inverse tendency is 
observed, during which, the in-vivo drug release is faster than the in-vitro performance. For 
formulation F, a further phase was observed, during which the slope of the correlation profile 
indicates similar release rate for both experimental conditions for the last days of the 
investigated period.  
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4. Discussion 
 
IVIVC methods are increasingly used in development of extended release dosage forms and 
are now FDA regulated [Guidance for industry, 1997; EMEA, 1999; Burgess et al., 2002; 
Burgess et al., 2004]. Such methods aim to establish quantitative and reproducible 
relationships between some easily measurable in-vitro characteristics of a dosage form, such 
as the in-vitro dissolution rate and in-vivo biological parameters of interest that are 
considerably more time, labor and costs expensive. However, the ultimate goal is to develop 
a predictive model connecting the time course of relevant in-vivo pharmacokinetic 
parameters to the in-vitro release profile. Predictability is a desirable attribute in the 
assurance of drug product quality, since extrapolation is often the practical solution to 
achieve a scientific decision, regarding drug product performance. Correlation between 
in-vitro testing and in-vivo performances are encouraged, guidelines were published and 
since 1995, a chapter about in-vitro and in-vivo evaluation of the dosage forms is included in 
the USP edition. [USP 28, 2005 <1088>; Guidance for industry, 1997; EMEA, 1999]. 
  
Dissolution tests were carried out in Chapter 3 for evaluation of the in-vitro drug release over 
a period of 40 days from sustained released injectables formed in-situ in regards to initial 
burst and overall drug release rate, as function of drug content, polymer content, polymer 
type and solvent type. Based on in-vitro drug release profiles, injectability properties of the 
formulations, therapeutic and toxic parameters of the active ingredient as well as tolerability 
parameters of the excipients, six sustained release formulations were selected for in-vivo 
testing in dogs (Chapter 4). There were similarities between in-vitro and in-vivo drug release 
properties, however, correlations were not really observed. For example, it was evident that 
the reduction of the amount of polymer, increased the initial burst in both in-vivo and in-vitro 
experiments. However, it was not explicit if the magnitude of this effect was comparable in 
both conditions. Therefore, an attempt was made to correlate in-vitro and in-vivo data sets, to 
evaluate the predictive quality as well as the relevancy of the in-vitro dissolution model used. 
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4.1. Level C evaluation model 
 
Level C correlation relates a dissolution parameter to a pharmacokinetic parameter. It 
represents a single point correlation and does not reflect the complete shape of the plasma 
concentration time curve. Due to its restrictive prediction, it is usually used as a guide for the 
formulation development or for routine production quality control [Guidance for industry, 
1997, EMEA, 1999]. 
 
Level C IVIVC represented in Figure 5.1 correlates maximal blood concentration with the 
cumulative percentage of drug released during dissolution test at this time point. No 
significant correlation could be calculate. However, with the exception of the correlation point 
of formulation A, a clear trend could be observed, in which the in-vivo maximal blood 
concentration was positively correlated to the magnitude of drug released in-vitro at the same 
time point. For this correlation model, in-vivo data (Cmax) were used as measured and 
therefore all parameters of the in-vivo test conditions were included. 
 
Level C IVIVC was then calculated for the four formulations which contained 17.00 % (w/w) 
PLA polymers, excluding formulations B and D which contained reduced amount of PLA 
(12.75 % w/w). Formulations A, C, E and F differed only in their solvent mixture (for exact 
composition of formulations, see Table 5.1). As investigated in Chapters 3 and 4, solvent 
mixture is an important parameter influencing both in-vitro as well as in-vivo drug release 
properties of the formulation.  
 
For time point t = 2 days, a significant level C IVIVC could be found by evaluating the 
relationship between the cumulative percentage of drug released in-vitro and the calculated 
percentage of drug released in-vivo using equation 5.1. The slope of regression line was 
significantly different from 0 (p = 0.0362) and the correlation coefficient was - 0.9638. 
 
Surprisingly, the slope of the regression line of level C IVIVC at time t = 2 days was negative 
in a significant manner, with regards to p-value and the correlation coefficient. In a first 
approach, it can be interpreted that the more active ingredient is released during in-vitro 
dissolution test, the less is released during in-vivo experiments. However, this would 
contradict the level C correlation with Cmax values, which was positively correlated as well as 
the data set measured in Chapters 3 and 4. In-vivo values used for correlation, more 
specifically percentage of drug released, were calculated as function of total AUC. As already 
mentioned in Chapter 4, total AUC differs highly for each particular formulation, despite the 
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same amount of drug injected to each dog. Therefore, at the same in-vivo concentration 
values, percentage of drug released is higher for a formulation with poor bioavailability (low 
total AUC) than for a formulation with high bioavailability (high total AUC). Level C IVIVC at 
day 2 indicates therefore that formulations with poor bioavailability released, in a significant 
manner, a relative higher amount of active ingredient during the first two days. 
 
By using data set of the six investigated formulations (formulations A to F), it was impossible 
to establish any confident correlation for in-vitro and in-vivo drug release at time point t = 2 
days. Level C IVIVC is generally not useful for supporting major variations in composition. 
Polymer concentration is a factor which influences too radically drug release at the beginning 
of the treatment to allow a level C IVIVC. As example, relationship between in-vitro and 
in-vivo drug release for formulation B at time point t = 2 days could by far not be related to 
the release performances of the other formulations (Figure 5.3). 
 
It was impossible to establish any confident correlation for the in-vitro and in-vivo drug 
release for time points t = 7 days and t = 14 days. However, by using the set of formulations 
containing 17.00 % PLA polymer, predictability was higher than by using all six formulations 
(p-value and correlation coefficient in Figures 5.2 to 5.4). The lack of significant correlation 
for the formulations containing 17.00 % of PLA polymer was attributed to the small amount of 
samples used, as there was a similar clear trend in the scatter plot represented in Figures 
5.4 and 5.5.  
 
For the three time points to which level C IVIVC correlation was evaluated by using equation 
5.1 (the fraction of drug released at a given time point related to the cumulative percentage 
of drug released at the same time point), slopes of regression lines were found to be all 
negative. Furthermore, to correlate the formulation data set with the same amount of polymer 
(formulation A, C, E and F containing 17.00 % of PLA polymer), the slope of the related 
regression lines for the three different time points were found to be very similar, between -2.4 
and -2.1. The negative value of the slope of the regression lines in level C IVIVC can be 
explained by the high variability of total AUC values for the different formulations during 
in-vivo trials. Furthermore, kinetic of the drug release profile was not strictly considered 
during transformation of in-vivo drug concentration time profiles values. By using the AUC 
values the kinetic parameter of the drug release was restrained.   
 
 
 
 Chapter 5: In-vitro in-vivo correlation 
 
 
132 
IVIVC must be validated by estimating the magnitude of error in prediction for in-vivo release. 
It is generally recognized that the IVIVC for special dosage forms are difficult to obtain, 
because of complexity of drug release mechanism. Therefore, expectations for predictability 
of IVIVC of special dosage forms should not be set as high as for traditional solid oral dosage 
forms with immediate release and loaded with water soluble compounds [Siewert et al., 
2003]. However, specifications for sustained release dosage forms are set as for oral 
extended release formulations: the percent prediction error must be less than or equal to 
10 % for the mean absolute prediction error, and must be less than or equal to 15 % for all 
formulations [Guidance for industry, 1997]. However, excellent level C correlation was found 
for slow release biodegradable implant formulations containing the water soluble active 
ingredient buserelin with correlation coefficients varying from 0.977 and 0.999 [Schliecker et 
al., 2004]. 
4.2. Level A correlation model 
 
For level A IVIVC, the calculated fraction of drug absorbed in-vivo, as calculated with 
equation 5.1, was plotted versus the cumulative percentage released in-vitro for each time 
point. The in-vitro dissolution curve is therefore compared to the drug input rate curve which 
may be obtained through various methods for mass balance model techniques such as 
Wagner-Nelson procedure, in case the absorption curve adjusts to a model of one 
compartment, Loo-Riegelman method in case the adjustment is significant for a model of two 
compartments, or by model-independent evaluation using pharmacokinetic parameters. The 
straightest way of demonstrating a correlation is to plot the fraction absorbed in-vivo versus 
the fraction released in-vitro.  
None of the correlation profile illustrated in Figure 5.6 was linear. However, some 
correspondences could be found between the various releasing rate patterns. The correlation 
profiles of formulation A showed constant faster release for in-vitro as for in-vivo conditions. 
 
Formulations B and D, which both contained only 12.75 % of PLA polymer, resulting in a 
polymer to drug ratio of 3:4, exhibited in the first period of the experiments a faster in-vitro 
release, followed by a second period where in-vivo release rate was higher. Correlation 
profile of formulation B was clearly divided into these two phases, as the changes in 
correlation profile of formulation D were smoother. 
 
Correlation profiles of formulations C, E and F (containing all 17.00 % of PLA polymer and 
10.00 % of co-solvent) were characterized by a short initial phase where the in-vitro release 
was greater than the in-vivo release, followed by a longer second phase with inverse 
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tendency. For formulations C and F, the slope of the correlation profiles indicates for the end 
of the experiment, similar release rates for both conditions tested. 
 
The principle of system analysis primarily deals with linear schemes showing dose 
proportionality and time invariance. Although this requirements are never completely met in 
biological systems, in most applications it provides a correct approach. In case of level A 
IVIVC, drug release profiles are directly super-imposable or can be made super-imposable 
by applying a time scaling factor. The time scaling factor takes into account that in-vitro 
release do not always follow the same time scale than in-vivo absorption [Schliecker, 2004]. 
 
If the system is essentially non-linear, traditional linear treatment would not provide suitable 
results with respect to blood concentration or physiological effects. However, principles of 
systems analysis can be extent to non-linear cases. According to the high complexity of 
static and dynamic non-linearity in biological systems, no general mathematical solutions can 
be used but individual solutions must be found. An example of non-linear IVIVC model 
development has been described for multi-particulate bead extended release capsule 
formulations containing the highly water soluble active ingredient diltiazem [Sirisuth et al., 
2002]. Although IVIVC did not fully met the criteria for a valid correlation as specified in the 
IVIVC guidance (2.4 % over the acceptable limits), the complexity and the most relevant 
parameters which must be taken into account are clearly presented.  
 
The advantage of a validated level A IVIVC is that, in-vitro dissolution profile can serve as a 
substitute for in-vivo performance with high predictability. Thus, modifications of 
manufacturing site or method, change of raw materials supplier, small changes in formulation 
or in product strength, may be assessed without the need for additional studies on living 
organisms.  
4.3. Limitations of in-vitro dissolution test models  
 
An essential feature to obtain a good IVIVC is to have an in-vitro dissolution test method 
which shows sufficient relevance concerning drug release at in-vivo physiological conditions. 
The challenge remains to develop and identify suitable and reliable methods which can 
predicatively characterize drug release from various formulations. Furthermore, the 
experimental test conditions should be discriminating enough to detect the influence of 
composition or manufacturing modifications that affect biopharmaceutical product 
performance [Siewert et al., 2003, Dash et al., 1999].  
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The current USP test apparatus for in-vitro release testing are primarily designed for oral and 
transdermal products and may not be appropriate for sustained release parenteral 
formulations. The probably most relevant dissolution test apparatus for sustained or 
controlled release parenteral drug delivery system is the USP apparatus 4. It allows flexibility 
in volume, sample cell, flow rate and can be altered for specific product applications [Burgess 
et al., 2004]. 
 
IVIVC can help in objectively evaluating in-vitro dissolution test methods for given products. 
Bioequivalence experiments performed with three marketed oral formulations containing 
250 mg of the very slightly water soluble active ingredient primidone revealed that the in-vitro 
dissolution test method which gave significant different drug release profiles was too 
discriminating in comparison to the in-vivo pharmacokinetic data which were all statistically 
equivalent  [Meyer et al., 1998]. 
 
Physiological conditions at the site of administration should be considered when selecting the 
in-vitro dissolution test parameters [Siewert et al., 2003]. Composition of the medium should 
include buffer capacity of the fluids at site of administration. In the body, natural surfactants 
increase the dissolution and subsequent the absorption of drugs with limited aqueous 
solubility. Therefore, the use of the surfactant Solutol HS 15® in the dissolution medium of the 
in-vitro tests performed in Chapter 3 is physiologically relevant. Sink conditions refer to the 
solubilizing capacity of the dissolution medium [Rohrs, 2001].  
 
The solidification of a subcutaneous implant in the case of sustained release injectables 
formed in-situ, is dependent on the rate of fluid flow at injection site. A certain quantity of 
water is required for precipitation of the polymers and for formation of the solid biodegradable 
matrix [Shively et al., 1995]. As determined in Chapter 3, quantity of water needed for implant 
formation tend to decrease as the polymer concentration is increased. This has important 
implications with regard to the design of appropriate in-vitro dissolution test methods, 
particularly in which concerns dissolution medium. The subcutaneous and intramuscular 
environment has been shown to have limited amounts of water [Shively et al., 1995]. Since 
fluid flow in adipose tissue may range from 7 to 53 ml/100 g per min., in-vitro implant 
formation in an aqueous milieu may be erratic. A delay in the in-vivo solidification of the 
implant may result in a higher initial release as the drug dissolved in the polymer solvent is 
more likely to diffuse out of the polymer and into the surrounding tissue [Shively et al.,1995]. 
Furthermore, movement of muscles and tissues may alter in-vivo drug release conditions. 
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The Biopharmaceutical Classification System (BCS) can provide a basis for predicting the 
likelihood of achieving a successful IVIVC, essentially for oral drug delivery systems. Based 
on drug solubility and permeability, the BCS divided active ingredients into four classes. The 
BCS suggest that for substances of high solubility and high permeability (class I), as well as 
for substances with high solubility and low permeability (class III), the bioavailability is not 
limited by dissolution. In the case of active ingredient of low solubility and high permeability 
(class II), drug dissolution may be the rate limiting step for drug absorption and a IVIVC may 
be expected. Concerning drug of low solubility and low permeability (class IV), likelihood of a 
successful IVIVC is not assumed [Guidance for industry, 1997]. In-vitro dissolution test 
should be used as a surrogate for the in-vivo performance of a drug only if the rate limiting 
step is the release of the drug from the formulation [Siewert et al., 2003]. In-vitro dissolution 
release test for special dosage forms should take into account relevant bioavailability data 
obtained by clinical research. The complexity of in-vivo release mechanisms from sustained 
release dosage forms increases the difficulty to design physiologically based in-vitro tests. 
 
The in-vitro dissolution test provides a simplified model in comparison to the multi-
compartments physiological models. Usually, the in-vivo parameter used for correlation is the 
detected blood level of the experimental animals. However, the in-vivo drug release from the 
implant is not necessary directly correlated to the measured blood level. After the injection of 
the liquid formulation in the subcutaneous milieu and the solidification of the polymeric 
matrix, the active ingredient has to pass various physiological barriers before it can be 
detected in the blood. Biopharmaceutical parameters influencing the active ingredient blood 
concentration include clearance, distribution volume, permeation rate from the subcutaneous 
milieu to the blood stream, eventual formation of a capsule around the polymeric matrix, 
possible degradation of the drug by enzymes, metabolism of the drug, protein bindings and 
even spontaneous drug degradation at 37°C. All these parameters, with exception of the 
spontaneous chemical degradation, are neglected during the in-vitro dissolution test and 
may, on their own, or in combination, dramatically influence the plasma drug profile. 
Therefore, it must be emphasized that the measured blood concentration data resulting from 
numerous parameters and may not necessarily primarily reflect the drug release from 
implants.  
 
An essential feature to obtain a good IVIVC is to have an in-vitro dissolution test method 
which shows sufficient relevance concerning drug release at in-vivo physiological conditions. 
The challenge remains to develop and identify suitable and reliable methods which can 
predicatively characterize drug release from various formulations. Furthermore, the 
experimental test conditions should be discriminating enough to detect the influence of 
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composition or manufacturing modifications that affect biopharmaceutical product 
performance [Dash et al., 1999; Siewert et al., 2003].  
 
The current USP method apparatus for in-vitro release testing are primarily designed for oral 
and transdermal products and may not be appropriate for sustained release parenteral 
formulations. The probably most relevant dissolution test apparatus for sustained or 
controlled release parenteral drug delivery system is the USP apparatus 4. It allows flexibility 
in volume, sample cell, flow rate and can be altered for specific product applications [Burgess 
et al., 2004]. 
 
IVIVC can help in objectively evaluating in-vitro dissolution test methods for given products. 
Bioequivalence experiments performed with three marketed oral formulations containing 
250 mg of the very slightly water soluble active ingredient primidone revealed that the in-vitro 
dissolution test method which gave significant different drug release profiles was too 
discriminating in comparison to the in-vivo pharmacokinetic data which were all statistically 
equivalent [Meyer et al., 1998]. 
 
Physiological conditions at the site of administration should be considered when selecting the 
in-vitro dissolution test parameters [Siewert et al., 2003; Dash et al., 1999]. Composition of 
the medium should include buffer capacity of the fluids at site of administration. In the body, 
natural surfactants increase the dissolution and subsequent absorption of drugs with limited 
aqueous solubility. Therefore, the use of the surfactant Solutol HS 15® in the dissolution 
medium of the in-vitro tests performed in Chapter 3 is physiologically relevant. Sink 
conditions refer to the solubilizing capacity of the dissolution medium [Rohrs, 2001].  
 
The solidification of a subcutaneous implant in the case of sustained release injectables 
formed in-situ, is dependent on the rate of fluid flow at injection site. A certain quantity of 
water is required for precipitation of the polymers and for formation of the solid biodegradable 
matrix [Shively et al., 1995]. As determined in Chapter 3, quantity of water needed for implant 
formation tend to decrease as the polymer concentration is increased. This has important 
implications with regard to the design of appropriate in-vitro dissolution test methods, 
particularly in which concerns dissolution medium. The subcutaneous and intramuscular 
environment has been shown to have limited amounts of water [Shively et al., 1995]. Since 
fluid flow in adipose tissue may range from 7 to 53 ml/100 g per min., in-vitro implant 
formation in an aqueous milieu may be erratic. A delay in the in-vivo solidification of the 
implant may result in a higher initial release as the drug dissolved in the polymer solvent is 
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more likely to diffuse out of the polymer and into the surrounding tissue [Shively et al.,1995]. 
Furthermore, movement of muscles and tissues may alter in-vivo drug release conditions. 
 
In-vitro dissolution release test for special dosage forms should take into account relevant 
bioavailability data obtained by clinical research. The complexity of in-vivo release 
mechanisms from sustained release dosage forms increases the difficulty to design 
physiologically based in-vitro tests. In-vitro dissolution test should be used as a surrogate for 
the in-vivo performance of a drug only if the rate limiting step is the release of the drug from 
the formulation [Siewert et al., 2003].  
 
The in-vitro dissolution test provides a simplified model in comparison to the multi-
compartments physiological models. Usually, the in-vivo parameter used for correlation is the 
detected blood level of the experimental animals. However, the in-vivo drug release form the 
implant is not necessary directly correlated to the measured blood level. After the injection of 
the liquid formulation in the subcutaneous milieu and the solidification of the polymeric 
matrix, the active ingredient has to pass various physiological barriers before detection in 
blood. Above the effective drug release from the implant matrix, further physiological or 
biopharmaceutical parameters influence active ingredient blood concentration. It includes 
clearance, volume of distribution, permeation rate from the subcutaneous milieu to the blood 
stream, eventual formation of a capsule around the polymeric matrix, eventual degradation of 
the drug by enzymes, metabolism of the drug, protein bindings and even spontaneous drug 
degradation at 37°C. All these parameters, with exception of the spontaneous chemical 
degradation, are neglected during the in-vitro dissolution test and may, on their own, or in 
combination, dramatically influence the plasma drug profile. Therefore it must be emphasized 
that measured blood concentration are in-vivo data resulting from numerous parameters and 
may not necessarily primarily reflect the drug release from implants.  
 
Therefore, it was suggested to establish IVIVC for various dissolution test parameters and 
choose the variables in order to reach optimal bio-relevant conditions. The in-vitro tests allow 
a first selection of formulations parameters, and helps to understand drug release 
mechanisms. In addition they, are important for batch control quality as well as similarity and 
reproducibility of the drug release for given conditions. Adjustments of the in-vitro data to fit 
better physiological conditions are justified for validation of level A IVIVC, as an established 
correlation may reduce the number of bioequivalence studies during product development, 
be helpful in setting specifications and be used to facilitate certain regulatory decisions such 
a scale up or post-approval variations [EMEA, 1999] 
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4.3. Evaluation of pharmacokinetic parameters  
 
Different approaches and methods have been designed to set IVIVC for biodegradable 
parenteral dosage forms. However, in the literature, only few examples can be found where 
an in-vitro drug method predicts the in-vivo release profiles for parenteral biodegradable 
depot systems [Negrín et al., 2001]. This points out the challenge in establishing IVIVC for 
these formulation types due to the various parameters affecting in-vivo and in-vitro drug 
release [Schliecker et al., 2004; Negrín et al., 2001; Dash et al., 1999; Woo et al., 2001]. 
Expectations with respect to quality and level of IVIVC of special dosage form should not be 
set as high as for solid oral dosage forms, because of their higher level of complexity 
[Siewert et al., 2003].  
 
The evaluation of in-vivo drug release was based on the observed total AUC[o,∞] using a 
independent profile model. According to the pharmacokinetics reported in Chapter 4, Table 
4.4, fraction of drug released during the whole duration of in-vivo experiments were 
surprisingly low and dissimilar. They represented 25 % and 76 % of the total active ingredient 
integrated in the implant of formulation A, 89 % and 64 % of formulation B, 42 % and 18 % of 
formulation C, 11 % and 15 % of formulation D, 16 % and 23 % of formulation E and 12 % 
and 13 % of formulation F. As the injected active ingredient amount was identical for all 
tested formulations (400 mg) and as the body weight of the experimental animals varied 
between 8.6 kg and 12.0 kg, the overall AUC
 
for the different release profiles were expected 
to be more similar. Hypotheses such as incomplete release from the implant due to a too 
dense polymeric matrix, encapsulation of the implant with connective tissues, degradation of 
the active ingredient within the implant or incomplete absorption of the active ingredient from 
the subcutaneous milieu have been proposed (Chapter 4). Such elements cannot be 
simulated during in-vitro drug release testing. As already mentioned in Chapter 4, in-vivo 
data obtained with two dogs per groups are not robust enough for further analysis like IVIVC. 
Inter-animal variation after injection of such formulation was in some cases too important, 
that the prediction based on such data are unreliable.   
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5. Conclusion 
 
The purpose of this study was to investigate the possibility to develop different levels of 
correlation between in-vitro dissolution parameters and in-vivo pharmacokinetic parameters 
for NOA449851 sustained release injectables formed in-situ.  
 
Therefore attempt for level C IVIVC was performed, using as pharmacokinetic parameter 
Cmax or an evaluated value of the fraction of drug released at given time points, in relation to 
cumulative in-vitro drug release at the same time point. The correlation level C for Cmax with 
the cumulative in-vitro drug release was positively correlated, however not in significant 
manner. A significant correlation, but negative, was found for formulations containing 
17.00 % of PLA polymers two days after injection. The relationship was negatively 
correlated, probably because of important differences in the total AUC values obtained in-
vivo for the various formulations. Level A correlation profiles showed no linearity correlation 
for any formulation profile. However, some similarities for in-vitro and in-vivo drug release 
relationship could be observed. In general, it should be concluded that for this type of dosage 
form and drug no satisfactory IVIVC could be observed. 
 
A simple kinetic model is unlikely to explain the overall in-vivo release behavior since the 
drug release is influenced by factors such as diffusion, dissolution and erosion. The in-vitro 
drug release studies permit a better comprehension of the different drug release mechanism 
from the particular delivery device, and help selecting parameters of the formulation to 
approach an ideal drug release. However, the model used for in-vitro drug release testing 
neglect some crucial aspects of the physiological conditions and cannot replace biological 
systems. Furthermore, the technique for mass balance model should be carefully evaluated 
to prevent alteration of data as function of relevant biopharmaceutical parameter, as in the 
present case. 
 
In view of the use of IVIVC as a surrogate for in-vivo performance, it should be verified that 
the predictability of the in-vivo performance of a product based on its in-vitro dissolution 
profile is valid for the in-vitro dissolution rates covered by the specifications. This evaluation 
should focus on the estimation of the predictive performance or, conversely prediction error.  
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Chapter 6 
 
Stability Studies of three Formulations containing the 
active ingredient NOA449851, PLA Polymers and Triacetin 
 
 
1. Introduction and objectives 
 
As part of development of new drug delivery systems, one of the most decisive issues is long 
term stability of formulations during storage. In sustained release injectables formed in-situ, 
various parameters should be investigated. Firstly, stability of the active ingredient 
NOA449851 and possible formation of by-products should be determined. Secondly, stability 
of the used PLA polymers, the excipient which confers to formulations modified release 
properties, should be evaluated. 
 
Three formulations investigated for their in-vitro and in-vivo release properties (see Chapter 3 
and 4) were selected for stability studies. These formulations, as well as their related 
placebos, were stored during six months at four different temperatures. An HPLC-method 
was utilized to determine drug content as well as appearance and quantification of four of 
known by-products. GPC was used to analyze molecular weight of the PLA polymers. 
Additionally, a NIR screening method was used as rapid, non destructive and innovative 
analytical method to follow various stability parameters of formulations and related placebos. 
To provide functional control, in-vitro release properties was investigated for a formulation 
stored for six months at 40°C, and compared with in-vitro release properties of the same 
formulation evaluated directly after manufacturing. 
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2. Materials and methods 
2.1 Materials  
 
The active ingredient NOA449851 was obtained from CarboGen Laboratories, Aarau, CH. 
PLA polymers (inherent viscosity: 0.68 dl/g in trichloromethane at 30°C) were provided by 
Birmingham Polymers Inc., Birmingham, AL, USA. Triacetin and THF were obtained from 
Fluka AG, Buchs, CH. Ethanol absolute, acetonitrile, phosphoric acid 85 % and water for 
chromatography were purchased from Merck Inc., Darmstadt, D. All solvents were of reagent 
analytical grade. 
 
2.2. Preparation of formulations 
 
Formulations were prepared as already described in Chapter 3, Section 2.2.1.1. All 
formulations contained PLA as biodegradable polymers, NOA449851 as active ingredient 
and triacetin as main solvent. Formulation A contained 17.00 % (w/w) of active ingredient 
NOA449851 as well as 17.00 % (w/w) of PLA polymers, resulting in a weight polymer to drug 
ratio of 1:1. In formulation B, PLA polymer concentration was reduced to 12.75 % (w/w), 
resulting in a weight polymer to drug ratio of 3:4. In formulation C, weight polymer to drug 
ratio was again 1:1, but a fraction of the solvent triacetin was replaced by the co-solvent 
ethanol absolute. Exact compositions of the three formulations are listed in Table 6.1. Beside 
the formulations, two kinds of placebos were prepared: placebos 1 without active ingredient 
and placebos 2, containing neither active ingredient nor PLA polymers. All placebos 
contained an increased amount of triacetin to compensate for the active ingredient or the 
PLA polymers. 
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Table 6.1: Compositions [% (w/w)] of formulations A, B and C as well the two kinds of placebos 
used for stability studies. 
 
Formulation Component 
Concentration of 
component 
Placebo 1 
(no drug) 
Placebo 2 
(no drug,  
no polymer) 
  
[% (w/w)] [% (w/w)] [% (w/w)] 
A 
NOA449851 
PLA 
triacetin 
17.00 
17.00 
66.00 
- 
17.00 
83.00 
- 
- 
100.00 
B 
NOA449851 
PLA 
triacetin 
17.00 
12.75 
70.25 
- 
12.75 
87.25 
- 
- 
100.00 
C 
NOA449851 
PLA 
triacetin 
ethanol 
17.00 
17.00 
56.00 
10.00 
- 
17.00 
73.00 
10.00 
- 
- 
90.00 
10.00 
 
 
2.3. Storage of formulations  
2.3.1. Storage for HPLC and GPC analysis 
 
Formulations A, B and C as well as placebos B1 and C1 were filled up in glass vials and 
closed with rubber stoppers and aluminum caps. The hermetically closed vials were stored 
for six months at four different temperatures set at 5°C, 25°C, 30°C and 40°C (Klimazelle 
Rosenmund, Liestal, CH).  
 
2.3.2. Storage for NIR-screening 
 
Approximately 200 mg of the liquid formulations A, B and C as well as their placebos 1 and 2 
were filled in glass sample vials. These were closed with a plastic cap and sealed with an 
epoxy mixture to prevent contamination. Sample vials were placed for six months in two 
racks of a Bruker SpecScreen X HTS apparatus heated at 25°C and 40°C.  
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2.4. Active ingredient and by-products determination 
 
In order to determine stability of the active ingredient and appearance of by-products during 
storage, HPLC-analysis was carried out directly after manufacturing as well as after 1, 3 and 
6 months storage at 5°C, 25°C, 30°C and 40°C for formulations A, B and C.  
 
2.4.1. Preparation of samples for HPLC-analysis 
 
Approximately 250 mg of each formulation were weighed into 100 ml volumetric flasks. The 
flasks were filled up to calibration line with acetonitrile. The mixtures were shaken manually 
and put in the ultrasonic bath until complete dissolution. Each active ingredient determination 
was made in triplicate. 
 
2.4.2. HPLC-method  
 
Content of NOA449851 and of four of its by-products in formulations was determined with 
HPLC. For this purpose, a LC HP 1100 (Hewlett Packard, Basel, CH) apparatus was used. 
Column (250 mm length and 4.6 mm internal diameter) was packed with Nucleosil 5 µm, C18 
(Macherey-Nagel, Düren, D) and maintained at a temperature of 25°C. Elution medium 
consisted of a mixture of acetonitrile and an aqueous solution of phosphoric acid 0.05 % 
(v/v). Composition of mobile phase permanently changed in relation to the time of 90 min. 
Flow rate was 1.3 ml/min during the whole analyze run. A volume of 15 µl of sample solution 
was injected per run with an auto-sampler. Samples were detected and analyzed with 
UV-light at a wavelength of 240 nm. 
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2.5. Molecular weight analysis of PLA polymers 
 
Molecular weights of the PLA polymers in formulations B and C as well as in the related 
placebos B1 and C1 were determined with GPC. Samples were analyzed directly after 
manufacturing as well as after 1, 3 and 6 months storage at 5°C, 25°C and 40°C. 
 
2.5.1. Preparation of samples for GPC-analysis 
 
Formulations and placebos samples containing PLA polymers were diluted with THF to 
obtain a polymer concentration of 0.3 % (w/v). Before GPC-analysis, the solutions were 
filtered through 1.0 µm pore size filters. 
 
2.5.2. GPC-method 
 
For molecular weight determination of PLA polymers, an HPLC system with a Spectra-
Physics Isochrom HPLC-pump and a Shodex RI-71 differential refractive index detector were 
used. Three GPC-columns (PSS SDV, styrenedivinylbenzene copolymer, particle size 5 µm, 
pore size 102 Ǻ, ID 8.0 mm x 300 mm; PSS SDV, styrenedivinylbenzene copolymer, particle 
size 5 µm, pore size 103 Ǻ, ID 8.0 mm x 300 mm and PSS SDV, styrenedivinylbenzene 
copolymer, particle size 5 µm, pore size 105 Ǻ, ID 8.0 mm x 300 mm) were connected in 
series and maintained at a temperature of 23°C. A guard column (PSS SDV, 
styrenedivinylbenzene copolymer, particle size 5 µm, pore size 102 Ǻ, ID 8.0 mm x 50 mm) 
was connected in front of the three GPC-columns. THF was used as mobile phase at a 
constant flow rate of 1.0 ml/min. A volume of 100 µl of each sample was injected with an 
auto-sampler (Spark-Triathlon Autosampler, Techlab GmbH, Erkerode, D). Molecular 
weights of PLA polymers were calculated from elution volume of polystyrene standards. 
Calibration line was established using a series of polystyrene standards of narrow molecular 
weight distribution, with a molecular weight in a range from 162 Da to 2’570’000 Da. 
 
Degradation rate constant k was determined for each sample at storage temperatures of 
5°C, 25°C and 40°C. A trendline was obtained for each sample stored at a defined 
temperature from charts illustrating molecular weight changes verses time. Values of kinetic 
constants k are obtained from the slopes of the linear trendlines.  
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2.6. Low field NMR-screening (NIR-screening)  
 
Low field NMR-spectroscopy (NIR-spectroscopy) provides a non-invasive, rapid, 
reproducible and relatively inexpensive means of characterizing formulations. This vibrational 
spectroscopic technique was used as complementary alternative method for storage stability 
determination of the three formulation candidates and corresponding placebos. 
 
2.6.1. NIR-method 
 
Formulations A, B and C as well as their placebos 1 and 2 were scanned by NIR-
spectroscopy using a Bruker SpecScreen x HTS apparatus at intervals of 24 h over a period 
of six months for storage temperatures of 25°C and 40°C. An Infrared Fourier Spectrometer 
Vector 22/N-T spectrometer was used. Scans were taken at a rate of 5 spectra/second and 
with a resolution of 8 cm-1.  
 
2.6.2. Low field NMR data evaluation (NIR data evaluation) 
 
Evaluation of low filed NMR spectroscopic data sets was performed by statistical analysis 
with respect to systematic changes in the spectra during storage period of the samples. Data 
analysis focused on statistical evaluation of a predetermined spectra range, in order to 
identify wavelength regions with detectable differences in time. Therefore, data evaluation 
algorithm was used: it consisted of data pretreatments, principal component analysis and 
linear regression analysis of the first two principal components regarding systematic 
modifications in the spectra during storage. Kinetic profiles of changes were calculated and 
comparison for related samples were made possible after further data pretreatment which fit 
both arbitrary Y-axis to the same input value. Slopes of the calculated regression lines 
indicated which samples or which storage conditions lead to better stability [Bruker User’s 
manual, 1996 ]. 
2.7. pH measurement of solvent triacetin 
 
The pH value of solvent triacetin was investigated after three months storage at 25°C and 
40°C. According to chemical structure of triacetin, degradation would affect first ester bounds 
of the molecule, leading to  acetic acid as degradations product. Therefore, a volume of 
25.0 ml of triacetin was mixed to 100.0 ml of water and the pH of this mixture was measured 
(Metrohm electrode, Type 3M KCl) under mechanical stirring.  
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2.8. In-vitro release of formulation A after six months storage at 40°C 
 
To evaluate impact of stability parameters on drug release performance, a functional control 
was required. Therefore, after six months storage at 40°C, formulation A was investigated for 
in-vitro drug release, using the same dissolution test method as in Chapter 3, Section 
2.2.1.3. Drug release profile of the stored formulation was compared with the one of the 
identical formulation tested directly after manufacturing (in-vitro drug release profile of 
formulation PLA-AI(1:1), illustrated in Figure 3.3, of Chapter 3). 
 
For comparison of two dissolution profiles, Moore and Flanner have proposed a simple 
model independent approach using mathematical indices to define difference factor (f1) and 
similarity factor (f2) [Moore et al., 1996]. These factors directly compare differences between 
percentage of drug dissolved per unit time for a test and a reference formulation. There were 
defined by Equations 6.1 and 6.2, 
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where Rt is the reference assay at time point t, Tt is the test assay at time point t and n is the 
number of pull points. Difference factor f1 is proportional to the average difference between 
both profiles. The percent error is zero when test and reference profiles are identical and 
increases with dissimilarity between the two profiles. Similarity factor f2 measures the 
closeness between the two profiles. It is a logarithmic transformation of the sum of squared 
error. It takes the average sums of squares of the difference between test and reference 
profiles and fits the results between 0 and 100. The similarity factor (f2) is 100 when the test 
and the reference profiles are identical and approaches zero as the dissimilarity increases. 
Similarity factor (f2) is recommended for dissolution profile comparison in the FDA’s 
Guidance for Industry. FDA has set a public standard of f2 value between 50-100 to indicate 
sameness or equivalence of two dissolution profiles [Shah et al., 1998]. 
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3. Results 
3.1. Active ingredient content and by-products determination 
3.1.1. Active ingredient content 
 
Content of active ingredient in the three formulations was determined after manufacturing 
with an HPLC-method and the results are depicted in Table 6.2. The declared concentration 
of active ingredient was 17.00 % (w/w). All active ingredient determinations were done in 
triplicate. The measurements were made directly after manufacturing and at three different 
time points during the six months storage at four selected temperatures.  
 
 
Table 6.2: Active ingredient contents in formulations A, B and C directly after manufacturing. 
The values are reported in percent [% (w/w)] of the weighted mass (n = 3 ± S.D.). 
 
Formulation Declared AI content  Real AI content ± S.D. 
Percent of declared 
content  
 [% (w/w)] [% (w/w)] [% (w/w)] 
A 17.00 17.18 ± 0.862 101.06 
B 17.00 17.38 ± 0.437 102.24 
C 17.00 17.47 ± 0.598 102.76 
 
 
Active ingredient content determined at four selected time points during the six months 
storage are depicted in Figures 6.1 to 6.4. Content of active ingredient is reported in percent 
of the corrected initial amount, 100 % representing the amount of drug at beginning of 
storage period. Each figure shows the active ingredient content in formulations A, B and C 
during the six months storage period for a defined temperature. 
 
Active ingredient content in percent of the initial value after six months storage at 5°C was 
determined to be 101.73 % (w/w) ± 0.84 for formulation A, 99.98 % (w/w) ± 1.76 for 
formulation B and 102.07 % (w/w) ± 0.39 for formulation C. All results for active ingredient 
stability study during storage at 5°C are graphically represented in Figure 6.1.  
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Figure 6.1: Active ingredient content in percent [% (w/w)] of the initial corrected value for 
formulations A ( ), B ( ) and C ( ) during six months storage at 5°C 
(n = 3 ± S.D.).  
 
 
After six months storage at 25°C, recovery of active ingredient in percentage of initial 
corrected value represented 100.99 % (w/w) ± 0.81 for formulation A, 100.35 % (w/w) ± 1.01 
for formulation B and 99.64 % (w/w) ± 1.28 for formulation C. Stability results of active 
ingredient concerning storage at 25°C are illustrated in Figure 6.2. 
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Figure 6.2: Active ingredient content in percent [% (w/w)] of the initial corrected value for 
formulations A ( ), B ( ) and C ( ) during six months storage at 25°C 
(n = 3 ± S.D.). 
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After six months storage at 30°C, active ingredient content in percent of initial corrected 
value was 100.41 % (w/w) ± 0.34 for formulation A, 100.19 % (w/w) ± 0.66 for formulation B 
and 98.51 % (w/w) ± 0.19 for formulation C. Results of active ingredient content during 
storage at 30°C are illustrated in Figure 6.3.  
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Figure 6.3: Active ingredient content in percent [% (w/w)] of the initial corrected value for 
formulations A ( ), B ( ) and C ( ) during six months storage at 30°C 
(n = 3 ± S.D.).  
 
 
Active ingredient content decreased in all three formulations after six months storage at 
40°C. The main decrease of active ingredient was observed in formulation C with an active 
ingredient content in percent of the initial corrected value of 92.89  % (w/w) ± 0.35, followed 
by formulation A with 94.09 % (w/w) ± 0.28 and formulation B with 95.46 % (w/w) ± 0.39. 
Results for active ingredient stability study during storage at 40°C are graphically 
represented in Figure 6.4.  
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Figure 6.4: Active ingredient content in percent [% (w/w)] of the initial corrected value for 
formulations A ( ), B ( ) and C ( ) during six months storage at 40°C 
(n = 3 ± S.D.). 
 
 
For storage temperature of 40°C, trendline of each formulation was calculated from the chart 
illustrated in Figure 6.4 and used to evaluate storage time until degradation of 10 % of the 
active ingredient. The equations of the linear trendline of type “y = ax + b” are listed in Table 
6.3. Time for degradation of 10 % of the active ingredient was obtained by calculating x-value 
when y-value was set as 90 in the related equation. Time until active ingredient content 
dropped to 90 % was evaluated to be 10.57 months for formulation A, 13.46 months for 
formulation B and 8.19 months for formulation C for storage at 40°C.  
 
 
Table 6.3: Equation of trendline for each formulation stored at 40°C as well as the evaluation 
of the time [month] to reach a drug content of 90 % (w/w). 
 
Formulation Equation of trendline Evaluated time until 10 % of AI degraded 
 [y = ax + b] [month] 
A y = -1.0055 x + 100.63 10.57 
B y = -0.7586 x + 100.21 13.46 
C y = -1.2551 x + 100.28 8.19 
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3.1.2. By-products analysis 
 
The HPLC-method described in Section 2.4.2 for determination of the active ingredient 
content also permitted to detect and quantify four known by-products of NOA449851. These 
substances are designated as BP-1, BP-2, BP-3 and BP-4. Degradation mechanisms of the 
active ingredient resulting in the various by-products are typical hydrolytic as well as 
oxidation reactions. None of the by-product is known to have any particular toxic effect. 
Detection of by-products in formulations A, B and C was performed directly after 
manufacturing and after 1, 3 and 6 months storage at 5°C, 25°C, 30°C and 40°C. The 
amount of by-products detected is reported in Figures 6.5 to 6.7, in percent of declared 
amount of active ingredient.  
 
During six months storage of formulation A at four different selected temperatures, 
by-products of active substance NOA449851 were detected with HPLC-method described in 
Section 2.4.2. At storage temperatures of 5°C, 25°C and 30°C, by-products content in 
percentage of declared amount of active ingredient was below 0.2 % (w/w). After six months 
storage at 40°C, BP-1 and BP-4, were found to be at concentrations of 0.45 % (w/w) and 
0.82 % (w/w), respectively. Results are graphically represented in Figure 6.5.  
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Figure 6.5: Amount of the four by-products of the active ingredient NOA449851 in formulation A 
during six months storage at 5°C, 25°C, 30°C and 40°C. The by-products 
concentration was given in percent [% (w/w)] of the declared amount of active 
ingredient in the formulation.  
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Four by-products of NOA449851 were detected with HPLC during the six months storage of 
formulation B. As for formulation A, by-product content in percent of the declared value of 
active ingredient remained below 0.2 % (w/w) for the storage temperatures 5°C, 25°C and 
30°C. After six months storage at 40°C, by-products BP-1 and BP-4 were found to be at 
concentrations of 0.41 % (w/w) and 0.66 % (w/w), respectively. All results concerning 
by-products detection in formulation B are represented in Figure 6.6. 
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Figure 6.6: Amount of the four by-products of the active ingredient NOA449851 in formulation B 
during six months storage at 5°C, 25°C, 30°C and 40°C. The by-products 
concentration was given in percent [% (w/w)] of the declared amount of active 
ingredient in the formulation.  
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By-products of the active substance NOA449851 were detected with HPLC-method during 
the six months storage of formulation C at four different temperatures. At storage 
temperatures of 5°C and 25°C, all by-products contents in percent of the declared value of 
the active ingredient, were below 0.2 % (w/w). After six months storage, BP-1 was detected 
for storage temperature of 30°C in a concentration of 0.21 % (w/w) and for 40°C in a 
concentration of 0.59 % (w/w). BP-4 reached after six months storage at 40°C a 
concentration of 0.45 % (w/w). All results concerning by-products analysis during storage of 
formulation C are represented in Figure 6.7.  
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Figure 6.7: Amount of the four by-products of the active ingredient NOA449851 in formulation C 
during six months storage at 5°C, 25°C, 30°C and 40°C. The by-products 
concentration was given in percent [% (w/w)] of the declared amount of active 
ingredient in the formulation.  
 
 
There were no noticeable differences between formulations A, B and C, concerning 
by-products appearance during six months storage. By-products concentrations tend to 
increase with time and temperature storage. In the three tested formulations, particularly 
BP-1 and BP-4 were present after six months storage at storage temperature of 40°C, but 
remained at concentrations lower than 1 % of declared amount of active ingredient.  
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3.2. Molecular weight analysis of PLA polymer 
 
Changes in molecular weight of PLA polymer in formulations B and C as well as in related 
placebos B1 and C1 were determined using GPC. Molecular weight of PLA polymer were 
measured at four time points during the six months storage at the selected temperatures of 
5°C, 25°C and 40°C. 
 
Molecular weight of PLA polymer measured directly after manufacturing was 69’500 Da for 
formulations B and C and placebos B1 and C1 (same PLA polymer batch). Changes in 
average molecular weight of PLA polymer are represented in percent of the initial value, 
100 % representing the molecular weight directly after manufacturing.  
 
Reduction of the average molecular weight of PLA polymer in formulation B and its related 
placebo B1 for storage temperatures of 5°C, 25°C and 40°C are illustrated in Figure 6.8. 
Changes in molecular weight of the PLA polymers were highly dependent on the temperature 
storage. The higher the storage temperature the more important was the reduction of 
molecular weight. After six months storage at 40°C, the molecular weight of PLA polymer in 
formulation B was reduced to 26.4 % of the initial value, whereby it was reduced during the 
same period of time to 80.9 % and to 90.6 % of the initial value for storage temperatures of 
25°C and 5°C, respectively.  
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At a determined storage temperature, PLA polymers of the placebo B1 were generally more 
reduced than PLA polymers of related active ingredient containing formulation B. Molecular 
weight of PLA polymer in active ingredient containing formulation B was reduced to 26.4 % of 
the initial value after six months storage at 40°C, whereby it was reduced to 9.5 % of the 
initial value for the related placebo B1 at the same storage conditions. Similarly, at storage 
temperature of 25°C, PLA polymers molecular weights were reduced to 80.9 % for 
formulation B, and to 59.4 % for placebo B1. 
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Figure 6.8: Molecular weight (MW) changes of PLA polymer in formulation B (black) and 
placebo B1 (white) at four selected time points during the six months storage at  
5°C ( , ), 25°C ( , ) and 40°C ( , ). 
 
 
Molecular weight changes of PLA polymer of formulation C and related placebo C1 during 
the six months storage at the three different temperatures 5°C, 25°C and 40°C are reported 
in Figure 6.9. As differences with formulation B, formulation C contained 17.00 % (w/w) of 
PLA polymer instead of 12.75 % (w/w) as well as 10.00 % (w/w) of ethanol absolute as 
co-solvent. The exact composition of the samples are described in Table 6.1. Changes in 
molecular weight of PLA polymer in formulation C and its relative placebo C1 are reported in 
percent of the initial value. Similarly to formulation B, reduction of molecular weight of PLA 
polymer of the formulation C and its related placebo C1 was highly dependent on storage 
temperature. Bigger changes were observed for formulations stored at 40°C than for 
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formulations stored at 25°C or 5°C. After six months storage at 40°C, molecular weight of 
PLA polymers in formulation C were reduced to 24.0 % of their initial value, whereby it was 
reduced during the same period of time to 69.5 % and to 85.5 % of their initial value for 
storage temperatures of 25°C and 5°C, respectively.  
 
Similarly to formulation B, changes in molecular weight of PLA polymers were more 
important in placebo C1 than in active ingredient containing related formulations C. After six 
months storage at 40°C, molecular weight of PLA polymers in active ingredient containing 
formulation C was reduced to 24.0 % of their initial value, whereby it was reduced to 9.5 % of 
their initial value for related placebo C1 at same storage conditions. 
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Figure 6.9: Molecular weight (MW) changes of PLA polymer in formulation C (black) and 
placebo C1 (white) at four selected time points during the six months storage at  
5°C ( , ), 25°C ( , ) and 40°C ( , ). 
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The molecular weight analysis of the PLA polymers in formulations B and C and their related 
placebos B1 and C1 was carried out during six months for storage temperature of 5°C, 25°C 
and at 40°C. As illustrated in the charts represented in Figures 6.8 and 6.9, the decrease in 
molecular weight seemed to follow a zero order kinetic.  
 
A linear trendline was obtained for each sample stored at a defined temperature from the 
charts illustrating the molecular weight changes verses time (Figures 6.8 and 6.9). The 
equations of these trendlines of type “y = ax + b” are reported in Table 6.6. The value of the 
kinetic constant k is obtained from the slope of the linear trendline. 
 
 
Table 6.4: Equation of the linear trendline and kinetic constant k, obtained for each sample 
stored at a defined temperature from the charts “molecular weight verses time” 
represented in Figures 6.8 and 6.9. 
 
 
Storage temperature 
Equation of trendline 
[y = ax + b] 
Kinetic constant k 
[kJ/mol] 
formulation B 
5°C 
25°C 
40°C 
y = -1.5182 x + 100.88 
y = -3.0808 x + 100.94 
y = -12.450 x + 100.47 
1.52 
3.08 
12.45 
placebo B1 
5°C 
25°C 
40°C 
y = -1.4159 x + 100.27 
y = -6.7050 x + 100.46 
y = -15.067 x + 95.945 
1.42 
6.71 
15.07 
formulation C 
5°C 
25°C 
40°C 
y = -2.4877 x + 100.90 
y = -5.3967 x + 100.70 
y = -12.900 x + 97.546 
2.49 
5.40 
12.90 
placebo C1 
5°C 
25°C 
40°C 
y = -3.0461 x + 101.39 
y = -6.9452 x + 97.359 
y = -14.367 x + 89.703 
3.05 
6.95 
14.37 
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3.3. Low field NMR-screening (NIR-screening) 
 
Formulations A, B and C and related placebos 1 and 2 were stored in temperature controlled 
racks of the SpecScreen x HTS apparatus at 25°C and 40°C. NIR spectra were automatically 
taken during six months at time intervals of 24 h. Evaluation of spectra data sets consisted in 
determination of process factor and of time profile. Process factor is the slope of the 
regression line shown in the spectra. It indicates wavelength regions with significant changes 
during storage period of the samples and support the identification of unstable components 
in formulations. The calculated time profile shows kinetics of significant processes in 
formulation.  
 
Absorption of NIR radiation is due to overtone and combination bands primarily of O-H, C-H, 
N-H and C=O groups. The fundamental molecular stretching and bending of these functional 
groups absorb in NIR region. These overtones are anharmonic and do not behave in a 
simple fashion, making NIR spectra complex and not directly interpretable. 
 
In Figure 6.12, prominent absorption bands related to overtone and combination bands of 
fundamental vibrations occurring in NIR region are depicted. It can be observed that 
absorbance regions of different functional groups are strongly overlapping. The absorbance 
bands in NIR spectra are therefore usually composites of different functional groups. In 
contrast to mid infrared and Raman spectroscopic range, unequivocal assessment of an 
absorbance band to a functional group is often not possible with NIR spectroscopy. However, 
despite low specificity, NIR-spectroscopy is used for stability as it bring advantages of high 
sensitivity in comparison with other vibrational methods. 
 
Figure 6.12: Absorbance bands of functional groups in NIR region. 
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3.3.1. Placebo 2 evaluation: solvent stability 
 
Placebo 2 samples contained neither active ingredient nor PLA polymer. They consist in 
solvent triacetin for placebos A2 and B2 and in mixture triacetin with 10.00 % ethanol for 
placebo C2. 
3.3.1.1. NIR evaluation for stability of triacetin (placebo A2 and B2)  
 
The solvent triacetin, which corresponds to placebos A2 and B2, was daily analyzed using 
NIR spectroscopy for a storage period of six months. During this time, the samples were 
stored in two racks of the SpecScreen x HTS apparatus, heated at 25°C and 40°C, 
respectively.  
 
An overlay plot of NIR-spectra for wavelength range from 830 nm to 2500 nm of triacetin, 
without baseline correction nor variance normalization is illustrated in Figure 6.13. On X-axis 
of plot, wavelengths are represented in nm while absorbance is illustrated on Y-axis. 
 
 
 
Figure 6.13: Overlay plot of NIR-spectra set of triacetin (placebo A2 and B2) without baseline 
correction nor variance normalization, in a wavelength range from 830 nm to 2500 
nm. 
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The same data set was used for an overlay plot of NIR-spectra of triacetin, after baseline 
correction and variance normalization for wavelength range from 830 nm to 2500 nm. As 
shown on plot of Figure 6.14, it is more convenient to detect the wavelengths region with 
spectroscopic changes after the procedure of data pre-treatments.  
 
 
 
 
Figure 6.14: Overlay plot of NIR-spectra set of triacetin (placebo A2 and B2), after baseline 
correction and variance normalization, in wavelength range from 830 nm to 
2500 nm. 
 
 
Not all wavelengths of NIR-spectra are ascertained for stability investigations of samples. 
Selection of wavelengths region utilized for stability storage investigation depends on the 
spectra data set as well as on the apparatus used. For further investigations, wavelength 
regions which may alter the results should be subsequently removed. In this particular case, 
wavelengths region below 1600 nm and over 2200 nm are systematically removed for 
stability determination. 
 
Superposition of NIR-spectra of the solvent triacetin taken during storage at 25°C for the 
wavelength range between 1600 nm and 2200 nm after baseline correction and variance 
normalization  is represented in Figure 6.15a. Process factor calculated from this overlay plot 
is illustrated in Figure 6.15b. Process factor shows which wavelength regions change 
significantly on the related overlay plot. The most important changes observed on 
superposition of NIR-spectra are located at wavelength region around 1900 nm. This was 
confirmed by the process factor graphic illustrated in Figure 6.15b, which curve shows an 
important deviation from the X-axis at wavelengths region around 1900 nm. 
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As indicated in Figure 6.12, functional groups with absorbance bands in region of 1900 nm 
are the first overtones for the RCOOR groups. The chemical structure of triacetin which is a 
triester of glycerin and acetic acid support this presumption. Other functional entities with 
absorbance bands in the region around 1900 nm are the groups RCOOH, which may be the 
degradation products of triacetin as well as RCONH2 and H2O which are likely not present 
here.  
 
Time profile calculated from the overlay plot of NIR-spectra as well as from process factor is 
illustrated in Figure 6.15c. X-axis of time profile represents storage time (in seconds) and 
Y-axis is an arbitrary unit illustrating vector evolution inputs. Each point represents a NIR 
spectrum and the points are lined in chronological order. Here, the sample shows a 
continuous process over time which started from spectrum taken on the first day and last 
until the end of the storage time of six months. 
 
 
 
 
 
 
Figures 6.15a-c: (a) Overlay plot of NIR-spectra set of triacetin (placebo A2 and B2) during six 
months storage at 25°C after baseline correction and variance normalization for 
wavelength between 1600 and 2200 nm. (b) Related process factor (c) Related time 
profile. 
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Solvent triacetin on its own (placebo A2 and B2), stored at 40°C was also screened on a 
daily basis with NIR spectroscopy. Superposition of NIR-spectra of solvent triacetin is 
represented after baseline correction and variance normalization in Figure 6.16a for 
wavelength range from 1600 nm to 2200 nm. Related process factor and time profile are 
illustrated in Figures 6.16b and 6.16c, respectively. Analog to the sample stored at 25°C, the 
main changes detected with NIR screening was located at wavelength 1900 nm as observed 
from the overlay plot of NIR-spectra set in Figure 6.16a and from process factor represented 
in Figure 6.16b. Time profile indicates that this effect is a continuous process over storage 
time.  
 
 
 
 
 
 
 
Figures 6.16a-c: (a) Overlay plot of NIR-spectra set of placebos A3 or B3 during six months storage 
at 40°C. (b) Process factor. (c) Time profile. 
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Overlay plots of triacetin show for both temperature storage (25°C and 40°C) changes at 
wavelength around 1900 cm-1. However, changes in the overlay plot at higher storage 
temperature (Figure 6.16a) seem to be more important than for lower storage temperature 
(Figure 6.15a). After proceeding to further data pretreatments which fit both arbitrary Y-axis 
of time profiles (6.15c and 6.16c) to the same scale for a given reaction, time profiles for 
storage conditions at 25°C and 40°C could be compared on the same chart for the solvent 
triacetin during the six months storage. 
 
In Figure 6.17, time profiles of triacetin stored at 25°C and at 40°C are superposed on the 
same chart, using constant arbitrary scale of Y-axis to examine influence of temperature on 
degradation kinetic. By comparing deviation of time profile curves from the X-axis, it can be 
confirmed that degradation rate was higher for formulation stored at 40°C (grey curve) than 
for the formulation stored at 25°C (black curve). These results are in accordance with 
expectations and with observations of the related overlay plots (Figures 6.15a and 6.16a). 
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Figure 6.17: Time profile comparison for sample triacetin during six months storage at of 25°C 
(black curve) and 40°C (grey curve). 
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3.3.1.2. Placebo C2 evaluation 
 
Placebo C2 which consist in mixture of triacetin and ethanol absolute in a proportion of 9:1 
was screened using NIR-spectroscopy during six months storage at 25°C and 40°C. Overlay 
plot of NIR-spectra set of placebo C2 in wavelength range between 1600 nm and 2200 nm 
after baseline correction and variance normalization is shown in Figure 6.18a. Related 
process factor represented in Figure 6.18b indicates that the main changes occur at 
wavelength of 1900 nm as well as in the range between 2000 nm and 2100 nm. As shown in 
Figure 6.12, functional groups which absorb in the wavelength range around 1900 nm are 
mainly the groups RCOOR, while absorption between 2000 nm and 2100 nm can be relied to 
groups such as ROH and CONH2(R). In this particular case, as the sample is comprised of 
triacetin and ethanol, absorption detected at wavelengths around 2000 nm are attribute to 
ROH groups. Time profile illustrated in Figure 6.18c suggest a continuous degradation 
process over time. 
 
 
 
 
 
 
Figures 6.18a-c: (a) Overlay plot of NIR-spectra set of placebo C2 during six months storage at 
25°C. (b) Process factor. (c) Time profile. 
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Placebo C2 comprising the solvents triacetin and ethanol absolute in a weight ratio of 9:1 
was also stored at 40°C and daily screened with NIR-spectroscopy. Overlay plot of the NIR-
spectra set is represented in Figure 6.19a after baseline correction and variance 
normalization for a wavelength range between 1600 nm and 2200 nm. From this NIR-spectra 
set, it can be observed that, similarly to placebo C2 stored at 25°C, changes are mainly 
located at wavelengths 1900 nm as well as at 2000 nm and 2100 nm. This is confirmed with 
the related process factor represented in Figure 6.19b. Kinetic of this reaction, as illustrated 
in Figure 6.19c, was very rapid during the first weeks storage and slowed down to a 
continuous process for the rest of storage time for this formulation.  
 
 
 
 
 
Figures 6.19a-c: (a) Overlay plot of NIR-spectra set of placebo C2 during six months storage at 40°C. 
(b) Process factor. (c) Time profile. 
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3.3.1.3. Comparison time profile A2 verses C2 
 
Overlay plots of placebo A2 and C2 show for both temperature storage (25°C and 40°C) 
changes at wavelength around 1900 cm-1. Placebo A2 consisted in the solvent triacetin as 
placebo C2 consisted in a mixture of triacetin and ethanol in a ratio of 9:1. Influence of 
co-solvent ethanol on stability of triacetin was investigated by comparing time profiles of both 
placebo samples. After proceeding to further data pretreatments which fit both arbitrary 
Y-axis of time profiles to the same scale for a given reaction, time profiles over six months of 
both placebo samples were compared on the same chart for a given storage temperature.  
 
In Figure 6.20, time profiles of samples A2 (triacetin) and C2 (triacetin and ethanol) during six 
months storage at 25°C are superposed on the same chart, using constant arbitrary scale of 
Y-axis to examine influence of the co-solvent ethanol on degradation kinetic. By comparing 
deviation of time profile curves from the X-axis, it can be observed that degradation rate was 
similar for both samples. For storage conditions at 25°C, addition of 10.00 % of co-solvent 
ethanol to triacetin did not seem to influence stability of the samples.  
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Figure 6.20: Time profiles for placebo A2 (black curve) and for placebo C2 (grey curve) during 
six months storage at 25°C.  
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In Figure 6.21, time profiles of samples A2 (triacetin) and C2 (triacetin and ethanol) during six 
months storage at 40°C are overlaid on the same chart, using constant arbitrary scale of 
Y-axis to investigate influence of the addition of co-solvent ethanol on degradation of the 
samples. 
 
Deviation of time profile curves from the X-axis of sample A2 (black curve) was more 
important than for time profile of sample C2 (grey curve). Addition of 10.00 % of co-solvent 
ethanol to the solvent triacetin seems to reduce degradation rate of the sample by storage at 
40°C.  
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Figure 6.21: Time profiles for placebo A2 (black curve) and for placebo C2 (grey curve) during 
six months storage at 40°C.  
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3.3.1. Placebos 1 evaluation 
 
Placebos 1 samples contain PLA polymers dissolved in triacetin or in a mixture of triacetin 
and ethanol. PLA polymer concentration was 17.00 % in placebos A1 and C1, while it was 
12.75 % in placebo B1. Exact compositions of the placebos samples are depicted in Table 
6.1. 
 
3.3.2.1. Placebo A1 and B1 evaluation 
 
Placebos A1 and B1 contained PLA polymers dissolved in triacetin at concentration of 
17.00 % and 12.75 %, respectively. Both samples gave very similar spectroscopic results. 
Therefore, only spectra data set of the placebo B1 are illustrated and commented here.  
 
Figure 6.22a represents overlay plot of NIR spectra of placebo B1 taken during the six 
months storage at 25°C for the wavelength range between 1600 nm and 2200 nm, after 
baseline correction and variance normalization. Changes of NIR spectra were observed at 
wavelength of 1900 nm. Process factor represented in Figure 6.22b confirmed that this 
region of the NIR-spectra overlay plot is the only wavelength region which was modified 
during storage time period.  
 
As placebo B1 contains, above PLA polymers, an excess of solvent triacetin, changes at 
wavelength of 1900 nm are logic. The instability of placebo B2 during storage at 25°C at 
wavelength of 1900 nm has been illustrated in Figures 6.15a-c. These changes were 
attributed to the esters groups (RCOOR) of the solvent triacetin. No changes in the NIR-
spectra set were specific for presence of PLA polymers in the placebos B1. Modifications of 
NIR-spectra of placebo B1 were located at the same wavelength region than changes in 
spectra set of placebo B2. However, GPC analysis carried out in Section 3.1.2 of this chapter 
for placebo B1 indicated a significant reduction of the molecular weight of PLA polymers, 
which can be attributed to hydrolysis of their ester functional group. Such modifications would 
be attested by spectral changes at wavelengths in the regions absorbed by ester functional 
groups RCOOR. This is precisely the wavelengths region around 1900 nm which is affected 
by the placebo effect during storage of this particular sample.  
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Time profile illustrated in Figure 6.22c shows kinetics of degradation reaction of the sample 
B1, containing 12.75 % of PLA polymers in triacetin. Its includes both alteration of the solvent 
triacetin observed with the NIR-spectroscopy in Section 3.3.1.1 and concomitant hydrolysis 
of PLA polymers observed with GPC in Section 3.2.1. Kinetic is very dissimilar to the time 
profile of the solvent triacetin during storage at the same conditions illustrated in Figure 
6.15c. This demonstrate that an additional parameter, in this case PLA polymers, do react 
during storage period. However, the indications obtained from the time profile of Figure 6.22c 
must be carefully evaluated. Spectral changes of two chemical reactions located at same 
wavelength regions should not be considered as cumulative. 
 
 
 
 
 
Figures 22a-c: (a) Overlay plot of NIR-spectra set of placebo B1 during six months storage at 25°C. 
(b) Process factor. (c) Time profile. 
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PLA polymers solution in triacetin stored at 40°C was also screened with NIR-spectroscopy. 
Overlay plot of NIR-spectra set in wavelengths range from 1600 nm to 2200 nm collected 
during the six months storage at 40°C are represented after baseline correction and variance 
normalization in Figure 6.23a. Changes in spectra can be detected at wavelength region of 
1900 nm as also confirmed by the Figure 6.23b, representing the process factor of the 
related reaction of placebo B1. Time profile is illustrated in chart of Figure 6.23c. Comments 
made for the spectra data set of the placebo B1 taken at storage temperature of 25°C, 
concerning lack of specificity for PLA polymers spectral changes can be reiterated here. 
Time profile of this particular spectral data set should also be prudently estimated. 
 
 
 
 
 
Figures 6.23a-c: (a) Overlay plot of NIR-spectra set of placebo A1 during six months storage at 40°C. 
(b) Process factor. (c) Time profile. 
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3.3.2.2. Placebo C1 evaluation with NIR-spectroscopy 
 
Placebo C1 consists in 17.00 % of PLA polymers dissolved in a solvent mixture of triacetin 
and ethanol. Overlay plot of NIR-spectra set obtained from placebo C1 during six months 
storage at 25°C is represented in Figure 6.24a, after baseline correction and variance 
normalization for wavelengths region between 1600 nm and 2200 nm. Process factor 
illustrated in Figure 6.24b shows main changes at wavelength region of 1900 nm. As 
illustrated in Figure 6.12, the functional groups absorbing in this region are mainly RCOOR 
groups. These changes can be attributed to ester groups of the solvent triacetin and of PLA 
polymers. Because of poor specificity of NIR-spectroscopy, the obtained indications should 
be wisely considered. 
 
 
 
 
 
Figures 6.24a-c: (a) Overlay plot of NIR-spectra set of placebo C1 during six months storage at 25°C. 
(b) Process factor. (c) Time profile. 
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Placebo C1, consisting in PLA polymers dissolved in triacetin and ethanol was stored also at 
40°C and was screened with NIR-spectroscopy on a daily basis. Overlay plot of NIR-spectra 
set in wavelengths range from 1600 nm to 2200 nm collected during the six months storage 
at 40°C are represented after baseline correction and variance normalization in Figure 6.25a. 
Changes in the spectra can be detected at wavelength region of 1900 nm 2000 nm and  
2100 nm as also confirmed by process factor represented in Figure 6.25b. Time profile is 
illustrated in the chart of Figure 6.25c and indicates a continuous process over storage time.  
 
 
 
 
 
Figures 6.25a-c: (a) Overlay plot of NIR-spectra set of placebo C1 during six months storage at 40°C. 
(b) Process factor. (c) Time profile. 
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3.3.3. Formulation evaluation 
 
Formulations containing both the active ingredient NOA449851 and the PLA polymers were 
evaluated using the SpecScreen x HTS apparatus.  
3.3.3.1. Formulation A and B 
 
Formulations A and B contained both 17.00 % of the active ingredient NOA449851 and 
17.00 %, respectively 12.75 % of PLA polymers solved in triacetin. Due to the similar results 
of both samples A and B, only graphics and spectra of formulation B are shown and 
commented here. 
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Overlay plot of NIR-spectra set for wavelength range between 1600 nm and 2200 nm taken 
during the six months storage at 25°C are represented in Figure 6.26a after procedure of 
baseline correction and variance normalization. Changes in various spectra can be observed 
at wavelength region of 1900 nm, which is confirmed by process factor illustrated in Figure 
6.26b. Time profile illustrated in Figure 6.26c indicate a continuous kinetic over time. 
 
 
 
 
 
Figures 6.26a-c: (a) Overlay plot of NIR-spectra set of formulation B during six months storage at 
25°C. (b) Process factor. (c) Time profile. 
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Superposition of NIR-spectra at wavelengths between 1600 nm and 2200 nm and taken from 
formulation B during the six months storage at 40°C is represented after baseline correction 
and variance normalization in Figure 6.27a. Process factor illustrated in Figure 6.27b 
indicates that the degradation reaction effects functional groups which absorption occurs at 
wavelength of 1900 nm. 
 
 
 
 
 
Figures 6.27a-c: (a) Overlay plot of NIR-spectra set of formulation B during six months storage at 
40°C. (b) Process factor. (c) Time profile. 
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3.3.3.2. Formulation C 
 
Formulation C was stored for six months at 25°C and 40°C and screened using NIR-
spectroscopy. Formulation C contained, additionally to solvent triacetin, 10 % of co-solvent 
ethanol absolute. Exact composition of formulation C can be found in Table 6.1. 
 
Figure 6.28a, which represents overlay plot of NIR-spectra taken during storage at 25°C, 
shows wavelength region such as 1900 nm, 2000 nm - 2100 nm and 2200 nm with poor 
superposition. Changes at these wavelengths were confirmed by process factor represented 
in Figure 6.28b. Absorbance in regions between 2000 nm and 2100 nm can be attribute to 
ROH functional groups. Solvent ethanol absolute as well as active ingredient NOA449851 
comprise such functional groups. 
 
 
 
 
 
Figures 6.28a-c: (a) Overlay plot of NIR-spectra set of formulation C during six months storage at 
25°C. (b) Process factor. (c) Time profile. 
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Formulation C, consisting in 17.00 % of active ingredient and 17.00 % of PLA polymers 
dissolved in triacetin and ethanol was stored also at 40°C and was screened with NIR-
spectroscopy on a daily basis. Overlay plot of NIR-spectra set in wavelengths range from 
1600 nm to 2200 nm collected during the six months storage at 40°C are represented after 
baseline correction and variance normalization in Figure 6.29a. Changes in the spectra can 
be detected at wavelength region of 1900 nm, 2000-2100 nm and 2200 nm as also 
confirmed by process factor represented in Figure 6.29b. Time profile is illustrated in the 
chart of Figure 6.29c and indicates a continuous process over storage time 
 
 
 
 
 
Figures 6.29a-c: (a) Overlay plot of NIR-spectra set of formulation C during six months storage at 
40°C. (b) Process factor. (c) Time profile. 
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3.4. pH measurements of the solvent triacetin 
 
To determine stability of triacetin, pH-values of a mixture of triacetin and water were 
measured. The measurements were done in triplicate after 1 and 3 months storage at 25°C 
and 40°C. No significant change in pH-value could be measured, indicating good stability of 
the solvent triacetin during storage.  
 
3.5. In-vitro drug release from formulation A after six months storage at 40°C 
 
In-vitro drug release performances of formulation A after six months storage at 40°C were 
investigated. Active ingredient concentration in formulation A after storage period of six 
months was determined in Section 3.1.1 to be 94.09 % (w/w). Molecular weight of PLA 
polymer as measured with GPC, decreased during storage period to 26.0 % of its initial value 
(Data not shown). 
 
Drug release was expressed in percent of cumulative amount of active ingredient released, 
reported to the corrected refunded value. In-vitro releasing test parameters were set as for 
dissolution test method carried out in Chapter 3, Section 2.2.1.3. Therefore, drug release 
profile of formulation A after six months storage at 40°C can be compared to release kinetic 
of formulation “PLA-AI(1:1)”, tested directly after manufacturing in Chapter 3 (Figure 3.2).  
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Release profiles of formulation A investigated directly after manufacturing and after six 
months storage at 40°C were very similar, as showed in Figure 6.30. Drug release after 40 
days dissolution test was 43 % for formulation investigated directly after manufacturing and  
38 % for formulation tested after six months storage. Both formulations showed a substantial 
initial burst corresponding to 17.00 % of active ingredient released within 6 days form 
formulation tested directly after manufacturing and 18 % from formulation tested after six 
months storage at 40°C.  
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Figure 6.30: Influence of storage on the release of NOA449851 [% (w/w)] from sustained release 
injectables formed in-situ, related to time. Formulation A was tested directly after 
manufacturing ( ) as well as after six months storage at 40°C ( ). 
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For comparison of two dissolution profiles, Moore and Flanner have proposed a simple 
model independent approach using mathematical indices to define difference factor (f1) and 
similarity factor (f2) [Moore et al., 1996]. These factors directly compare difference between 
percentage of drug dissolved per unit time for a test and a reference formulation and can be 
defined by Equations 6.1 and 6.2. The results are reported in Figure 6.5. 
 
 
Table 6.5: Difference factor and similarity factor for drug release form formulation A measured 
directly after manufacturing and after six months storage at 40°C. 
 
  Results for formulation A 
Difference factor f1 7.01 % 
Similarity factor f2 61.76 % 
 
 
Factor f1 is proportional to average difference between both profiles. Percent error is zero 
when test and reference profiles are identical and increases with dissimilarity between the 
two profiles. Similarity factor f2 measures the closeness between the two profiles. It is a 
logarithmic transformation of the sum of squared error. It takes the average sums of squares 
of the difference between test and reference profiles and fits the results between 0 and 100. 
Similarity factor (f2) is 100 when test and reference profiles are identical and approaches zero 
as dissimilarity increases. Similarity factor (f2) is recommended for dissolution profile 
comparison in FDA’s Guidance for Industry. FDA has set a public standard of f2 value 
between 50-100 to indicate sameness or equivalence of two dissolution profiles [Shah et al., 
1998]. 
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4. Discussion 
 
Stability properties of three selected formulations were investigated with various analytical 
methods during a storage period of six months at four determined temperatures. First, 
content of active ingredient and of by-products in the three selected formulations was 
determined with an HPLC-method. Then, molecular weight of PLA polymers was measured 
using GPC for formulations B and C and relative placebo B1 and C1. Finally, NIR-
spectroscopy was used as a vibration spectroscopic screening system for supporting storage 
stability studies of new formulation candidates. 
 
4.1. Active ingredient and by-products analysis with HPLC 
 
HPLC is a commonly used method to analyze drug content and by-products. HPLC-analysis 
are specific for substance identity and very accurate for quantitative measurements. As 
disadvantages, samples preparation and analysis run need both large amount of organic 
solvents and time.  
 
HPLC-method used in this chapter has the advantage, compared to HPLC-method described 
in Chapter 2, Section 2.2.1, to separate additionally to the peaks of the active ingredient, four 
of its by-products. Therefore, time of the HPLC-run was increased from 30 min to 90 min per 
run. 
 
Content of active ingredient during six months storage at temperatures of 5°C, 25°C and 
30°C was found to be stable in a range of ± 2.5 % (w/w) for all three formulations. At storage 
temperature of 40°C, content of drug in the three formulations decreased to reach a content 
in percent of the initial corrected value of 94.09 % for formulation A, 95.46 % for formulation 
B and 92.89 % for formulation C. For storage temperatures of 5°C and 25°C, no difference 
between the three formulations was observed. At storage temperatures of 30°C and 40°C, 
the active ingredient contents in formulation C containing the co-solvent ethanol absolute 
were found to be slightly lower than for the two others formulations containing only triacetin 
as solvent. 
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For storage temperature conditions of 40°C, trendline of each formulation was calculated 
from the chart and used to evaluate storage time until degradation of 10 % of the active 
ingredient. This represented a storage time of 10.6 months for formulation A, 13.5 months for 
formulation B and 8.2 months for formulation C.  
 
After six months storage, by-products were found to be in a concentration below 1 % of the 
content of active ingredient, with a tendency to appear after long storage duration at higher 
temperatures. The by-products concentrations were acceptable as no substance had a 
specific toxicity. Degradation mechanisms of the various by-products are typical hydrolytic as 
well as oxidation reactions. As investigated in Section 3.1.2, there was no significant 
differences between the three formulations A, B and C concerning the by-products 
appearance during the six months storage.  
 
4.2. PLA polymer analysis with GPC 
 
GPC also called size exclusion chromatography uses porous particles to separate molecules 
of different sizes. Its most important use is to determine molecular weights and molecular 
weight distributions of polymers. Polymer molecules that are smaller than the pore sizes in 
the particles of the column can enter the pores and therefore have a longer path and transit 
time than larger molecules that cannot enter the pores. Movements in and out of the pores is 
governed by Brownian motion. Small particles which are entering the pores have a longer 
way to pass through the column and elute later than large molecules which do not enter the 
pores and have shorter way. GPC is a relative molecular weight method and such 
instrumentation needs to be calibrated. Therefore, synthetic anionic polystyrenes beads of 
narrow molecular weight distributions are used for calibration [Sperling, 2001]. 
 
GPC results indicated a reduction of the weight-average molecular weight of PLA polymers 
highly dependent on storage temperature. Decrease in molecular weight of PLA polymers in 
solution was much more important for formulations stored at 40°C than for formulations 
stored at 5°C or 25°C. Kinetic constant k give good indication of the magnitude of the 
influence of storage temperature: at storage temperature of 40°C, kinetic constant of all 
investigated samples were between 12.45 kJ/mol and 15.07 kJ/mol, while they were between 
3.08 kJ/mol and 6.95 kJ/mol for storage temperature of 25°C and even between 1.41 kJ/mol 
and 3.05 kJ/mol for storage temperature of 5°C. This temperature dependent effect is usual 
for chemical reactions like hydrolysis, which probably occurred to the PLA polymers during 
storage.  
 Chapter 6: Stability properties  
 
184 
Decrease in molecular weight of PLGA polymers dissolved in benzyl benzoate was already 
described as a function of time and temperature [Wang et al., 2003]. The unstable character 
of the ester bounds is an inconvenient property of the PLA polymers, especially regarding 
storage of formulations. However, this is a necessary aspect of these excipients to allow 
biodegradation of the solid matrix at physiological conditions [Shih, 1995; Wang et al., 1997; 
Li et al., 1999].  
 
In formulation C and related placebo C1, the substitution of a fraction of triacetin with ethanol 
absolute did slightly increase degradation rate of the PLA polymers. Examination of kinetic 
rate constants k indicates a value of 2.5 kJ/mol for formulation C stored at 5°C, while it was 
only 1.5 kJ/mol for formulation B stored at the same conditions. As an other example, kinetic 
rate constant k was 3.1 kJ/mol for placebos C1 formulation stored at 5°C and only 1.4 kJ/mol 
for placebo B1, the sample without the co-solvent ethanol absolute. 
 
Furthermore, results of the GPC indicated that, when stored at same temperature, PLA 
polymers of placebo solutions degraded faster than PLA polymers of active ingredient 
containing formulations. The active ingredient NOA449851 may have played a role of 
stabilizator, by competitively attracting water molecules responsible for polymer hydrolysis.  
 
Polymeric dosage forms are often used to provide sustained release of various 
pharmaceutical entities. When polymer acts as a solid matrix, release rate is controlled by 
physicochemical property of the polymer. It is therefore essential to define specifications for 
PLA polymers and for storage conditions. 
 
The charts obtained with GPC data indicate evident influence of storage temperature on PLA 
polymers stability. However, with a data set of only four molecular weight measurements for 
each samples at defined storage conditions, kinetic of reactions cannot be reliably 
determined. In these experiments, kinetic of the reactions seemed to be linear; however, it 
was not possible to exclude totally other kinetic orders. Furthermore, mechanism or pathway 
of the chemical breakdown can change with storage temperature.  
 
Dependence of the drug release as function of the molecular weight of the PLA polymers 
should be carefully investigated. An in-vitro dissolution test was performed with a formulation 
stored for six months at 40°C and compared with drug release parameter of a formulation 
tested directly after manufacturing. 
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4.3. low field NMR-screening (NIR-screening) 
 
Low field NMR (NIR) is a rapid, non-destructive and non-invasive analytical tool which is 
gaining acceptance in pharmaceutical industry as a technique for qualitative and quantitative 
analysis. The NIR applications in pharmaceutical industry include qualitative identification of 
raw materials, quantitative analysis of drug content in tablets, determination of moisture 
content as well as detection of degradation products within a solid. Low field NMR-
spectroscopy offers a lot of options for fast and easy analyses of liquids, powder and solids 
without time consuming sample preparation. This method is non destructive and therefore 
the same sample is used for all spectral analysis, circumventing the problem of samples 
collection [Blanco et al., 2002; Reich, 2002].  
 
Low field NMR region covers a wavelength range from 700 nm to 2500 nm (1400 cm-1 -  
4000 cm-1). It contains primarily overtones and combinations band of C-H, N-H and O-H 
stretching frequencies which are adequate for studying many organic compounds. Because 
absorbance regions of different functional groups are strongly overlapping, absorbance 
bands in NIR spectra are usually composites of different functional groups. In contrast to mid 
infrared and Raman spectroscopic range, unequivocal assessment of an absorbance band to 
a functional group is often not possible. Therefore, requirements of spectroscopic selectivity 
are normally not fulfilled and the selectivity must be generated by experimental study design.  
 
Evaluation of the spectra data sets was performed with different software tools. Efficient data 
pre-treatment algorithm reduces contribution of the instrument and the experimental variance 
without having significant effects on the variance caused by systematic changes in the 
samples. As examples of data pre-treatment algorithm, baseline correction and variance 
normalization can be mentioned. Baseline correction of NIR-spectra reduces light diffractive 
effects caused by surface of the glass sample vial. Variance normalization eliminates the 
noise in the spectra by weighting absorbance at each wavelength with the corresponding 
noise level. For illustrating the effect of the data pre-treatments, Figure 6.13 should be 
compared to Figure 6.14. 
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The first level for data evaluation performs statistical data analysis of each test sample stored 
in the SpecScreen X HTS apparatus and informs about ongoing degradation processes in 
the sample. After baseline correction, variance normalization and wavelength selection, an 
overlay plot of NIR-spectra set is obtained from which process factor can be calculated. This 
represents the slope of the regression line shown in the spectra space. Process factor 
indicated the wavelength regions with significant spectral modifications during the storage of 
the samples. Additionally, time profile of the process is calculated and shows the kinetic of 
significant processes in the formulations. 
 
The second level of data analysis focuses on comparison of different related test samples. 
Based on further data pre-treatments and evaluation algorithms which fit magnitude of Y-axis 
value of the time profiles to a same scale, allowing direct comparison. Therefore, it was 
possible to evaluate the impact of storage temperature for samples B2 (Figure 6.17). Further, 
the influence of the addition of ethanol on stability for a given storage temperature was 
investigated (Figures 6.20 and 6.21). 
 
One of the concept of low field NMR screening method is to save time by avoiding 
development of a specific method for each compound. Therefore, no calibration is performed 
and in case of modifications in the NIR spectra set, stability of the sample is defined by 
comparison of the various data sets and their related time profiles. Stability assumptions are 
therefore more qualitative than quantitative. In the present case, this concept could not be 
successfully applied because of an extensive placebo effect of the solvent triacetin. The 
instability of the solvent triacetin was detected at same wavelength region on the NIR spectra 
as the predicted labile functional group of the PLA polymer. Because there was no previous 
experience with the NIR screening method for PLA polymer solutions, it was necessary to 
compare the NIR-screening results with a reliable method. Therefore, results obtained with 
NIR screening method were systematically compared to GPC results obtained in section 3.2.  
 
The overlay plot of the NIR-spectra set of the solvent triacetin (Figures 6.15 and 6.16) 
showed spectral changes for wavelengths at 1900 nm. As no calibration of this specific 
component was previously made, it could not be determined if the degradation process of the 
solvent was significant or not. Therefore pH-measurements of solvent triacetin were 
performed to detect eventual degradation products such as acetic acid. No changes in the 
pH-values could be measured, confirming a very high sensitivity of the NIR-screening 
method, which probably do not have any consequence for formulation storage conditions. 
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Technically, instability of triacetin was very incommoding for the next NIR-spectroscopy 
investigations of samples using this excipient as solvent. This excipient was in excess in 
each further analyzed sample, as it was the selected solvent for the PLA polymers. Spectral 
changes at wavelengths of 1900 nm were consistent in every analyzed spectra sets (Figures 
6.15 to 6.27).  
 
According to GPC investigations performed in Section 3.2.1, weight average molecular 
weight of PLA polymers decreased dramatically during storage. Reduction of molecular 
weight of PLA polymers is due to hydrolysis of ester bounds of polymer chains. Such effects 
should be detected with NIR-spectroscopy, as functional groups RCOOR and RCOOH 
absorb in the wavelength region around 1900 nm (Figure 6.12). However, this region 
correspond to the wavelength affected by degradation of the solvent triacetin (Figures 6.15 
and 6.16) and changes due to the polymer hydrolysis are masked by the solvent effect 
(Figures 6.20 and 6.21). The influence of the solvent effect could not be removed by study 
design, as no specific wavelength could be attributed to the PLA polymers parameter when 
the solvent triacetin was used. 
 
When two different chemical reactions interfere at the same wavelength region in a spectra, 
comparison of modifications should be carefully considered. Spectral changes are not 
cumulative and it is not possible to compare quantitatively two unstable formulations with 
more than one variable influencing one unique wavelength region. Comparison would be 
possible with a stable placebo (solvent system) or with an unstable placebo which changes 
are located at other specific  wavelengths than the new investigated parameter.  
 
Spectroscopic selectivity requires that at least one relevant absorbance band of the test 
substance does not interfere with absorbance bands of the other excipients in formulation. In 
such cases, data evaluation is simple and determination of degradation of the tested 
substance can be directly performed. However, this requirement is usually not fulfilled for 
NIR spectroscopy and alternative should be evaluated. Selectivity should therefore be 
generate by experimental design of the study. The first assumption is that different samples 
with similar compositions will have same changes in spectra during storage at same 
conditions. This is a successful approach for investigation of the effect for a large number of 
variables. However, the result of comparison of data evaluation of different sample is more 
qualitative than quantitative. 
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Unfortunately, it must be concluded that this new analytical screening method is suitable for 
stability investigations, only when changes in NIR spectra can be properly interpreted. A 
direct interpretation of the NIR spectral changes was here not possible because of the lack of 
specificity of the changes attributed to the solvent triacetin and to the PLA polymers, which 
were located at same wavelength regions in the NIR spectra. Evaluation of a spectroscopic 
data set should give clear evidence about the stability of a substance in a formulation. 
However, this requirement makes high demands on the spectra properties with respect to 
selectivity and specificity. However, this pointed out the labile stability of the solvent triacetin, 
which was a neglected aspect with the other traditional analytical methods. Due to the 
missing calibration step, this effect was not quantified and it could not be determined if the 
solvent degradation was a significant issue with regards to storage stability. 
 
Both PLA polymer and solvent triacetin have labile ester bounds which are likely degraded 
during storage. The solvent triacetin has a molecular weight of 218 g/mol (Pharmacopoe) 
and comprises three ester bounds in the chemical structure (triester of glycerin). As 
determined with GPC (Section 3.2.1), PLA polymers used have, directly after manufacturing, 
a molecular weight of about 70’000 Da. The lactic units of the polymers, which each 
represents a molecular weight of about 90 g/mol are joined with ester bounding. So the ester 
functional groups is present in a similar frequency for both components, PLA polymers and 
solvent triacetin. However, the labile ester bound of the lipophilic and long polymer chains 
are probably less accessible to water molecules than the ester bounding of small solvent 
molecule, according to steric hindrance as well as hydrophilic interactions. Furthermore, in all 
tested formulations, the solvent triacetin was in excess compared to the amount of PLA 
polymer which was at maximum in a concentration of 17.00 % (w/w). Theoretically, 
hydrolysis of one unique ester bounding in the middle of a polymeric PLA chain reduces 
molecular weight of PLA from 70’000 Da to 35’000 Da. Average molecular weight of the 
polymer decrease drastically, while the physico-chemical properties of the polymeric chains 
are not affected as fundalmentally as it could seem.  
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4.4. In-vitro drug release from formulation A after six months storage at 40°C 
 
Dissolution test was performed for formulation A after six months storage at 40°C. As 
reported in previous sections, refund of active ingredient was 94.09 % and molecular weight 
of the PLA polymers dropped to 26.0 % of its initial value. In order to investigate the impact 
of the decrease of the polymer molecular weight on drug release performances, in-vitro drug 
release was compared to the one of the same formulation tested directly after manufacturing.  
 
Formulations containing lower molecular weight polymers were able to form implants after 
injection in aqueous milieu. Drug release was surprisingly similar to release from 
formulations tested directly after manufacturing. Difference factor f1 and similarity factor f2 
were calculated for a quantitative comparison of both dissolution profiles. Difference factor f1 
was measured to be 7.41 % and similarity factor f2 had a value of 60.60. The f2 value is 
between 50 and 100 and therefore within the standard set by FDA to indicate equivalence 
[Shah et al., 1998]. 
 
As already mentioned in the previous chapters, drug release is assumedly mainly diffusion 
controlled and not erosion controlled. Therefore, molecular weight of polymer did not 
influence drug release during the 40 days of the dissolution test. However, in various 
published papers, the release is reported to be function of molecular weight of polymers 
[Hatefi et al., 2002; Yewey et al., 1997; Eliaz et al., 2002]. Yewey et al. investigated in-vitro 
release of myoglobin from injectables implants based on PLA polymers of various molecular 
weight (inherent viscosity of 0.05 dl/g and 0.33 dl/g). Initially, the two formulations released 
the protein at similar rates, but with time, the lower molecular weight formulation released at 
higher rates [Yewey et al., 1997]. Further, release of plasmid DNA from implants formed with 
polymer of various molecular weight (inherent viscosity of 0.24 dl/g and 0.59 dl/g) were 
investigated by Eliaz et al.. Drug release was more rapid from the low molecular weight 
polymer but in both cases, the DNA was released before complete erosion of the polymeric 
matrix [Eliaz et al., 2002]. 
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5. Conclusion 
 
Different analytical methods were used for stability studies of sustained release injectables 
formed in-situ during six months storage at four selected temperatures. Formulations were 
based on PLA polymers, active ingredient NOA449851 and solvent triacetin. Co-solvent 
ethanol was added in formulation C. 
 
An HPLC-method was utilized for determination of active ingredient content and detection of 
by-products. No differences between the three formulations in active ingredient content and 
in apparition of by-products were observed. Content of active ingredient NOA449851 
decreased with time and temperature. Concomitantly, four degradation products of the 
NOA449851 were found to increase. 
 
Molecular weights of the PLA polymers were determined with GPC. It was found that the 
decrease in molecular weight of the PLA polymers was significant increased with storage 
temperature. No significant influence of the co-solvent ethanol absolute on the changes of 
the molecular weight of the PLA polymers in the formulation could be measured. However, 
the presence of the active ingredient in the formulation seemed to decrease hydrolysis 
process of PLA polymer.  
 
NIR data analysis of solvent triacetin showed spectral changes for wavelengths at 1900 nm. 
Spectral changes at these wavelengths were consistent in every analyzed spectra sets as 
the solvent triacetin was in excess in all samples. The influence of the solvent effect could 
not be removed by study design, as no specific wavelength could be attributed to the PLA 
polymers parameter. 
 
Drug release from formulation A tested directly after manufacturing and after six months 
storage at 40°C were found to be similar for the investigated 40 days, despite reduction of 
molecular weight of PLA polymers. This is surprising, as the molecular weight of the 
polymers is reported to influence drug release form matrix. However, this confirm a drug 
release mechanism mainly diffusion controlled and not erosion controlled. 
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Chapter 7 
 
Exploration of microspheres as comparison technology for 
sustained release injectables formed in-situ 
 
 
1. Introduction and objectives 
 
Polymeric microspheres are a thoroughly investigated and well described drug delivery 
technology with regard to manufacturing process and drug release mechanisms [Jalil et al., 
1990; Choi et al., 2002; Mandal et al., 2001; Dalpiaz et al., 2002; Berckland et al., 2002; 
Sinha et al., 2003; Zhou et al., 2003]. They provide sustained release of active ingredient 
after subcutaneous or intramuscular application. The excipients needed are water insoluble 
polymers with biodegradable and biocompatible properties. Therefore, polymers such as 
PLA or PLGA are often used as excipients to form the matrix of microspheres. Formulations 
of PLA/PLGA microparticles containing active ingredients such as triptorelin (Decapeptyl® 
Depot, Ferring), leuprorelin (Enantone® Gyn Monats-Depot, Takeda Pharma), bromocriptin 
(Parlodel® LAR, Sandoz), risperidon (Risperdal Consta®, Janssen-Cilag) or octreotide 
(Sandostatin® LAR-Monatsdepot, Novartis Pharma) are on the market for human use. For 
veterinarian use, Proheart® 6 (Fort Dodge), which was recently removed from the 
marketplace because of severe side effects, consisted in hydroxypropylmethylcellulose 
based microparticles with the active ingredient moxidectine and was used for prevention of 
heartworm disease caused by Dirofilaria immitis. 
 
Sustained release injectables formed in-situ and microspheres are both technologies 
intended for parenteral application, designed to achieve a long acting release of the drug. In 
both technologies, the sustained effect is caused by the slow biodegradable PLA/PLGA 
polymer matrix in which the active ingredient is embedded. In order to better understand the 
release mechanisms of the implants formed in-situ, microspheres were manufactured, using 
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the same polymer types and the same drug to polymer ratios as for formulations investigated 
in Chapter 3. The microsphere batches were analyzed with regard to yield, drug content, 
encapsulation efficiency, particle size distribution and in-vitro drug release properties. 
Additionally, microspheres were used as simplified two-components models, containing 
polymers and active ingredient NOA449851, but lacking the solvent in comparison to the 
sustained release injectable formed in-situ. Raman and NIR spectroscopy were used to 
determine conformation/polymorphism of the active ingredient within the polymer matrix and 
also to detect possible interactions between polymer and active ingredient. Vibrational 
spectroscopy has already been successfully used for investigations of the conformation of 
active ingredients within various polymeric matrices as well as for detection of polymer/drug 
interactions [Bolton et al., 1984; Taylor et al., 1997; Breitenbach et al., 1999]. 
 
2. Materials and methods 
2.1. Materials 
 
The active ingredient NOA449851 was obtained from CarboGen Laboratories, Aarau, CH. 
The polymers PLA, 85/15 PLGA and 75/25 PLGA (inherent viscosity of 0.68 dl/g, 0.63 dl/g 
and 0.67 dl/g in trichloromethane at 30°C, respectively) were provided by Birmingham 
Polymers Inc., Birmingham, AL, USA. PVA 15000 was purchased from Fluka Chemie AG, 
Buchs, CH. The solvents acetonitrile, methanol, methylene chloride and water for 
chromatography were supplied by Merck Inc., Darmstadt, D. Solutol HS 15® was purchased 
from BASF, Ludwigshafen, D. All solvents were of at least reagent analytical grade. 
 
2.2. Methods 
2.2.1. Preparation of the microspheres 
 
Twelve microspheres batches were manufactured using three types of polymer (PLA, 85/15 
PLGA and 75/25 PLGA) and four different concentrations of the active ingredient (placebo, 
0.99 %, 16.67 % and 50.00 %), corresponding to weight polymer to drug ratios of 100:1, 5:1 
and 1:1, as already used for the sustained release injectables formed in-situ investigated in 
Chapter 3. 
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Microspheres were prepared using an O/W emulsion solvent evaporation method according 
to Conti et al. (Conti et al., 1992). The polymers were dissolved in methylene chloride to give 
a 20 % (w/v) solution. An accurate amount of active ingredient (listed in Table 7.1) was 
added to the polymer solution, which was stirred until complete dissolution. The solution was 
then emulsified in 100 ml of water containing 5 % PVA 15000 for 3 min under mechanical 
stirring with 1200 rpm (Merck Eurolab, Typ Euro-ST D, Staufen, D). The resulting O/W 
emulsion was poured into a 20 times larger volume of distilled water preheated at 40°C. The 
diluted O/W emulsion was stirred for 30 min at 40°C to remove the organic solvent 
methylene chloride. The resulting hardened microspheres were collected by filtration, 
washed with distilled water and dried under reduced pressure at room temperature for two 
days (Salvis Trockenschrank, Typ KVTS11, Reussbühl, CH). The exact compositions of the 
twelve microsphere batches are listed in Table 7.1. 
 
 
Table 7.1: Composition in percent [% (w/w)] of microsphere batches.  
 
Microspheres Polymer to drug 
weight ratio Components 
Content of 
components 
   [% (w/w)] 
PLA-placebo placebo PLA 100.00 
85/15 PLGA-placebo placebo 85/15 PLGA 100.00 
75/25 PLGA-placebo placebo 75/25 PLGA 100.00 
PLA-(100:1) 100:1 PLA NOA449851 
99.01 
0.99 
85/15 PLGA-(100:1)  100:1 85/15 PLGA NOA449851 
99.01 
0.99 
75/25 PLGA-(100:1) 100:1 75/25 PLGA NOA449851 
99.01 
0.99 
PLA-(5:1) 5:1 PLA NOA449851 
83.33 
16.67 
85/15 PLGA-(5:1)  5:1 85/15 PLGA NOA449851 
83.33 
16.67 
75/25 PLGA-(5:1) 5:1 75/25 PLGA NOA449851 
83.33 
16.67 
PLA-(1:1) 1:1 PLA NOA449851 
50.00 
50.00 
85/15 PLGA-(1:1) 1:1 85/15 PLGA NOA449851 
50.00 
50.00 
75/25 PLGA-(1:1) 1:1 75/25 PLGA NOA449851 
50.00 
50.00 
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2.2.2. Yield 
 
The total microsphere yield was calculated gravimetrically on the basis of the polymer/drug 
recovery after the final drying step. 
 
2.2.3. Determination of active ingredient content in the microspheres 
 
The drug content of each microsphere batch was analyzed in triplicate after manufacturing. 
Approximately 100 mg of microspheres were weighed into a 100 ml volumetric flask. The 
flasks were filled up to the calibration line with acetonitrile. The mixtures were shaken 
manually and put into the ultrasonic bath until complete dissolution of the microspheres. The 
concentration of NOA449851 in the solution was determined using the HPLC-method as 
described in Chapter 2, Section 2.2.1. 
 
2.2.4. Size distribution of microspheres 
 
Size distribution of microspheres was determined before and after dissolution test (Section 
2.2.7) using a laser particle size analyzer (Granolomètre 715™, Cilas, Paris, F). 
Approximately 500 mg of microspheres were dispersed in the water bath of the analyzer by 
stirring and use of ultrasound. During measurements, a circulating pump transported the 
particles from the water bath via a flexible tube into a glass cuvette. Each batch was 
analyzed in triplicate. 
 
2.2.5. Raman spectroscopy 
 
Raman spectroscopy was used for determination of the different spectra related to each 
copolymer used to form the microspheres matrices. In addition, the following qualitative 
aspects of the incorporated drug were studied: crystallinity, presence of other polymorphic 
structures and possible interactions with the polymer. Raman measurements were performed 
according to the method described in Chapter 2, Section 2.2.5. 
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2.2.6. IR spectroscopy 
 
IR spectroscopy was used for investigation of possible active ingredient interactions with the 
polymorphic matrices, especially regarding its capability of building hydrogen bonds. 
Therefore, the three microspheres batches with the weight polymer to drug ratio 1:1 were 
analyzed with IR spectroscopy according to the method described in Chapter 2, Section 
2.2.4. 
 
2.2.7. X-ray analysis 
 
Powder X-ray diffraction patterns of the drug loaded microspheres batch PLA-(1:1) were 
analyzed to study the physical state of both components, the PLA polymer and the active 
ingredient NOA449851, when formulated as microspheres. The test was carried out 
according to the method described in Chapter 2, Section 2.2.6. 
 
2.2.8. In-vitro drug release from microspheres 
 
The in-vitro drug release from microspheres was determined by dissolution testing in 
triplicate of the nine active ingredient containing microsphere batches. The influence on the 
in-vitro drug release of different polymer types and of different drug loadings was 
investigated. 
 
An amount of 500 mg microspheres, corresponding to a drug load of about 5 mg for the three 
microspheres batches with the polymer to drug ratio 100:1, 83 mg for the microspheres 
batches with the polymer to drug ratio 5:1 and of 250 mg for the microspheres batches with 
the polymer to drug ratio 1:1 was accurately weighed in felt bags and placed into the basket 
of the USP dissolution test apparatus (AT 7 SmartTM, Sotax AG, Basel, CH). The same 
experimental conditions were applied as for the dissolution tests of the sustained release 
injectables formed in-situ (Chapter 3, Section 2.2.1.3). The dissolution medium consisted of 
one liter of a 5 % solution of Solutol HS 15® in distilled water which was replaced weekly by a 
fresh solution to keep sink conditions. The temperature was maintained at 37°C, the rotation 
speed of the baskets at 100 rpm. Drug concentration in the dissolution medium was 
determined by HPLC-analysis according to the method described in Chapter 2, Section 
2.2.1. As for the dissolution tests of the sustained release injectables formed in-situ, the 
experiments were stopped after 40 days. 
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3. Results 
 
Twelve microsphere batches were manufactured using three different polymer types and four 
different drug concentrations. They were analyzed with regard to yield, drug content, 
encapsulation efficiency, particles size distribution, release properties, cristallinity and 
drug/polymer interactions. The microsphere technology was studied to better understand the 
in-vitro sustained release characteristics of the implants formed in-situ and to investigate the 
interaction between the drug and the polymer matrix, using these simplified two-components 
models. Therefore, special attention was paid to produce microspheres with the same 
excipients and with the same polymer to drug ratios as for the sustained release injectables 
formed in-situ which have already been investigated. Whenever possible, the same test 
conditions were applied for analysis to assure a valid comparison with the sustained release 
injectables formed in-situ. 
 
3.1. Yield, drug content and encapsulation efficiency  
 
The yield of the microsphere preparation was found to be around 90 % in average (from 
88.8 % to 95.0 %) for all twelve batches. The drug content, measured in triplicate, was 
0.99 % in average for the three batches with a polymer to drug ratio of 100:1, 16.35 % for the 
batches with a ratio of 5:1 and 47.32 % for the batches with a ratio of 1:1. This represented 
an encapsulation efficiency of 99.02 %, 98.11 % and 94.65 %, respectively. The 
encapsulation efficiency is defined as the ratio of the effective measured content compared 
to the theoretical drug content of the microspheres. The results concerning yield, drug 
content and encapsulation efficiency of the twelve microsphere batches are listed in Tables 
7.2 to 7.5. 
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Table 7.2: Yield of the three placebo microsphere batches. 
 
Microspheres Yield 
 [% (w/w)] 
PLA-placebo 91.8 
85/15 PLGA-placebo 88.9 
75/25 PLGA-placebo 89.2 
Average 90.0 
 
Table 7.3: Yield, active ingredient content (n = 3) and encapsulation efficiency of the three 
microsphere batches with the weight polymer to drug ratio 100:1. 
 
Microspheres Yield Drug content 
± S.D. 
Theoretical drug 
content 
Encapsulation 
efficiency 
 [% (w/w)] [% (w/w)] [% (w/w)] [%] 
PLA-(100:1) 89.3 0.99 ± 0.46 0.99 99.01 
85/15 PLGA-(100:1) 90.7 0.99 ± 0.21 0.99 98.97 
75/25 PLGA-(100:1) 95.0 0.99 ± 0.03 0.99 99.09 
Average 91.7 0.99 ± 0.26 0.99 99.02 
 
Table 7.4: Yield, active ingredient content (n = 3) and encapsulation efficiency of the three 
microsphere batches with the weight polymer to drug ratio 5:1. 
 
Microspheres Yield Drug content 
± S.D. 
Theoretical drug 
content 
Encapsulation 
efficiency 
 [% (w/w)] [% (w/w)] [% (w/w)] [%] 
PLA-(5:1) 89.3 16.43 ± 0.13 16.67 98.58 
85/15 PLGA-(5:1) 90.7 16.60 ± 0.78 16.67 99.60 
75/25 PLGA-(5:1) 95.0 16.05 ± 4.27 16.67 96.15 
Average 91.7 16.35 ± 2.64 16.67 98.11 
 
Table 7.5: Yield, active ingredient content (n = 3) and encapsulation efficiency of the three 
microsphere batches with the weight polymer to drug ratio 1:1. 
 
Microspheres Yield Drug content 
± S.D. 
Theoretical drug 
content 
Encapsulation 
efficiency 
 [% (w/w)] [% (w/w)] [% (w/w)] [%] 
PLA-(1:1) 91.6 47.04 ± 2.31 50.00 94.08 
85/15 PLGA-(1:1) 88.8 47.43 ± 0.11 50.00 94.86 
75/25 PLGA-(1:1) 90.9 47.49 ± 4.15 50.00 95.01 
Average 90.4 47.32 ± 2.87 50.00 94.65 
 
3.2. Granulometrie 
 
The particle size distribution of the microsphere batches was determined in triplicate, using a 
laser particle size analyzer, immediately after manufacturing as well as after dissolution tests. 
Immediately after manufacturing, the microspheres based on PLA polymers had a diameter 
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of 86.62 µm in average, whereas for 85/15 PLGA and 75/25 PLGA microspheres, the 
diameters were 100.93 µm and 110.50 µm in average. The particle size distribution 
histograms of the twelve different microsphere batches as measured after manufacturing are 
depicted in Figures 7.1 to 7.12. 
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Figures 7.1-7.3: Particle size distribution histograms of the three placebo microsphere batches 
determined after manufacturing.  
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Figures 7.4-7.6: Particle size distribution histograms of the three microsphere batches with the 
polymer to drug ratio 100:1 determined after manufacturing.  
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Figures 7.7-7.9: Particle size distribution histograms of the three microsphere batches with the 
polymer to drug ratio 5:1 determined after manufacturing.  
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Figures 7.10-7.12: Particle size distribution histograms of the three microsphere batches with the 
polymer to drug ratio 1:1 determined after manufacturing.  
 
PLA-placebo 85/15 PLGA-placebo 75/25 PLGA-placebo 
75/25 PLGA-(100:1) 
75/25 PLGA-(5:1) 
75/25 PLGA-(1:1) 
85/15 PLGA-(5:1) 
85/15 PLGA-(1:1) 
85/15 PLGA-(100:1) PLA-(100:1) 
PLA-(1:1) 
PLA-(5:1) 
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The median sizes of the twelve microsphere batches determined after manufacturing as well 
as after dissolution test are listed in Table 7.6. Additionally, the differences of both 
measurements are represented in percent of the initial value.  
 
After dissolution tests, the diameter of the microspheres was reduced by 0.99 % on average 
(0.37 % to 2.07 %) for microspheres with the polymer to drug ratio 100:1, by 1.4 % on the 
average (0.63 % to 2.01 %) for the microspheres with the polymer to drug ratio 5:1 and by 
5.1 % on the average (4.75 % to 5.22 %) for the microspheres with the polymer to drug ratio 
1:1. 
 
 
Table 7.6: Median size [µm] of the twelve microsphere batches after manufacturing and after 
dissolution test (n = 3). The differences of the median size are represented in 
percent of the initial value. 
 
Microspheres Median size after 
manufacturing 
Median size after 
dissolution test Difference 
 [µm] [µm] [%] 
PLA-placebo 
85/15 PLGA-placebo 
75/25 PLGA-placebo 
86.07 
106.30 
113.80 
-* 
-* 
-* 
- 
- 
- 
PLA-(100:1) 
85/15 PLGA-(100:1) 
75/25 PLGA-(100:1) 
83.07 
94.47 
102.27 
82.70 
94.00 
100.20 
- 0.37 
- 0.47 
- 2.07 
PLA-(5:1) 
85/15 PLGA-(5:1) 
75/25 PLGA-(5:1) 
79.57 
94.53 
112.37 
77.97 
93.93 
110.73 
- 2.01 
- 0.63 
- 1.46 
PLA-(1:1) 
85/15 PLGA-(1:1) 
75/25 PLGA-(1:1) 
97.77 
108.43 
113.53 
92.67 
102.80 
108.14 
- 5.22 
- 5.19 
- 4.75 
 
* No dissolution test performed. 
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3.3. Raman spectroscopy 
 
Raman spectra were obtained from the microspheres batches in order to study the difference 
related to each copolymer as well as to characterize the drug incorporated into the polymer 
matrices. Figure 7.13 represents the Raman spectra of the three placebo microsphere 
batches in the wavenumber region between 300 cm-1 and 2000 cm-1. Each placebo 
microspheres batch was based on a different polymer type such as PLA, 85/15 PLGA and 
75/25 PLGA polymers. The curve (a) represents the PLA-placebo microspheres, (b) the 
85/15 PLGA-placebo microspheres and (c) the 75/25 PLGA-placebo microspheres.  
 
 
 
 
 
 
 
 
 
 
    a 
 
 
    b 
 
 
    c  
 
Figure 7.13: Raman spectra of the placebo microspheres plotted in the wavenumber region 
between 300 cm-1 and 2000 cm-1: (a) PLA-placebo microspheres, (b) 85/15 PLGA-
placebo microspheres, (c) 75/25 PLGA-placebo microspheres. 
 
 
Some bands of the Raman spectra can be specifically attributed to the lactate units and to 
the glycolate units of the copolymers [Kister et al., 1997; Kister et al., 1998 (1), (2)]. These 
assignments are listed in Table 7.7. 
 
 
Table 7.7: Assignment of bands specific for the lactate units and for the glycolate units from 
the Raman spectra of the placebo microspheres. 
 
Lactate units Assignment Glycolate units Assignment 
[cm-1]  [cm-1]  
1773-1749 νC=O 1760 νC=O 
1455 δasCH3 1426 δasCH2 
1386 δsCH3 1274 twCH2 
1300 δCH 890 νCC 
873 νCC 848 rCH2 
Wavenumber [cm-1] 
R
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n
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The νasCH2 deformation band observed at 1426 cm-1 and the νasCH3 deformation band 
located at 1455 cm-1 in the Raman spectra (dotted lines) allow differentiation of copolymers 
with different compositions in lactate and glycolate units. The variations of the intensity ratio 
for the Raman lines change as a function of content in glycolate units and are in agreement 
with the expectations. 
 
The νCC stretching modes appear as sharp Raman lines of high intensity. Raman spectra of 
the PLA and PLGA copolymers show a strong and sharp line at 873 cm-1 (dotted lines) 
typical for the lactate units, and well identified shoulders at 848 cm-1 and at 890 cm-1 (dotted 
lines) due to the glycolate units. The intensity ratio is different for the various proportions in 
lactate and glycolate units in the polymer. This again allows the determination of the 
proportion of monomers within the polymer chains.  
 
Raman spectroscopy was also applied for qualitative and semi-quantitative characterization 
of the drug incorporated within the different polymeric matrices. Four Raman spectra are 
represented in Figure 7.14. The spectrum of the amorphous configuration of the active 
ingredient NOA449851 is represented as curve (a). The amorphous configuration of the 
active ingredient was confirmed with X-ray analysis in Chapter 2, Section 3.4. Curves (b) and 
(c) represent spectra of PLA-microspheres with a drug loading of 50 % and 16.67 %, 
respectively (batches PLA-(1:1) and PLA-(5:1)). The spectrum of the PLA placebo 
microspheres is represented as curve (d). The normation of the three spectra of the 
microspheres was made in reference to the νCC band at 890 cm-1.  
 
Analogue representations of the four Raman spectra for the microspheres with polymer 
matrices 85/15 PLGA and 75/25 PLGA are shown in Figures 7.15 and 7.16, respectively. 
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Figure 7.14: Raman spectra of amorphous drug substance and PLA-microspheres loaded with 
drug substance plotted in the region between 300 cm-1 and 2000 cm-1: amorphous 
active ingredient NOA449851 (a), PLA-(1:1) (b), PLA-(5:1) (c) and PLA-placebo (d). 
 
 
 
Figure 7.15: Raman spectra of amorphous drug substance and 85/15 PLGA microspheres 
loaded with drug substance plotted in the region between 300 cm-1 and 2000 cm-1: 
amorphous active ingredient NOA449851 (a), 85/15 PLGA-(1:1) (b), 85/15 PLGA-
(5:1) (c) and 85/15 PLGA-placebo (d). 
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Figure 7.16: Raman spectra of amorphous drug substance and 75/25 PLGA microspheres 
loaded with drug substance plotted in the region between 300 cm-1 and 2000 cm-1: 
amorphous active ingredient NOA449851 (a), 75/25 PLGA-(1:1) (b), 75/25 PLGA-
(5:1) (c) and 75/25 PLGA-placebo (d). 
 
 
In Figures 7.14 to 7.16, the curves (b) and (c) represent the spectra of NOA449851 loaded 
microspheres with the polymer to drug ratios 1:1 and 5:1, respectively. They logically 
contained both drug and polymer bands whereas the intensity of the bands reduced with the 
relative concentration of the components. The spectra did not reveal any noticeable change 
as compared with their respective model Raman patterns (curve (a) for the amorphous active 
ingredient and curve (d) for the placebo microspheres). Therefore, no indication either of 
structural modification of the active ingredient NOA449851 or PLA/PLGA matrix or of their 
interactions could be discerned in the studied wavelength range.  
 
The band positions and shapes in the spectra indicate the absence of crystalline drug 
substance and the presence of an amorphous form of the active ingredient in each 
microspheres batch, independently of active ingredient concentration and of polymer matrix. 
As a control, the Raman patterns of the active ingredient NOA449851 were previously 
investigated in Chapter 2, Section 3.3. Figure 2.5 of Chapter 2 illustrates the relative Raman 
spectra of the active ingredient for a crystalline (curve a) and an amorphous (curve b) 
sample. 
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3.4. IR spectroscopy 
 
The overlay plot of the IR spectra of the three microsphere batches with the polymer to drug 
ratio 1:1 is illustrated in Figure 7.17, plotted in the wavenumber region between 2500 cm-1 
and 4000 cm-1. As already investigated in Chapter 2, Section 3.3.1, the wavenumber region 
between 3100 cm-1 and 3700 cm-1 is typical for the –NH and –OH signals of the active 
ingredient and therefore very sensitive to the external environment, with which these 
chemical groups can build hydrogen-bonds. Figure 2.4 of Chapter 2 illustrates the changes in 
the wavenumber region between 2500 cm-1 and 4000 cm-1 of the IR spectra of the active 
ingredient, depending on the polarity of the solvent used, and therefore confirms the 
capability of the active ingredient NOA449851 to build hydrogen bonds with the external 
milieu.  
 
IR spectra of the three microspheres batches with the polymer to drug ratio 1:1 were identical 
in this particular region (not shaded wavenumber region between 3100 cm-1 and 3700 cm-1). 
This indicates that there were no detectable interaction of the nature of hydrogen bond in the 
micrsopheres between polymer matrix and active ingredient NOA449851, independent of the 
polymer type used.  
 
The spectra variations at wavenumber 2997 cm-1 are specific for νasCH3 group of the lactic 
units in the matrix poylmers. These differences confirm that three different polymer types 
were used as matrix for the microspheres. 
 
 
Figure 7.17: Overlay plot of IR spectra of the three microspheres batches with polymer to drug 
ratio 1:1, plotted in the wavenumber region between 2500 cm-1 and 4000 cm-1. 
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3.5. X-ray analysis 
 
Powder X-ray diffraction was carried out for the microsphere batch PLA-(1:1), directly after its 
manufacture. The diffractogram represented in Figure 7.18 shows a halo pattern. This 
indicates that both the active ingredient NOA449851 and the PLA polymer were in 
amorphous state in the microsphere batch PLA-(1:1).  
 
As a control, diffraction patterns of active ingredient NOA449851 without polymer matrix 
were previously investigated in Chapter 2, Section 3.4. Figures 2.6 and 2.7 of Chapter 2 
illustrate the relative diffractograms of the active ingredient for a crystalline and an 
amorphous sample, respectively. 
 
 
 
Figure 7.18: X-ray diffractogram of microsphere batch PLA-(1:1). The broad diffusion band 
indicates that both components of the microparticles were in the amorphous state.  
 
 
3.6. In-vitro drug release from microspheres 
 
In-vitro drug release profiles from microspheres were determined in triplicate using a 
modified USP basket dissolution test method. Release studies were performed over a period 
of 40 days, under the same test conditions as described for the sustained release injectables 
formed in-situ (Chapter 3, Section 2.2.2). 
 
 Chapter 7: Microsphere technology 
 
 
206 
The release profiles of NOA449851 from the three microsphere batches based on different 
polymer types with the polymer to drug ratio 100:1 are represented in Figure 7.19. During the 
40 days of dissolution testing, no active ingredient could be detected in the dissolution 
medium, keeping the cumulative released amount at 0 during the whole experiment for all 
three microparticle batches.  
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Figure 7.19: In-vitro cumulative release profiles of NOA449851 from PLA ( ), 85/15 PLGA ( ) 
and 75/25 PLGA ( ) microspheres (n = 3) with a polymer to drug ratio 100:1. 
 
 
The release profiles of NOA449851 from the three microsphere batches based on different 
polymer types with the polymer to drug ratio 5:1 are represented in Figure 7.20. The drug 
release profiles suggest a small and instantaneous burst of 1.02 % of the total amount of 
active ingredient for batch PLA-(5:1), of 1.21 % for batch 85/15 PLGA-(5:1) and of 1.91 % for  
batch 75/25 PLGA-(5:1), followed by a lag phase. At the end of the experiment, the total 
amount of active ingredient released in the medium was 1.04 % for the batch PLA-(5:1), 
1.31 % for batch 85/15 PLGA-(5:1) and 2.23 % for batch 75/25 PLGA-(5:1).  
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Figure 7.20: In-vitro cumulative release profiles of NOA449851 from PLA ( ), 85/15 PLGA ( ) 
and 75/25 PLGA ( ) microspheres (n = 3) with a polymer to drug ratio 5:1. 
 
 
The release profiles of NOA449851 from the three microsphere batches based on different 
polymer types with the polymer to drug ratio 1:1 are represented in Figure 7.21. The drug 
profiles indicate an initial burst release of 3.46 % of the total amount of active ingredient for 
batch PLA-(1:1), of 3.38 % for batch 85/15 PLGA-(1:1) and of 3.13 % for batch 75/25 PLGA-
(1:1) during the first two days of dissolution testing. During the second phase of the profiles, 
very little active ingredient was released in the medium. After 40 days the total amount of 
active ingredient released from the microspheres was 3.87 % for batch PLA-(1:1), 3.56 % for 
batch 85/15 PLGA-(1:1) and 3.47 % for batch 75/25 PLGA-(1:1). 
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Figure 7.21: In-vitro cumulative release profiles of NOA449851 from PLA ( ), 85/15 PLGA ( ) 
and 75/25 PLGA ( ) microspheres (n = 3) with a polymer to drug ratio 1:1. 
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4. Discussion 
4.1. Preparation of microspheres and encapsulation efficiency 
 
A conventional method for preparation of O/W emulsions [Conti et al., 1992; Jalil et al., 1990; 
Jain, 2000] was successfully applied to manufacture the twelve microsphere batches with a 
drug load up to 50 % (w/w). A loss of 10 % in weight is common for this manufacturing 
method [Jalil et al., 1990; Choi et al., 2002]. 
 
The active ingredient NOA449851 is a hydrophobic drug, highly soluble in methylene 
chloride which was the solvent for the PLA/PLGA polymers. The physicochemical properties 
of the active ingredient designated it as an ideal candidate for incorporation into 
microspheres by a O/W emulsion solvent evaporation method [Jalil et al., 1990; Conti et al., 
1992; Jain, 2000]. The active ingredient NOA449851 was very efficiently entrapped in the 
PLA/PLGA microspheres: the encapsulation efficiency was 99.02 % for the microspheres 
with the polymer to drug ratio 100:1, 98.11 % for the microspheres with the polymer to drug 
ratio 5:1 and 94.65 % in average for the microspheres with the polymer to drug ratio 1:1. 
Independent of the polymer type used, the encapsulation efficiency slightly decreased when 
the amount of polymer was reduced (Tables 7.3 to 7.5). These observations are in 
agreement with the finding of Choi et al., who investigated microspheres loaded with the 
slightly water soluble drug fentanyl, as well as Schlicher et al., who investigated 
microspheres loaded with the water soluble drug desferrioxamine. Both reported that an 
increased polymer concentration in the microspheres composition resulted in an enhanced 
encapsulation efficiency [Choi et al., 2002; Schlicher et al., 1997]. 
 
4.2. Granulometry 
 
Particle size of microspheres is an important formulation parameter that influences 
pharmaceutical properties of the particulate delivery system. Decreasing particles size leads 
to a large increase of total surface area per unit volume and therefore facilitates exchanges 
between polymer matrix and medium. Further, the drug release profile type depends strongly 
on microparticle diameter. The release of small molecule drugs can be varied from typical 
diffusion controlled profiles to slower sigmoid profiles as microsphere diameter is increased 
in the range of 10-100 µm [Berkland et al., 2002; Siepmann et al., 2004]. 
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Analysis of particle sizes revealed a median size of 86.62 µm for microspheres based on 
PLA polymers, of 100.93 µm for 85/15 PLGA polymers and of 110.50 µm for 75/25 PLGA 
polymers. The median diameter size changed with regard to the type of polymer used: the 
higher the glycolate units in the polymer matrix, the larger the microspheres size. This can 
probably be attributed to the different surface tensions of the polymer emulsions. A change in 
the polymer to drug ratios from placebo to 100:1, 5:1 or 1:1 did not affect the median particle 
size. In a similar experimental set up, Mandal et al. found that microparticles formulated with 
50/50 PLGA polymer and the water soluble active ingredient pentamidine had similar median 
particles size in all manufactured batches, independent of the polymer to drug ratio used. 
However, these authors did only vary the polymer to drug ratio in a tight range from 2:1 to 8:1 
[Mandal et al., 2001].  
 
After immersion in an aqueous medium for 40 days at 37°C for the dissolution tests, a 
decrease of the median particle size of 0.9 % in average for the microspheres batches with 
the polymer to drug ratio 100:1, of 1.4 % in average for the microspheres batches with the 
polymer to drug ratio 5:1 and of 5.1 % in average for the microspheres batches with the 
weight polymer to drug ratio 1:1 was observed. Surprisingly, the decrease in diameter was 
independent of the polymer type. PLA and PLGA polymers degrade via random chain 
scission of ester linkage in the polymer backbone. The extent of hydrolytic degradation 
depends on many physicochemical characteristics of the polymers, including molecular 
weight, proportion of monomer units and hydrophilicity.  
 
It can be hypothesized that no significant erosion of the polymers could occur during the 
dissolution test and therefore no differences were observed between the polymer types. The 
diminution of the median particle size may be attributed to the dissolution of the active 
ingredient from the surface of the microspheres. The diameter reduction of the microspheres 
can be correlated with the magnitude of the initial burst release observed during the in-vitro 
dissolution tests. 
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4.3. Spectroscopy methods 
 
IR and Raman spectroscopy are complementary methods for studying molecular vibrations. 
They both give information if the vibration is accompanied by a variation of electric dipole 
moment, however Raman scattering is only observed if a variation of molecular polarizability 
appears during the vibration [Dean, 1995]. Vibrational spectroscopy has been reported to be 
suitable for investigation of polymeric materials used in biomedical applications, particularly 
for the analysis of morphology, chemical composition and configurational structure of the 
homopolymers and copolymers based on poly(lactic acid), poly(glycolic acid) and poly(-
caprolactone) [Kister et al.,1997, 1998 (1), (2), 2000; Qin et al., 1998; Taddei et al., 2001].  
 
The various polymer types can be differentiated with Raman spectroscopy. The distinction of 
PLA/PLGA copolymers with various compositions in monomer units was possible 
considering the CH and CC stretching regions of the Raman spectra of the placebo 
microspheres [Kister et al., 1997; Kister et al., 1998 (1), (2)]. Assignments of these bands 
with localization of the corresponding vibrations at lactate or glycolate units were proposed in 
Table 7.7. The specific bands for distinguishing the different copolymers were located at the 
wavenumbers 1455 cm-1, 1426 cm-1, 890 cm-1, 873 cm-1 and 848 cm-1 [Kister et al., 1998 (1), 
(2)]. 
 
Characterization of drugs within a polymer support is an important prerequisite to understand 
physicochemical mechanisms which control the release of drugs from a biomedical polymer. 
Raman spectroscopy has been used for investigation of various drugs embedded in polymer 
extrudates such as sulfathiazole in povidone [Bolton et al., 1984], diclofenac in sodium 
alginate [Tudor et al., 1990; Davies et al., 1990], ibuprofen in PVP [Breitenbach et al., 1999] 
or indomethacin in PVP [Taylor et al., 1997]. Also, drugs embedded in polymer matrices 
formulated as microspheres were investigated using Raman spectroscopy [Watts et al., 
1991; Roman et al., 1999; Geze et al., 1999].  
 
The physicochemical properties of the embedded active ingredient helps to determine the 
nature of the release process and the rate of diffusion of the drug into the environment. 
Several factors are considered to contribute to the increase in release rates of drugs 
including the greater solubility of the amorphous drug relative to the crystalline material as 
well as the absence of drug interaction with the polymeric matrix. In the spectroscopic 
investigations of the sulfasalazine containing microspheres described by Watts [Watts et al., 
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1991], the authors presume a drug/polymer interaction, as a shift of an active ingredient band 
was detected in Raman spectra.  
 
IR and Raman spectroscopy were used to characterize microspheres produced from  
pharmaceutical PLA/PLGA polymers containing a range of concentrations of the drug 
NOA449851 from 0 % to 50 %. The qualitative information included the analysis of the 
spectral shape, the band position and their relative intensity. This allowed the molecular 
characterization of the samples and therefore detection of probable structural changes of the 
drug or of the polymer matrix induced by interaction.  
 
The Raman spectra bands of the active ingredient NOA449851 can clearly be distinguished 
from the PLA/PLGA polymer bands in these two-components systems. The Raman spectra 
show that the active ingredient NOA449851 had always the same conformation when 
integrated in microspheres, independent of active ingredient concentration and polymer type. 
As previously investigated with Raman spectroscopy (Chapter 2, Section 3.3) the major 
change in the active ingredient spectra between the crystalline and the amorphous 
conformation was illustrated with the shift of the band from 1520 cm-1 to 1528 cm-1. As 
previously determined in Chapter 2, Section 3.2, this band corresponds to the amid II and the 
benzene ring of the side chain of the active ingredient molecule. Therefore it can be 
concluded that the active ingredient was always in the amorphous conformation when 
integrated into the microspheres. These results are in agreement with the predictions of 
Taylor who assumes that drugs are most of the time present in the amorphous conformation 
when embedded in a polymeric matrix [Taylor et al., 1997]. However, this was not the case 
for the microspheres studied by Mandal et al., where the active ingredient pentamidine was 
found to be mostly present in the crystalline form in the PLGA microparticles [Mandal et al., 
2001]. 
 
No changes were detected for any band related to the different copolymers, independent of 
presence of the active ingredient. After investigation of all Raman spectra, there was no 
evidence for any drug/polymer interaction. Despite the capability of the active ingredient to 
form hydrogen bonds with external medium (Figure 2.4, Chapter 2), the substance does not 
interact with the polymeric matrix, most probably because of superior thermodynamic 
stability.  
 
As already investigated in Chapter 2, Section 3.5, the active ingredient NOA449851 showed 
strong modifications in the IR spectra, which depend on the external solvent medium, 
particularly concerning the wavenumber region between 3100 cm-1 and 3700 cm-1 of the IR 
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spectra, where the hydrogen bonding of -OH and -NH groups with other molecules can easily 
be detected. This implies that the active ingredient NOA449851 is able to form H-bonds. 
(Chapter 2, Figure 2.4). The IR spectra of the three microsphere batches with the drug to 
polymer ratio 1:1 showed identical spectra for the active ingredient in this region (between 
3100 cm-1 and 3700 cm-1), indicating no detectable interaction with the surrounding polymers 
(Figure 7.17).  
 
With both Raman and IR spectroscopy, no evidence for any drug/polymer interaction in 
microspheres was found. If there was interaction between the drug and the polymer matrix 
drug release and stability would be influenced. A significant polymer/drug interaction could 
give rise to a decreased release rate and possibly stabilization of an amorphous state [Sinha 
et al., 2003].  
 
4.4. X-ray 
 
X-ray measurement of microsphere batch PLA-(1:1) permitted to determine that both active 
ingredient and  PLA polymer of the measured batch are in an amorphous conformation. This 
is in agreement with the finding of the Raman spectroscopy investigations of this chapter. 
The cross-comparison of Raman measurements confirmed that the active ingredient was in 
amorphous conformation in all microsphere batches, independent on drug content and 
polymer type. 
 
4.5. In-vitro drug release from microspheres 
 
The drug release profiles from microspheres was determined using a modified USP basket 
method over a period of 40 days. No active ingredient could be detected in the medium 
during the dissolution test of microspheres batches with the polymer to drug ratio 100:1, 
independently of the polymer used. For microsphere batches with the polymer to drug ratio 
5:1 and 1:1, the observed drug release occurred in two distinct phases: first, a small initial 
burst release in a range of 1 % to 5 % occurred, followed by a second phase characterized 
by a negligible release until the end of the experiment after 40 days. The initial burst release 
was slightly more important for microspheres containing a higher amount of active ingredient. 
The use of three different polymer types for the microspheres matrix did not affect drug 
release profiles. The total amount of drug released was found to be particularly low for all 
microsphere batches tested. Microspheres with the polymer to drug ratio 1:1 showed a 
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higher cumulative percent drug release (from 3.47 % to 3.87 %) compared to microspheres 
with the polymer to drug ratio 5:1 (from 1.07 % to 2.22 %) within the 40 days of the 
experiment.  
 
Release mechanisms of microspheres have been widely studied and can be summarized in 
four main processes: release from the microspheres surface, diffusion through the polymer 
barrier, polymer erosion and bulk degradation. Particularly the two last mechanisms are 
affected by the rate of hydrolysis of polymer chains [Jalil et al., 1990]. As a consequence for 
these various release mechanisms, a typical triphasic release profile for lipophilic drug has 
been reported in the literature. This effect has been observed for microspheres with low drug 
loads, i.e., from 1 % to 5 % [Puri et al., 2000; Wang et al., 1996; Cleland et al., 1997], as well 
as for microspheres with higher drug load, i.e. from 16 to 25 % [Singh et al., 1997 (2)]. The 
second phase has also been reported to vary in a lag time from one week [Singh et al., 1997 
(2)] to six weeks [Hampl et al., 1996], depending on the polymer matrix type and on the 
physicochemical characteristics of the active ingredient. Diverse authors have further 
discussed parameters influencing the triphasic release such as diameter of microparticles, 
influence of additives and porosity of the matrix [Berkland et al., 2002; Hora et al., 1990; 
Cleland, 1998].  
 
The triphasic release profile is characterized by an initial burst followed by a lag phase and 
finally a secondary burst [Singh et al., 1997 (3)]. The initial burst is caused by the release of 
drug that is loosely bound to the surface or embedded in a superficial region of the 
microspheres [Choi et al., 2002; Berkland et al., 2002; Shah et al., 1992]. The lag period may 
be due to the medium being diffused into the polymer matrix. The second burst effect occurs 
when the matrix becomes more water soluble which results in erosion and collapse of the 
matrix. Initial burst release followed by a period of no or low drug release from PLA/PLGA 
matrices is a major problem for the microsphere technology. In the present case, only the 
two first phases were observed, since the experiments were stopped after 40 days. 
 
As observed in Figures 7.19 to 7.21, the release patterns of the active ingredient from the 
microspheres were not affected by the polymer type. Generally, the various properties of the 
polymeric drug carrier are used to control the drug release. As widely described in the 
literature [Middleton et al., 2000; Wang et al., 1997; Sinha et al., 1998], the different polymers 
are characterized by various erosion rates in an aqueous medium. After evaluation of the 
release properties and of the granulometry data, it was concluded that not the polymer types 
but much rather the ratio of polymer to drug influenced the drug release properties.  
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The very low active ingredient amount released from the microspheres was very surprising. 
With an active ingredient concentration up to 50 % (w/w), a significant faster drug release 
was expected. The hydrophobic characteristics of the active ingredient NOA449851 may 
have prevented penetration of water molecules of the dissolution medium into the polymeric 
microsphere matrix. This would have resulted in a reduced rate of hydrolysis of the ester 
bounds of the polymer and consequently in a delay of the secondary burst of the triphasic 
drug release profile. The polymer bulk may therefore need more than the 40 days of the 
duration of the dissolution test for significant hydrolytic degradation. However, reduction of 
the lipophilic active ingredient concentration in the microspheres from 50.00 % to 16.67 % or 
even 0.99 % did not increase the relative drug release. This can be attributed to the 
concomitant reduction of the concentration gradient which is the major driving force for the 
assumed primarily drug release mechanism, the passive diffusion of the drug molecules 
through the polymeric matrix.  
 
The microsphere batches as investigated in the present experiment are not suitable as 
injectable sustained release technology for this active ingredient. The release profiles did not 
fulfill the required drug release characteristics for a sustained release parenteral drug 
delivery system. Changes in composition or in manufacturing method of the microspheres 
are necessary to improve the drug release rate. The formulation variables include decrease 
of polymer amount, use of lower molecular weight polymers, increase of porosity of polymer 
matrix, decrease of diameter, addition of releasing modifying factors such as manitol or fatty 
acid esters [De Rosa et al., 2000; Urata et al., 1999; Mandal et al., 2001; Jain et al., 2000 (2); 
Dalpiaz et al., 2002; Conti et al, 1992]. As this technology was primarily investigated for 
comparison with the sustained release injectable formed in-situ and for detection of 
drug/polymer interaction, no further optimization of the microsphere formulation was planed. 
Comparison of drug release from microparticles and from the related sustained release 
injectables formed in-situ will be discussed in Chapter 8.  
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5. Conclusion 
 
Microspheres were evaluated as an alternative technology for sustained release injectable 
dosage form for the active ingredient NOA449851. Microspheres were manufactured with the 
same types of polymer as for the sustained release injectables formed in-situ. Attention was 
paid for keeping the same polymer to drug ratios as for the injectable implants. The lipophilic 
active ingredient NOA449851 was very efficiently incorporated in the microspheres, when 
prepared with a conventional O/W solvent evaporation method. 
 
No active ingredient was detected in the external medium during the dissolution test of the 
microparticles with a polymer to drug ratio 100:1. For microspheres with weight polymer to 
drug ratios of 5:1 and 1:1, the in-vitro drug releases were between 1 % and 5 % during the 
first two days, probably corresponding to the drug loosely bound at the surface of the 
microspheres. After this small initial burst, drug releases were close to zero, independent of 
polymer type and of the polymer to drug ratio of the microspheres. These in-vitro drug 
release profiles, combined with granulometry data, indicate that, most probably, the 
mechanism for active ingredient release from the polymeric matrices was primarily diffusion 
controlled. Polymer erosion appeared not to play an important role in active ingredient 
release from the microspheres during the 40 days of the in-vitro dissolution testing. Drug 
release profiles from the microparticles investigated in this chapter will be compared in 
Chapter 8 with the ones from the related sustained release injectables formed in-situ as 
investigated in Chapter 3.  
 
Raman and IR spectroscopy as well as X-ray investigations revealed that the active 
ingredient was incorporated in amorphous conformation in all microsphere batches, 
independent of the polymer type and of the active ingredient concentration. No evidence for 
any interaction between active ingredient and polymer matrix could be detected. The 
microspheres were used as a simplified two-components model, lacking the solvent in 
comparison to the sustained release injectables formed in-situ.  
 
The NOA449851 loaded microspheres did not meet the drug release requirements for a 
sustained release delivery system. The release profiles could probably be improved by 
changing the composition of the microspheres or by modifying the method of preparation. As 
this technology was primarily investigated for comparison with the sustained release 
injectable formed in-situ and for detection of drug/polymer interaction, no further optimization 
of the microsphere formulations was performed. 
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Chapter 8 
 
General Discussion and Outlook 
 
 
1. Introduction 
 
The aim of this PhD thesis was to investigate properties of sustained release injectables 
formed in-situ for use in dogs, comprising an organic solvent or solvents mixture in which the 
biodegradable PLA/PLGA polymers and the lipophilic anti-infective NOA449851 were 
dissolved. Dissolution tests were performed to investigate in-vitro drug release 
characteristics of various formulations. Tolerability and pharmacokinetic properties were 
explored after subcutaneous administration to experimental animals. Additionally, stability of 
formulations at different storage conditions over a period of six months was investigated and 
a comparison with microspheres technology was made with regard to manufacturing method 
and in-vitro release properties.  
 
The new sustained release injectables formed in-situ showed a prolonged active ingredient 
release under in-vitro as well as in-vivo conditions, confirming that this drug delivery 
technology is suitable to achieve a controlled release of the selected active ingredient 
NOA449851. The technology used has several attractive features such as the simplicity of 
concept, ease of manufacturing as well as the use of FDA approved polymers. However, the 
limitations of this technology include the use of organic solvents, its high viscosity and its 
release variability, particularly with respect to the initial burst. These difficulties need to be 
addressed in the future in more detail, in order to allow a safe use of this injectable 
technology in the market. 
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In the next section, the findings of the previous chapters are re-discussed in relation with 
each other. In particular, the correlation of in-vitro and in-vivo active ingredient release 
parameters as well as comparison between in-situ forming implant technology and 
microparticles technology are discussed. 
 
Finally, the principal critical issues related to the use of this new technology are pointed out, 
especially with regard to the adaptations still needed to make this studied in-situ forming 
implant suitable for market. To achieve a marketable product accepted by regulatory 
authorities and end-users, additional investigations and improvements have to be performed. 
The main concerns are the high viscosity and the consequently inferior syringeability of 
formulation, the choice of an adequate active ingredient as well as the stability of 
biodegradable polymers during storage of formulation.  
 
2. Relationship between the findings of the various chapters 
2.1. Comparison of the in-vitro and the in-vivo drug release profiles 
 
Drug release properties from in-situ forming implants were already discussed in Chapter 5 
which was especially dedicated to in-vitro/in-vivo correlation of drug release. The comparison 
is, logically, only possible for formulations which were tested in-vitro as well as in-vivo. This 
concerned six formulations, varying in polymer content and in solvent composition. 
Particularly the influence of the presence of hydrophilic co-solvents such as glycerol formal, 
anhydrous glycerol and ethanol absolute in the formulation on the drug release 
characteristics was investigated. 
 
The in-vitro dissolution tests reported in Chapter 3 showed a significant reduction of initial 
burst when concentration of PLA polymer was increased in the composition of the 
formulation as well as when a fraction of the main solvent triacetin was substituted by 
hydrophilic co-solvents. During the first week of the in-vitro dissolution test, 60.13 % of the 
active ingredient integrated in the formulation was released from the sustained release 
injectable formed in-situ containing 12.75 % (w/w) of PLA polymers while only 17.57 % of the 
active ingredient was released from the formulation containing 17.00 % (w/w) of the PLA 
polymers during the same period of time (Chapter 3, Figure 3.4). Substitution of 10.00 % of 
the main solvent triacetin reduced initial drug release during the first week of the in-vitro 
dissolution test from 17.57 % to 15.86 %, to 11.41 % and to 9.82 % by using the hydrophilic 
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co-solvents glycerol formal, anhydrous glycerol and ethanol absolute, respectively (Chapter 
3, Figures 3.8 to 3.10).  
 
The formulations applied subcutaneously to the dogs, as described in Chapter 4, tend to act 
in an analog manner. Reduction of polymer content in the formulations gave rise to a higher 
initial burst and use of the various hydrophilic co-solvents reduced maximum drug burst 
concentration of the dog blood profiles. Maximal blood concentrations were 89.2 ng/ml and 
87.6 ng/ml for the dogs to which formulation containing 17.00 % of the PLA polymer was 
applied (Chapter 4, Figure 4.5). By reducing the concentration of biodegradable polymer to 
12.75 %, higher maximal blood concentrations of 92.7 ng/ml and 117.2 ng/ml were reached 
(Chapter 4, Figure 4.6). In contrast, lower maximal blood concentrations were obtained after 
subcutaneous injection of formulations containing the hydrophilic co-solvents ethanol 
absolute (44.2 ng/ml and 47.5 ng/ml), glycerol formal (35.6 ng/ml and 37.4 ng/ml) or 
anhydrous glycerol (35.0 ng/ml and 40.6 ng/ml) in comparison to the formulation containing 
triacetin as sole solvent (89.2 ng/ml and 87.6 ng/ml), (Chapter 4, Figures 4.7, 4.9 and 4.10). 
 
To evaluate how far a correlation between the in-vitro drug release and the in-vivo release 
could be found, further investigations were carried out. Correlation between in-vitro 
dissolution parameters and in-vivo pharmacokinetic data was investigated. Cmax was 
positively correlated to cumulative in-vitro drug release at Tmax, however not in a significant 
manner. In general, for this type of dosage form and drug, no satisfactory IVIVC are 
observed. The model used for in-vitro drug release testing neglect some crucial aspects of 
physiological conditions and cannot replace biological systems. 
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2.2. Comparison of the properties of sustained release injectables formed in-
situ with microspheres 
 
Sustained release injectables formed in-situ and microspheres are both technologies 
intended for parenteral application, planned to achieve a sustained drug release. In both 
technologies, sustained effect is caused by biodegradable PLA/PLGA polymer matrix in 
which the active ingredient is embedded. Active ingredient release is controlled by a  mixed 
process of drug diffusion and polymer matrix erosion. However, both technologies differ 
considerably in manufacturing procedures and in in-vitro release properties. 
 
2.2.1. Manufacturing procedure 
 
Manufacturing procedure for microspheres is much more elaborate as for sustained release 
injectables formed in-situ. A wide range of microencapsulation techniques have been 
developed to date. The selection of a specific technique is dependent on polymer type and 
on physico-chemical properties of the active ingredient. In the present study, an O/W 
emulsion solvent evaporation method was used as a simple and common preparation 
process for polylactid microspheres loaded with a lipophilic active ingredient [Conti et al., 
1992]. However, this manufacturing procedure includes preparation of an O/W emulsion, 
followed by evaporation phase to remove the organic solvent phase in which the polymers 
are dissolved. A filtration is then needed to recover the solid microspheres and finally a 
drying step is required to remove solvent traces from the PLA/PLGA polymer particles. 
These different steps are time consuming and require the utilization of excess of organic 
solvents. Furthermore, the scaling up is a delicate procedure and a good batch to batch 
reproducibility is difficult to achieve, particularly with regard to parameters such as 
encapsulation efficiency, diameter of the particles, porosity and removal of residual solvent. 
For these considerations, it can be concluded that microspheres manufacturing procedures 
are very sensitive and challenging [Jalil et al., 1990; Conti et al., 1992; Cleland, 1998]. 
 
Sustained release injectables formed in-situ are prepared by using much more 
straightforward methods. Polymers are simply dissolved in the adequate amount of solvent 
and active ingredient is then dispersed or dissolved in this polymer solution. In the present 
study, the active ingredient NOA449851 was dissolved in the polymer solution. This 
manufacturing process though requires stirring equipments able to deal with the high 
viscosity of the polymer solutions. Filling process into the syringes needs also powerful 
pumps able to cope with viscous formulations. 
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2.2.2. In-vitro drug release 
 
In-vitro drug release profiles of the different microspheres batches can be compared with the 
ones of related sustained release injectables formed in-situ. Formulations “PLA-AI(1:1)”, 
“85/15 PLGA-AI(1:1)” and “75/25 PLGA-AI(1:1)” are related to the three microspheres 
batches having a weight polymer to drug ratio 1:1, formulations “PLA-AI(5:1)”, “85/15 PLGA-
AI(5:1)” and “75/25 PLGA-AI(5:1)” to the three microspheres batches with the weight polymer 
to drug ratio 5:1 while formulations “PLA-AI(100:1)”, “85/15 PLGA-AI(100:1)” and “75/25 
PLGA-AI(100:1)” to the three microspheres batches with the weight polymer to drug ratio 
100:1. Compositions and the in-vitro dissolution profiles of sustained release injectables 
formed in-situ formulations are described in Chapter 3 whereas compositions and in-vitro 
dissolution profiles of microspheres are described in Chapter 7. 
 
Microspheres are small in size (from about 10 µm to 100 µm in diameter) and therefore have 
large surface to volume ratios. The high surface area of the microspheres facilitate water 
penetration into the particles and at the same time allow a faster diffusion of the active 
ingredient in the medium. Whereas, implants arisen from the sustained release injectables 
formed in-situ generate a single bulk matrix with little surface to volume ratio. 
 
Surprisingly, in every investigated case drug release from sustained release injectables 
formed in-situ was faster than from the related microparticles. In-vitro drug release from 
microspheres with weight polymer to drug ratio 1:1 was in a range between 3.47 % and 
3.87 % of the total amount of active ingredient integrated after 40 days of dissolution test, 
whereby it was between 39.08 % and 42.64 % for the related sustained release injectables 
formed in-situ with same weight polymer to drug ratio. For formulations with weight polymer 
to drug ratio 5:1, active ingredient release after 40 days of dissolution test represented 
between 1.04 % and 2.23 % of the drug integrated in the microspheres and between 
14.75 % and 16.39 % of the drug integrated in related sustained release injectables formed 
in-situ. Drug release from sustained release injectables formed in-situ with polymer to drug 
ratio 100:1 was influenced by the polymer type used and reached 76.54 % of the active 
ingredient for 75/25 PLGA based formulation, 25.06 % for 85/15 PLGA based formulations 
and 21.69 % for PLA based formulation. In contrast, the amount of active ingredient released 
form the related microspheres with weight polymer to drug ratio 100:1 during the 40 days of 
the dissolution test was not sufficient to be detected by HPLC method, independently of the 
polymer type used.  
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In order to understand the faster release from sustained release injectable formed in-situ 
than from microspheres, it should be realized that diffusion of active ingredient through the 
polymer matrix plays a major role in drug release process. The polymer matrix of the 
microspheres is already solidified before injection in the aqueous medium. Therefore it 
presents other permeability properties for the active ingredient as polymer matrix of implants 
formed in-situ which is not immediately solidified, but coagulates slowly in-situ as result of the 
diffusion of the organic solvent in the surrounding milieu. The drug release related to the 
solidification phase of the implant and therefore concomitant to the organic solvent diffusion 
is one of the major releasing property of the sustained release injectables formed in-situ. 
Active ingredient diffusion out of the implant during coagulation phase of the polymeric matrix 
is responsible for the initial burst effect.  
 
These observations are in agreement with those from R.A. Jain [Jain et al., 2000] who 
compared in-vitro release of cytochrom C from PLGA microspheres and from sustained 
release injectables formed in-situ, based on PLGA and triacetin. In-situ formed implant also 
exhibited faster drug release than related microspheres. The authors attributed this 
phenomenon to the rigid and dense nature of the microspheres matrix. 
 
Microspheres and sustained release injectables formed in-situ with high drug loads (polymer 
to drug ratios of 1:1 and 5:1) exhibit drug release characteristics independent of poly-glycolic 
acid to poly-lactic acid ratios of the PLA/PLGA copolymers used to form the drug delivery 
device matrix (Chapter 3, Figures 3.3 and 3.4 as well as Chapter 7, Figures 7.19 to 7.21). 
This confirms the hypothesis that the major releasing mechanism for both technologies, 
microparticles and sustained release injectables formed in-situ, is drug diffusion through 
polymer matrix following the Fickian’s diffusion theory and not polymer matrix degradation. 
Therefore, the active ingredient concentration gradient influence release rate process. 
Actually, for both technologies, a bigger fraction of active ingredient was released when drug 
loading was higher. 
 
Drug loading of sustained release injectables formed in-situ can change release rate in 
various ways. The drug release rate may be increased at high drug loadings because of 
formation of large and interconnected pores throughout the matrix [Shah et al., 1993; Eliaz et 
al., 2000 (1), (2); Eliaz et al., 1997; Chandrashekar et al., 1996]. In contrast to this, an 
increased drug/drug interaction within the polymer matrix can occur at high active ingredient 
loading, leading to a lower release rate [Yewey et al., 1997]. 
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Raman and IR spectroscopy investigations of sustained release injectables formed in-situ 
and of microspheres were performed to detect interactions between active ingredient and 
polymer matrix. In all investigated formulations, independently on active ingredient loading 
and on polymer type used to form the matrix, no evidence of any type of interaction between 
both components was detected (Chapter 3, Section 3.4 and Chapter 7, Sections 3.3 and 
3.4). Additionally, conformation of the active ingredient within the polymer matrix was 
investigated using Raman spectroscopy as well as X-ray diffraction. The active ingredient, 
when embedded in the PLA/PLGA polymer matrix, was found to be in the amorphous state, 
independently of drug loading and of polymer type. The lack of interaction between active 
ingredient and polymer matrix as well as the amorphous state of the drug within polymer 
matrix are parameters which both increase drug release rate.  
 
With these considerations, the faster release of active ingredient from highly drug loaded 
sustained release injectables formed in-situ is in agreement with the expectations. In the 
present experiment, no drug/drug interaction or polymer/drug interaction seem to slow down 
the active ingredient release from the different formulations. Additionally, diffusion rate is 
enhanced by a higher concentration gradient for higher drug loaded formulations and by 
probable formation of pores within the polymer matrix. 
 
As already mentioned, the active ingredient release patterns from the sustained release 
injectables formed in-situ with weight polymer to drug ratio 1:1 and 5:1 as well as from the 
microspheres were not affected by the polymer type. The different properties of the polymeric 
drug carrier are generally used to control the drug release. As widely reported in the literature 
[Middleton et al., 2000; Wang et al., 1997; Sinha et al., 1998], the different PLA/PLGA 
copolymers are characterized by various hydrolysis rate when placed in an aqueous 
medium. The highly lipophilic character of the active ingredient NOA449851 may have 
prevented penetration of the water molecules into the polymeric matrix. This would have 
resulted in a reduced rate of hydrolysis of the ester bounds of the polymer and consequently 
in a low erosion of the polymeric matrix. All these considerations confirm that the active 
ingredient release mechanism is primarily based on drug diffusion through the polymeric 
matrix. Diffusion as main release mechanism from sustained release injectables formed 
in-situ has been suggested various times in the related publications [Lambert et al., 1995; 
Dunn et al., 1996; Singh et al., 1997; McHugh et al., 1999; Graham et al., 1999; DesNoyer et 
al., 2001; Eliaz et al., 2002]. 
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However, drug release was dependent on the polymer type in case of sustained released 
injectables formed in-situ with very low drug load. After 20 days of in-vitro dissolution testing, 
drug release from 75/25 PLGA based formulation began to increase, whereas active 
ingredient release from implants based on 85/15 PLGA and PLA polymers remained 
constantly low (Chapter 3, Figure 3.5). At this stage, drug release from 75/25 PLGA 
formulation was mainly determined by polymer erosion, as hydrolysis of these polymers is 
known to occur faster than for 85/15 PLGA and pure PLA polymers [Middleton et al., 2000; 
Wang et al., 1997]. The important decrease lipophilic active ingredient content in the 
formulation (polymer to drug ratio 100:1) may have facilitated water permeation into polymer 
matrix in comparison to formulation with much higher drug contents, as for example with the 
polymer to drug ratios 5:1 or 1:1.  
 
No active ingredient was released during the 40 days of the dissolution test from the three 
microparticles batches with weight polymer to drug ratio 100:1, as illustrated in Chapter 7, 
Figure 7.19. This may be explained by both the low concentration gradient and the difficulty 
of water to permeate into the densely solidified microparticles. As already mentioned above, 
the drying step of the manufacturing of the microparticles may result in denser packing of the 
polymer matrix which results in slower diffusion properties of the microspheres polymer 
matrix.  
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3. Critical issues of sustained release injectables formed in-situ 
technology  
 
Some critical issues pointed out during investigations of sustained release injectables formed 
in-situ are discussed in the next section. This includes inconvenient syringeability due to high 
viscosity of formulations, selection criteria of an adequate active ingredient as well as stability 
of polymers during storage of injectable formulations. Finally, some comments on 
marketability of this technology and on further investigations which may be necessary to 
meet requirements from regulatory authorities are discussed. 
3.1. Viscosity and syringeability of formulations  
 
The high viscosity of sustained release injectables formed in-situ turned out to be a critical 
issue. The application of formulation through a 16 G or a 18 G needle was well tolerated by 
the dogs but would probably not be accepted by customers and veterinarians. Pain during 
injection procedure suffered by the companion animals is a pet-owner compliance and 
acceptance issue. 
 
Viscosity of formulations was improved by reducing polymer or the active ingredient content. 
The viscosity of formulation containing 17.00 % of the PLA polymer and 17.00 % of the 
active ingredient NOA449851 was found to be 49.0 Pa*s at shear rates of 1 s-1, while it was 
found to be 12.3 Pa*s for the formulation containing a reduced amount (12.75 %) of the PLA 
polymer at the same measurement conditions. Viscosity of related placebo formulations were 
found to be 7.2 Pa*s and 2.3 Pa*s, respectively (Chapter 4, Table 4.2). As an alternative to 
lower the viscosity, amount of solvent and therefore of injection volume could be increased. 
Moreover, the use of larger injection volumes may also result in more pain at the injection 
site and therefore can only solve the problem to a limited extent. Changes in the composition 
of the formulation must be carefully balanced as the drug release properties and particularly 
the initial burst effect can dramatically change with slight modifications of formulation. This 
has been reported for the in-vitro dissolution tests with the reduction of the polymer amount 
from 17.00 % to 12.75 % (Chapter 3, Figure 3.6).  
 
Use of co-solvents modified viscosity and syringeability of the sustained release injectables 
formed in-situ. Viscosity of formulation was increased with substitution of 10.00 % of the 
main solvent triacetin with co-solvent anhydrous glycerol, whereby it was lowered with 
glycerol formal and ethanol absolute as co-solvent. For shear rate of 1 s-1, the viscosity of the 
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anhydrous glycerol containing formulation was 118 Pa*s, while it was 49.0 Pa*s for the 
formulation containing triacetin as sole solvent. The addition of the co-solvents glycerol 
formal and ethanol absolute decreased the viscosity of formulations from 49.0 Pa*s to  
30.3 Pa*s and 5.5 Pa*s, respectively. Co-solvents can be used as release modifying agents, 
since initial burst was clearly influenced by the solvent mixture composition. As investigated 
in-vitro (Chapter 3, Figures 3.8 to 3.10) and in-vivo (Chapter 4, Figures 4.7, 4.9 and 4.10), it 
was found that addition of hydrophilic co-solvents to the triacetin composition of the 
formulation reduced the magnitude of initial burst. This positive impact of use of co-solvents 
is desired since an important initial burst can lead to systemic side effects and to shorter 
release of the drug. As ethanol absolute was the excipient which reduced the most 
considerably viscosity and simultaneously lowered the initial burst effect, it was selected as 
co-solvent for a candidate formulation for stability testing (Chapter 7). 
 
To reduce efficiently the viscosity and therefore improve syringeability of formulation, an 
injectable containing simultaneously a reduced amount of PLA polymer as well as 10.00 % of 
the co-solvent ethanol absolute was prepared. The viscosity of 2.2 Pa*s was found to be 
lower than formulations containing only the co-solvent ethanol absolute (5.5 Pa*s) or only the 
reduced amount of polymer (12.3 Pa*s) as related in Chapter 4, Table 4.2. The in-vitro 
release profile as illustrated in Chapter 3, Figure 3.11 had a “b/a” factor of 129.7 and was 
therefore qualified as very bad. It showed an important initial burst representing a release of 
31 % of the total active ingredient during the first 7 days, followed by a slow continued 
release of only 0.3 % of the total integrated drug substance per day. Surprisingly, in-vivo 
blood profile of this formulation showed a satisfactory release of the active ingredient. 
Maximal concentrations reached values of 61.2 ng/ml and 48.9 ng/ml, which are lower than 
the maximal concentrations of 92.7 ng/ml and 117.2 ng/ml obtained after the application of 
the corresponding formulation without the hydrophilic co-solvent ethanol absolute. It is 
probably disadvantageous to lower the active ingredient concentration in the formulation to 
improve the syringeability of the formulation, because of the consequently reduced efficacy 
and duration of the treatment.  
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3.2. Requirements for active ingredient 
 
The therapeutic agents suitable for sustained release injectable drug delivery systems should 
need to be administered for long period of time, be highly potent and have compliance 
issues. In addition, the resulting controlled release formulation with the active ingredient in 
question should have an attractive benefit/cost ratio for the customer. In order to reduce the 
risk that a possible significant initial burst cause prohibitive side effects, the active ingredients 
should have broad therapeutic index. Finally, the active ingredient should be sufficiently 
stable at 37°C during the envisaged depot injection release period, to allow a guaranteed 
and reproducible release form the injected depot formulation. 
 
The active ingredient selected for the present study, the anti-infective NOA449851, was 
dissolved in the polymer solution and showed good stability during storage of the injectable 
formulations at different temperatures (Chapter 7). It generated no toxic effect at the injection 
site as well as no systemic effects during the whole duration of the in-vivo trials (Chapter 4). 
In addition, its lipophilic character prevented a too fast diffusion from the lipophilic PLA 
polymer matrix.  
 
However, the selected active ingredient was not an ideal candidate for such a technology. 
The high drug loading of 17.00 % was necessary to assure sufficient blood level for about six 
months. With a more potent active ingredient, its required content would decrease and 
consequently polymer concentration could be reduced, leading to a lower viscosity and a 
better syringeability of formulation. Therefore, it can be assumed that high potent and save 
active ingredients such as proteins, vaccines or chemotherapeutics would be more adequate 
for this technology. 
3.3. Stability of PLA polymers 
 
The use of biodegradable polymers alleviates the need for surgical removal of the implant 
after termination of the therapy, thereby increasing patient acceptance and compliance. 
Therefore, to reach biodegradation, chemical properties of polymers should allow hydrolysis 
of their ester-bonding at physiological conditions. During storage, the stability of these 
polymers, especially when dissolved in organic solvents, are consequently relatively poor. 
Degradation rate of the PLA polymers was investigated in Chapter 7 by measuring their 
apparent molecular weight during six months storage. It was found that hydrolysis process 
and therefore stability of the formulation was strongly influenced by the storage temperature. 
Polymers showed better stability at a storage temperature of 5°C in contrast to storage 
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conditions tested such as 25°C and 40°C. Decrease in molecular weight for PLA polymers 
was smaller than 20 % of the initial value during the six months storage at 5°C, while it 
reached about 50 % for storage temperature of 25°C and even 90 % for storage temperature 
of 40°C in the same period of time. Therefore, storage conditions at 5°C is indispensable for 
maintaining the molecular weight of the polymer relatively stable. Although these storage 
conditions are not optimal, especially for the veterinarian use, it should be realized that the 
use of more sophisticated release principles most of the time require more demanding 
storage conditions allowing the use of these products.   
3.4. Marketability 
 
Chronic oral administration of tablets to companion animals is particularly challenging and 
therefore there is a continuing need for alternative options like long acting injections and 
implants, with a desired duration of release varying from two weeks to two years [Ahmed et 
al., 2002]. One limitation of these newly developed drug delivery systems is that their 
development and sales cost to benefit ratio is too high which restricts their use over 
conventional dosage forms. Formulation and drug delivery considerations for companion 
animals are dictated by a set of circumstances such as ease of use to the pet-owner, pet 
compliance and dosing flexibility. Systemic safety and toleration of the animal are also 
important considerations along with owner safety and convenience. Therapy for companion 
animals is not usually as cost sensitive as for livestock. 
 
To obtain approval from regulatory authorities, additional parameters must be tested. All of 
these factors can be severely detrimental to commercial success of the product. Parenteral 
delivery systems have to meet pharmacopoeial requirements with respect to sterility. The 
chemical instability of the polymeric matrix material limits the options for obtaining a 
guaranteed sterile product. Usual methods such as dry or moist heat sterilization methods 
cause an unacceptable degree of degradation and hydrolysis of the polymers. Toxicological 
problems due to residual amounts are encountered with the use of ethylene oxide. In the 
case of sustained release injectables formed in-situ, the best option for terminal sterilization 
is the use of gamma-irradiation. This method showed good efficacy as terminal sterilization 
method for PLA/PLGA polymer based drug delivery systems. However, γ-irradiation of 
saturated polyesters can result in simultaneous chain scission and crosslinking. As 
mentioned in the literature, there is an evidence of the decrease in weight average molecular 
weight of polymers after different dose of gamma-irradiation [Mohr et al., 1999; Montanari et 
al., 1998; Volland et al., 1994]. The active ingredient can also be sensitive to this sterilization 
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method. Therefore, sterilization conditions need to be carefully adjusted for the final dosage 
form. 
 
As already extensively discussed, the high viscosity of the formulation leads to acceptance 
problems due to the required big needle diameter. Reduction of viscosity is limited by some 
factors including polymer concentration, active ingredient loading as well as maximal 
injectable volume. The use of a high pressure injector gun which permits the rapid 
subcutaneous application of such viscous formulations without demanding to much force to 
be applied by the veterinarian could eventually solve this problem. 
 
Finally, one of the most crucial properties to judge whether a depot injectable is useful is the 
degree of obtained efficacy of the treatment. In the present study, pharmacokinetic 
parameters such as blood values were measured, but no efficacy tests were performed with 
artificial infection of the animals with the target parasite. 
3. Conclusion 
 
New active ingredients are continuously being developed. By utilizing new form of sustained 
release drug delivery systems, it will be possible to deliver these drugs at constant rates over 
a prolonged period of time. Sustained release injectables formed in-situ based on PLA/PLGA 
polymers seem to be a suitable approach for subcutaneous long term release of the new 
lipophilic anti-infective NOA449851. This technology fulfills, for this particular compound, 
some basic requirements such as a good tolerability, controlled release of the active 
ingredient over a long period of time as well as an acceptable stability of the formulation 
during storage for several months at low temperature conditions. The release properties of 
the active ingredient could be modified by changing composition of formulation and possible 
detrimental burst effects could be suppressed by careful selection of the formulation 
co-solvents. It is always important for further development of formulation to match its 
composition with requirements of the market and authorities. It is to be expected that in the 
future, development of new implantable systems will, increasingly, help reducing the cost for 
drug therapy, and potentiate medical treatments and, simultaneously enhance patient 
compliance. 
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